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CHAPTER 1 
 
Introduction: 
the concept of polymer therapeutics. 
 
 
1.1 HISTORICAL PERSPECTIVE 
The use of polymers in medicine is not new. Natural polymers have been used as components of 
herbal remedies for several millennia. The notion of synthetic, water-soluble polymers as 
macromolecular drugs or components of injectable drug delivery systems has, in contrast, a 
relatively short history - not surprising given the relative youthfulness of polymer science itself. In 
fact polymer science was borne only in the 1920s- less than a hundred years ago, thanks to 
Hermann Staudinger and his contemporaries. Moreover, it wasn't until 1953 that Staudinger was 
honoured with the first "polymer" Nobel Prize "for his discoveries in the field of macromolecular 
chemistry". Coincidentally, this is the same year that Watson and Crick published their Nature 
articles on the structure of DNA (Watson, Crick, 1953). Around this time we saw the beginning of 
water soluble synthetic polymers as healthcare aids for parenteral administration. During the 
Second World War synthetic polymeric plasma expanders were widely adopted (e.g. 
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poly(vinylpyrolidone)) and after few time the first polymer-drug conjugates appeared (e.g. 
mescaline-N-vinylpyrolidine conjugates with drug attached via non-degradable or enzymatically 
degradable (gly-leu) side chains (Jatzkewitz, 1955). Biologically active polymeric drugs also started 
to gain popularity, and divinylether-maleic anhydride copolymer (pyran copolymer) was tested 
clinically as an anticancer agent in the 1960s. From that moment on, a wide range of polymers - 
modified polysaccharides, synthetic polypeptides and synthetic polymers - have been successfully 
transferred into the market as polymeric drugs, giving rise in 1970s to more clearly defined 
chemical and biological rationale for the design of polymeric drugs, polymer-protein conjugates 
(Davis, 2002) and polymer-drug conjugates (Ringsdorf, 1975), the so called “polymer therapeutics” 
family, which will be treated more extensively below. 
 
1.2 CURRENT STATUS 
The first poly(ethyleneglycol) (PEG)ylated proteins were approved by regulatory authorities for 
routine clinical use in the early 1990s: PEG-adenosine deaminase used to treat acute 
immunodeficiency syndrome and PEG-L-asparaginase to treat acute lymphoblastic leukaemia. At 
the same time in Japan, a stryene-co-maleic anhydride conjugate of the anticancer protein 
neocarzinstatin called SMANCS, developed by Maeda and colleagues, was successfully used as a 
treatment of patients with primary liver cancer (a very difficult disease to treat) and this led to 
market approval for the treatment of this disease. During his research, Maeda also discovered the 
passive tumour-targeting phenomenon called the "enhanced permeability and retention effect" (EPR 
effect). This phenomenon is attributed to two factors: the disorganised pathology of angiogenic 
tumour vasculature with its discontinuous endothelium leading to hyperpermeability towards 
circulating macromolecules, and the lack of effective tumour lymphatic drainage, which leads to 
subsequent macromolecular accumulation. It is now well established that long circulating 
macromolecules including polymer conjugates, and even polymer-coated liposomes, accumulate 
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passively in solid tumour tissue by the EPR effect after intravenous administration and can increase 
tumour concentration many fold (Matsumura et al., 1986; Maeda et al., 2000).  
In recent years a wide number of synthetic polymers have been produced for therapeutic aims, 
including synthetic random copolymer of L-alanine, L-lysine, L-glutamic acid and L-tyrosine (M, = 
5000- 11000 g/mol) given subcutaneously to treat multiple sclerosis patients (Teitlebaum et al., 
1997) and also those poly(allylamine)s developed clinically as polymeric sequestrants for oral 
administration to hypercholesterolemic patients (Mandeville et al., 1997). The first synthetic 
polymer anticancer drug conjugate entered clinical trials in 1994. This was an N-(2-
hydroxypropyl)methacrylamide (HPMA) copolymer conjugate of doxorubicin (Duncan, 2003). 
Since then, five more HPMA copolymer conjugates have progressed into the clinic, and the first 
conjugate bearing antiangiogenic therapy is now being tested in vivo Anticancer conjugates based 
on other polymeric carriers including poly(glutamic acid), PEG and polysaccharides are also now in 
clinical trials. 
With growing appreciation of the molecular basis of disease in the late 1980s, the hope of "gene 
therapy" began to gain momentum. While the viral vectors are still preferred for gene delivery, 
there has been a continuing hope that polymeric non-viral vectors can become a feasible alternative 
- i.e. biomimetics delivering DNA safely without the threat of toxicity. Early research used simple 
polycationic vectors such as poly(L-lysine) and poly(ethyleneimine). Since then a wide variety of 
complex multicomponent, polymer-based vectors have been designed as gene delivery systems 
(Pack, 2005). With still some distance to the first polymeric viral vectors as marketed products, 
there is still much to do. 
 
1.3 THE AIM OF THE PHD WORK 
The term "polymer therapeutics" has been adopted to encompass several families of constructs all 
using water-soluble polymers as components for design polymeric drugs, polymer-drug conjugates, 
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polymer-protein conjugates, polymeric micelles to which a drug is covalently bound, and those 
multi-component polyplexes being developed as non-viral vectors.  
The main object of this PhD work has been the synthesis, characterization and in some extent 
application of poly(amidoamine) (PAA) derivatives that can be considered belonging to the 
polymer therapeutics family. In particular three groups of PAAs have been studied:  
 
• a family of polymeric precursors designed for obtaining polymer conjugates with 
sulfhydryl containing molecules, both drugs and/or proteins, that will be treated in 
Chapter 4;  
• a family of amphiphilic polymers, composed by hydrophilic PAA backbone with 
cholesterol pendants, designed to self assemble in water media in nanoparticles 
capable to transport lipophilic drugs, that will be treated in Chapter 5; 
• a special PEG-PAA cationic block co-polymer containing reversibly cross-linkable 
functions, capable to form polyplexes with “environment sensitive” stability; this 
work treated in Chapter 6.  
 
Beside this three main objects, a preliminary work concerning kinetic study of Michael 
polyaddition reaction in organic solvents is presented in Chapter 3, while in Chapter 7 a study 
concerning liposomes and lipids bilayer deposition on purposely fuctionalized glass surfaces is 
reported. General features concerning introduced topics will be treated below.  
 
1.3.1 Polymer-drug and polymer-protein conjugates 
In the early ’70, Ringsdorf identified a model for polymer-drug conjugates (Figure 1.1) that 
represent still nowadays the starting point for developing a polymeric adducts. In the Ringsdorf’s 
model, a number of drug molecules are bound to a macromolecule through a spacer molecule, 
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which can incorporate a predetermined breaking point to ensure release of the drug at the site of 
interest. The polymer conjugate can additionally contain moieties, for example, antibodies or sugar 
moieties, which target disease related antigens or receptors. In addition, solubilizing groups can be 
attached to the polymer backbone to modify the bioavailability of the drug–polymer conjugate. 
 
 
Figure 1.1. Ringsdorf’s model for drug-delivery systems based on synthetic 
polymers. 
 
Macromolecules chosen for the preparation of drug– polymer conjugates should ideally be water-
soluble, nontoxic, and nonimmunogenic, as well as degraded and/or eliminated from the organism. 
Finally, the macromolecular carrier should exhibit suitable functional groups for attaching the 
respective drug or spacer. 
There is a large number of advantages that can be achieved through a polymer conjugation. Some 
examples worth to be mentioned are: 
• stabilization of labile active molecules from chemical and biological degradation 
• protection from proteolytic degradation 
• reduction of immunogenicity 
• decreased antibody recognition 
• increased plasma half life 
• modification of organ disposition 
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• drug penetration into selected cell compartments through endocytosis 
• enhanced possibilities of drug targeting 
 
Cancer therapy represent one of the fields in which polymer-drug conjugation could bring major 
advantages. In fact, the possibility to exploit EPR effect constitute another important improvement, 
since consequent passive tumour targeting lead to enhanced efficacy of drugs with reduced side 
effects.  Several drug–polymer conjugates are being investigated in phase I–III studies at present.  
 
Another important field of research regards polymer-protein conjugation. Therapeutically 
relevant proteins such as antibodies, cytokines, growth factors, and enzymes are playing an 
increasing role in the treatment of viral, malignant, and autoimmune diseases. The development and 
successful application of therapeutic proteins, however, is often impeded by several difficulties, for 
example, insufficient stability and shelf-life, costly production, immunogenic and allergic potential, 
as well as poor bioavailability and sensitivity towards proteases. Consequently, frequent 
administration at an excessively high dose is required to reveal their therapeutic effects in vivo. As 
a result, homeostasis is destroyed, and unexpected side effects occur. Therefore, there has been a 
continuing search for improved alternatives. Bioconjugation with water-soluble polymers improves 
the plasma clearance and body distribution, resulting in increased therapeutic effects and decreased 
side effects.  
As previously discussed, starting from the 1970s several conjugates of polyethylene glycol (PEG) 
to proteins have been produced. This technique is now well established and is called PEGylation 
PEGylation increases protein solubility and stability, and hence prolongs plasma half-life, and can 
reduce protein immunogenicity Although there are other available polymers for protein conjugation 
such as HPMA copolymers, poly(ethyleneimine) (PEI), linear polyamidoamines, 
polyvinylpyrrolidone (PVP), polyacrylamide (PAAm), polydimethylacrylamide (PDAAm), 
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polyvinyl alcohol (PVA), chitosan, dextrin and dextran, PEG is still the most popular option since 
the clinical value of PEGylation is now well established.  
 
 
1.3.2 Polymeric micelles 
The development of drug nanocarriers for poorly soluble pharmaceuticals is an important task, 
particularly because large proportions of new drug candidates emerging from highthroughput drug 
screening initiatives are water-insoluble, but there are some unresolved issues. The therapeutic 
application of hydrophobic, poorly water-soluble agents is associated with some serious problems, 
since low watersolubility results in poor absorption and low bioavailability. sometimes associated 
with complications as embolism and local toxicity. On the other hand, the hydrophobicity and low 
solubility in water appear to be intrinsic properties of many drugs, since it helps a drug molecule to 
penetrate a cell membrane and reach important intracellular targets.  
To overcome the poor solubility of certain drugs, the use of various micelle forming surfactants 
in formulations of insoluble drugs is suggested. This is why micelles and nanoparticles, including 
polymeric ones, represent a promising type of pharmaceutical carriers. Micelles and nanoparticles 
form colloidal dispersions with a particle size between 5 and 1000 nm. These nanostructure are 
designed to increase the solubility and bioavailability of poorly soluble pharmaceuticals, therefore 
they are often composed by special amphiphilic molecules as building blocks.  
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Figure 1.2. Formation and architecture of block-copolymer micelles which spontaneously form by self-assembly in 
water. The characteristic features are a pronounced core–shell architecture which can be controlled by the individual 
polymer blocks. Typical examples of block copolymers are PEO-b-PPO, PEO-b-PCl, and PEO-b-PAsp. 
 
Because of their small size (5-100 nm), micelles demonstrate spontaneous penetration into the 
interstitium in the body compartments with leaky vasculature (tumors and infarcts) by the EPR 
effect. Specific ligands (eg, antibodies and/or certain sugar moieties) can be attached to the 
waterexposed termini of hydrophilic blocks. By virtue of their small size and by functionalizing 
their surface with synthetic polymers and appropriate ligands, nanoparticulate carriers can be 
targeted to specific cells and locations within the body after intravenous or subcutaneous injection. 
Such approaches may enhance detection sensitivity in medical imaging, improve therapeutic 
effectiveness, and decrease side effects. Some of the carriers can be engineered in such a way that 
they can be activated by changes in the environmental pH, by chemical stimuli, by the application 
of a rapidly oscillating magnetic field, or by application of an external heat source.  
 
1.3.3 Polyplexes  
Viral vectors, bionanoparticles with diameters of 100 nm or less, have long been proven to be the 
most efficient and stable transgene vectors into the cell and thus are suitable for vaccine and gene 
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therapy Viruses are able to use the host cell machinery for protein synthesis, and some of them are 
able to stably insert into the host cell genome and provide a long-term transgene expression in 
transduced cells. Thus, viral gene carriers possess higher gene transfection efficiency than non viral 
vectors However, despite some successes in clinic trials, viral vector gene transfer still has some 
safety issues. The immune response caused by the expression of viral proteins has to be overcome.  
For these reasons the use of polymers as synthetic non-viral carriers for introducing nucleic acids 
into cells appears very appealing. Several diseases could be potentially cured by means of gene 
therapy, i.e. cancer, Alzheimer disease, arthritis reumatoide and other auto-immune diseases, 
genetic diseases and syndromes. Moreover gene therapy seems to be very promising to improve in 
vivo tissue engineering.  
Polymers can be generated in large quantities in chemically defined, non-antigenic and non-
immunogenic form. A plethora of different chemical structures and polymer sizes may be applied to 
tailor-made polymers with optimized characteristics for the extracellular delivery of nucleic acid to 
the target tissue and the subsequent intracellular delivery into the target cells. For the purpose of 
nucleic acid transfer, polymers have been applied for incorporating nucleic acids into nanoparticles 
or microspheres. Alternatively, cationic polymers are applied as carriers for complexing gene 
vectors into polyplexes. Polyplexes form spontaneously upon mixing negatively charged nucleic 
acid with the polycationic polymer due to electrostatic interaction. This process can be controlled to 
result in the formation of particles with defined virus-like sizes which efficiently transfect cell 
cultures and also have shown encouraging gene transfer potential in vivo administration.  
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Figure 1.3. three dimensional model of PEI-PEG polyplexes 
 
With first-generation polymeric carriers, gene therapeutic effects have been demonstrated in 
animals, although modest efficiencies and significant toxicity restrict broader therapeutic 
application. Key issues for future optimization of polyplexes include improved specificity for the 
target tissue, enhanced intracellular uptake, and reduced toxicity and immunogenicity. Novel 
cationic polymers have to be made more biocompatible by reducing their potential for unspecific 
adverse interactions with the host, and by designing them in a biodegradable form. “Smart” 
polymers and polymer conjugates are being developed that in a dynamic manner present virus-like 
delivery functions in the appropriate phase of the gene delivery process. 
 
1.3.4 AFM imaging in the field of drug delivery. 
The ability to fully characterise drug systems, to provide drug targeting with high specificity and 
drug delivery with integrated controlled release are all a major challenge to the pharmaceutical 
industry. These challenges have, in part, been difficult to meet due to often poor understanding of 
the physicochemical properties of drug systems.  
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The family of scanning probe microscopes (SPMs) has revolutionised our ability to characterise 
and understand the interactions between drug systems and their exposed environments. These 
microscopes have enabled the study of pharmaceutical devices and drug particles with minimal pre-
treatment in both air and liquid at the nanoscale level.  
The AFM was invented 1986. The main features of the AFM include its ability to image non-
conductive samples (therefore a range of biological and drug particles can be studied) and to 
measure the surface topography of samples at subnanometer resolution. Most importantly of all for 
pharmaceuticals the AFM can work under a range of conditions including in air and liquid over a 
range of temperatures, with minimal sample manipulation and low running costs. 
During AFM imaging a sharp probe tip, usually made of silicon (Si) or silicon nitride (Si3N4) 
located on the underside of a flexible cantilever, raster scans over a sample surface. This motion is 
achieved using a piezoelectric scanner (Fig. 1). The bend and twist of the cantilever due to the 
forces of interaction between the tip and sample are monitored via a laser beam that is reflected 
from the back of the cantilever onto a position sensitive, quadrant photodiode detector. A resolution 
of few nanometres can be achieved, thus allowing reliable investigation upon nanoscaled systems. 
AFM is at present, one of the most powerful techniques in nano (bio) technology investigation. 
Some example of AFM imaging application are reported in the Figures 1.4 and 1.5. 
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Figure 1.4: Examples of AFM imaging in the fild of biological investigations. 
 
 
Figure 1.5: AFM study of DNA. Taken from Chim et al., 2006 [Y.T.A. Chim, Direct Nanoscale Visualisation of 
DNA Systems for Gene Therapy, in School of Pharmacy, LBSA, University of Nottingham, Nottingham, 2006, p. 208] 
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CHAPTER 2 
 
PAAs, a family of  
bioactive and biocompatible polymers 
 
 
2.1 POLY(AMIDOAMINE)S’ PROPERTIES 
Poly(amidoamine)s (PAAs) represent a family of biodegradable and biocompatible polymers 
with a recognised potential in the pharmaceutical field (Lin et al., 2007; Lavignac et al, 2005; 
Griffiths et al., 2004; Richardson et al, 2001). The first extensive studies on PAA synthesis have 
been published in 1970 (Danusso, Ferruti, 1970) and their chemical properties and biomedical 
applications reviewed in several instances (Ferruti et al., 2002; Ferruti et al., 1985) 
 
2.1.1 GENERAL SYNTHESIS AND STRUCTURE 
PAAs are obtained by stepwise Michael type polyaddition reaction of primary or bis-secondary 
amines to bisacrylamids. The polymer obtained presents tert-amino and amido groups regularly 
arranged along the main chain (Scheme 2.1).  
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Scheme 2.1: Synthesis of linear PAAs R1, R2, R3, R4 can be any alkyl residues eventually containing carboxyl, 
amide, ester, ether groups. 
 
The polymerisation reaction takes place in solvents carrying mobile protons, such as water or 
alcohols, without added catalysts (Scheme 2.2). The number-average and weight-average molecular 
weights of the PAAs usually range between 5000 – 40000 and 10000 – 70000 respectively, with a 
polydispersity index around 2 depending on the isolation method.  
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Scheme 2.2: Michael type addition mechanism. 
 
The reaction is considerably influenced by temperature. High temperatures accelerate the 
polyaddition reaction rate but the resulting polymers showed lower molecular weights because of 
the larger increase of hydrolysis reaction rate (Ferruti et al, 1994) . 
It is possible to obtain amphoteric PAAs using carboxyl containing starting monomers, carboxyl 
groups not influencing the polyaddition reaction. In this case, a stoichiometric amount of base 
(inorganic such as lithium or sodium hydroxide, or organic, such as triethylamine) must be added to 
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the monomer mixture in order to prevent amine protonation by the acid groups. Amphoteric PAAs 
show remarkable biological properties as will reported later in this chapter. 
Non amphoteric PAAs are soluble in water as well as chloroform, lower alcohols, dimethyl 
sulfoxide and other polar solvents. However, amphoteric PAAs dissolve only in water. The intrinsic 
viscosities of PAAs in organic solvents or aqueous media usually range from about 0.15 to 1 dl/g. 
As a rule, PAAs exhibit relatively large hydrodynamic volumes in solution if compared with vinyl 
polymers of similar molecular weight, indicating a tendency to assume an extended chain 
conformation in solution 
It is possible to obtain cross linked PAAs using polyfunctional monomers, such as bis-primary 
amines, by totally or partly replace the bis-functional amine monomer during the reaction (Scheme 
2.3). The soft hydrogels obtained have been studied as substrate for cell culture but can be also used 
as synthetic intermediates for special purposes (Ferruti, Caruso et al., 2005; Ferruti, Piras et al, 
2005). 
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Scheme 2.3: Synthesis of cvalently cross-linked PAAs hydrogels. R1, R2, R3, R4 can be any alkyl residues 
eventually containing carboxyl, amide, ester, ether groups. 
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2.1.2 FUNCTIONALISATION OF PAAS 
PAAs are inherently highly functional polymers, however, further functionalisation of PAAs may 
be useful for special purposes. Functional groups not capable of undergoing Michael addition under 
the conditions of PAA synthesis, for instance hydroxy, tert-amino, allyl, amido and ether groups, do 
not compete with the polimerisation reaction. Therefore, the introduction of these additional 
functions in PAAs as side substituents can be simply achieved by using monomers properly 
functionalised. Chemical groups capable of reacting with activated double bonds under the 
conditions of PAA synthesis such as SH, NH2, NHR and PH2, if unprotected, cannot as a rule be 
introduced directly as side substituents in PAAs. However, it is possible to obtain these types of 
functional groups by functionalization of purposely pre-synthesised polymers. Syntheses of PAAs 
carrying primary amines or sulphidryl containing pendants have been recently published.  
 
2.1.3 DEGRADATION OF PAAS 
All PAAs, containing amidic bonds in their main chain, are degradable in aqueous solution. The 
degradation of several PAAs has been extensively studied by means of viscometric and 
chromatographic techniques (Ferruti, 2002; Ferruti, 1994). The mechanism of PAA degradation 
seems to be purely hydrolytic as no vinyl groups, such as those which would have derived from a β-
elimination reaction, could be determined. It has been demonstrated that degradation rate of PAAs 
in aqueous media is strongly influenced by temperature and pH, as well as by the structure of both 
the amine and amide moieties. Degradation seems not to be affected by the presence of isolated 
lysosomal enzymes at pH 5.5. 
 
2.1.4 ACID-BASE PROPERTIES OF PAAS 
All PAAs contain tert-amino groups in their main chain and therefore can be classified as 
polyelectrolytes (Richardson et al., 2001; Ferruti et al., 2002). Normally, the values of the 
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protonation constants (log K) of polyelectrolytes depend on the degree of protonation of the whole 
macromolecule. They follow the modified Henderson-Hasselbach equation: 
( ) ( )⎥⎦
⎤⎢⎣
⎡ −−+= α
α1log1loglog 0 nKK ii    (Eq 2.1) 
where logK0i  is the protonation constant of a group present in a completely unionised polymer 
and α = degree of protonation. 
The protonation constants of polyelecrolytes are usually referred to as “apparent” constants, as 
opposed to the “real” constants of non macromolecular acids and bases. However, in most PAAs 
the results of the potentiometric titrations are consistent with n values very close to 1. This means, 
that in PAAs, the tendency of the aminic nitrogen atoms of each repeating unit to assume a proton 
in practice does not depend on the degree of protonation of the whole macromolecule. Therefore, 
real or “quasi real” basicity constants can be determined. As a  consequence, non ampohoteric 
PAAs behave as polycations and show the same number of basicity constant than the amino groups 
present in their repeating unit (Figure 2.1).  
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Figure2.1: Protonation profiles the cationic PAA represented above the chart, in which each curve represent relative 
abundance of different protonation profiles of the repeating units. pH scale is from 1 to 11.  
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By a proper choice of the starting monomers, the acid and basic strength of the amino and the 
carboxyl groups can be controlled in such a way that the polymer passes from a prevailingly anionic 
to a prevailingly cationic state as a consequence of relatively modest pH changes (Figure 2.2). 
 
N
H
N
H
HN
O O
N
O O
 
0 . 0
0 . 1
0 . 2
0 . 3
0 . 4
0 . 5
0 . 6
0 . 7
0 . 8
0 . 9
1 . 0
1 3 5 7 9 1 1
p H
a
lf
L 2 +
L +
L 0
L -
L 2+
 
L 0
L 1-
pH
R
el
at
iv
e 
co
nc
en
tra
tio
n
 
Figure2.2: Protonation profiles the amphoteric PAA represented above the chart, in which each curve represent 
relative abundance of different protonation profiles of the repeating units. pH scale is from 1 to 11.  
 
 
2.1.5 BIOLOGICAL PROPERTIES OF PAAS  
PAAs are endowed with many interesting properties for using in biological and biomedical 
applications. Cationic PAAs are usually one or two order or magnitude less cytotoxic (IC50 between 
0.5 and 3 mg/ml) than other commonly used polycations such as poly-L-lysine and 
polyethyleneimine ( IC50 0.01 mg/ml) but show the same properties in DNA complexing ability. 
For this reason they can be regarded as potential transfection promoters (Richardson et al., 2001; 
Lavignac, 2004). 
Moreover, amphoteric PAAs are often non-cytotoxic (IC50 above 5 mg/ml, similar to dextrane) 
and stealth-like: when parenterally administered to living animals, mice or rats, they don’t 
accumulate in liver or kidneys but can circulate for prolonged time in the bloodstream (Franchini et 
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al., 2006; Ferruti, Franchini et al., 2007) . This property is very important in designing polymer 
therapeutics for cancer therapy.  
PAAs are internalized by cells via the endocytic pathway. In intracellular compartments, where 
the pH is lowered to first 6.5 (endosomes) then 5.0 (lysosomes), they become prevailingly cationic 
and display endosomolytic properties.  
The degradability of the PAAs is very important as well, in order to allow renal clearance once 
the polymer has completed his function in the body. The hydrolysis degradation mechanism, 
completely non-enzimatic, allow a fine tuning of the polymer life in the body. The cytotoxicity of 
different PAAs degradation products have been also tested, always leading to IC50 values similar or 
larger than the native polymers.  
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2.2 PAAS AS POLYMER THERAPEUTICS.  
2.2.1 RADIOACTIVE LABELLED PAAS 
Radioactive labelled PAAs have been obtained by substituting a small amount (4 % on a molar 
basis) of tyramine (Figure 2.3) for the same amount of aminic monomers. This allows 
radioiodination by I125 .  
N
CH2
CH2
OH
a
 
Figure 2.3: Structure of tyramine units in PAA. 
 
2.2.2 FLUORESCENT LABELLED PAAS 
A wide choice of fluorescent labels for proteins is commercially available. They usually contain 
an activated carboxyl group that will couple with the ε-amino groups of L-lysine units of proteins. It 
is obviously of advantage to introduce primary amino groups as side substituents in PAAs, to render 
them amenable to the same labelling techniques as proteins. However, the potential interest in 
polymer therapeutics of PAAs carrying pendant primary amino groups is not limited to that. In fact, 
they may act as general purpose polymer carriers for carboxylated drugs and will easily yield PAA-
protein conjugates by consolidated techniques. The direct introduction of primary amino groups in 
PAAs by using primary amino-substituted monomers in the polymerisation recipe is not possible 
under the synthetic conditions normally adopted for PAAs, since all primary amino groups will 
participate to the polimerisation reaction. 
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Under non selective conditions primary bis(amine)s usually give crosslinked products on reaction 
with bis(acrylamide)s, because they react as tetra-functional monomers. To prepare PAAs carrying 
primary NH2 groups as side substituents (NH2-PAAs), a general-purpose synthetic strategy is to use 
as monomers primary diamines, in which one of the aminic functions has been protected by a group 
capable of preventing its addition reaction on activated double bonds. The protecting group must be 
stable under the conditions of PAA synthesis, but easily removable under conditions not affecting 
PAA stability. A convenient synthesis and discussion about the synthetic considerations have been 
recently published (Malgesini et al., 2003) 
 
2.2.3 MITOMYCINC-PAA CONJUGATES 
PAA-MMC adducts were synthesised from ISA4. After in vitro studies, preliminary experiments 
were carried out to investigate the efficacy and toxicity of these PAA-MMC conjugates in vivo. The 
PAA-MMC conjugates were equi-active compared to MMC given i.p. route and indeed in this pilot 
experiment a long term survivor was observed in each group treated with conjugate. It was found 
that PAA-MMC conjugates were less toxic than free MMC when administered at a MMC-
equivalent dose of 5 mg/kg, that is, the maximum tolerated dose of free MMC that can be given to 
animals.  
 
2.2.4 PLATINATES-PAA CONJUGATES 
ISA23 and two other PAAs containing pendant β-cyclodextrins were used to synthesise PAA-
platinates by reaction with cisplatin. The conjugates had a content of 8-70 wt % platinum and in 
vitro at pH 5.5 and pH 7.4 they released low molecular weight platinum species (0 - 20 %/72 h). In 
vitro the PAA-platinates were generally less toxic than cisplatin towards lung tumour cell lines 
(IC50 for cisplatin was 2-5 µg/ml and 1-130 µg/ml for the PAA-platinates). In in vivo experiments 
the PAA-Pt derivatives were equi-active compared to cisplatin in an i.p. L1210 leukaemia model 
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thus confirming their ability to liberate biologically active platinum species. Whereas ISA23-
platinate was significantly less toxic in vivo than cisplatin, the cyclodextrin-containing PAAs did 
show significant toxicity on repeated dosing and thus are unsuitable for further development. As 
regards activity, preliminary experiments have shown that the ISA23-platinum conjugate displayed 
similar antitumour activity to that reported for other platinum conjugates of similar molecular 
weight. PAA-platinates have the advantage of good water solubility which is maintained during 
storage in contrast with other polymer-platinates, which often show reduced solubility after very 
short times (1-2 weeks). 
 
2.2.5 RICIN- AND GELONIN-PAA CONJUGATES 
Plant and bacterial toxins have been widely explored as anticancer agents, particularly in the form 
of immunotoxins. PAAs ability to mediate intracellular delivery of ribosome-inactivating toxins, in 
particular ricin and gelonin have been proved (Pattrick et al., 2001). Ricin, derived from Ricinus 
communis beans, is a highly cytotoxic protein when present in the native dimeric form, consisting 
of an A-chain (RTA) and a B-chain (RTB) linked by a disulphide bridge. RTB is the cell binding 
moiety which acts to promote binding and endocytosis of RTA. Once inside the cell, RTA is 
believed to utilize the E-R associated protein degradation pathway (ERAD pathway) and is 
translocated to the cytosol in a partially unfolded state. Once in the cytosol, RTA refolds and 
exhibits pharmacological activity by cleavage of the N-glycosidic bond of adenosine nucleoside 
leading to inhibition of protein synthesis. RTA alone does show some inherent toxicity towards 
cells but this is a very inefficient process. This effect is greatly reduced compared to the toxicity of 
the holotoxin. Gelonin toxin does not contain the cell-binding subunit of ricin and is completely 
non-toxic to intact cells. Cationic membrane interacting PAAs were chosen to investigate their 
ability to promote intracytoplasmic delivery. They were incubated with B16F10 cells in vitro 
together with two non permeant toxins: either ricin A-chain (RTA) or gelonin. The relatively non 
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toxic PAAs (IC50 1.8 mg/ml) restored activity to the inherently inert toxins. The addition of a small 
quantity of tyramine to the PAA structures designated ISA4 to allow radiolabeling had no effect on 
their pKa values. Ricin and RTA displayed IC50 values of 0.3 and 1.4 μg/ml, respectively, and 
gelonin was non-toxic over the range studied. In all further experiments, non-toxic concentrations 
of RTA (250 ng/ml) and gelonin (1.4 μg/ml) were used. When B16F10 cells were incubated with a 
combination RTA-PAA conjugates (250 ng/ml), the observed IC50 fell to 0.65±0.05 mg/ml. 
Similar results were obtained with gelonin.  
Cytotoxicity assays were again performed using B16F10 cells but in this case a fixed 
concentration of ISA4 was combined with increasing concentrations of RTA (0-10 μg/ml). As the 
PAA concentration increased, less RTA was required to achieve the IC50 level. It can be clearly seen 
that a mixture of this PAA and RTA can be used to promote cytotoxicity to a greater level than seen 
for the holotoxin at a polymer concentration of 1.5 mg/ml. These observations suggest that specific 
PAA-toxin combinations warrant further development as novel therapeutics. 
 
2.2.6 MELLITIN-PAA CONJUGATES 
Mellitin (MLT) is a peptide of α-helical conformation and it is the main constituent of the venom 
of the European honey bee (Apis mellifera). It is a cationic and it spontaneously associates with 
natural and artificial membranes. The peptide has a molecular weight of 2860 and it is a typical 
representative of biologically active peptide drugs with high therapeutic potential. Bee venom has 
been found to have a marked effect on the immune system, cardiovascular system and it also 
exhibits anti-tumour activity. Melittin is commonly used in the treatment of arthritic disorders, such 
as rheumatoid arthritis and osteoarthritis but it has been used as an endosomolytic agent, too. A 
poly(ethyleneimine) (PEI)–MLT conjugate was used to form polyplexes that increased gene 
expression in several cell lines. More recently a maleic anhydride derivative of MLT was used to 
deliver oligonucleotides to the cytosol of Hela cells. 
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Novel ISA1- and ISA23-like MLT conjugates have been prepared. Both conjugates displayed pH 
dependent haemolytic activity and ISA1–MLT also enhanced intracellular delivery of the non-
permeant toxin gelonin compared to the parent ISA1 polymer. Whilst ISA23–MLT did not deliver 
gelonin, its lack of haemolytic activity at pH 7.4, and retention of cytotoxicity, suggests it worthy of 
further evaluation as an anticancer polymer therapeutic (Lavignac et al., 2005). 
 
2.2.7 AGMATINE CONTAINING PAAS 
Recently a peptidomimetitc PAA, labeled AGMA1, have been obtained by polyaddition reaction 
of bis(acrylamido)acetic acid and agmatine (4-aminobutylguanidine) (Annunziata et al, 2007; 
Franchini et al., 2007; Ferruti, Franchini et al., 2007).  
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Figure 2.3 : structure of agmatine containing amphoteric PAA (left part) compared to the RGD tripeptide sequence. 
 
Despite the large amount of cationic charge in physiological conditions (55% at pH 7.4 and 945 
at pH 5, see Figure 2.5), this amphoteric polymer showed a very low toxicity, probably due to the 
structural similarities with the tripeptide arginine-glycine-aspartic (RGD sequence). This 
oligopeptide, in fact, interacts wit avb3 integrins, and it is involved in cell proliferation and adhesion 
mechanisms.  
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Figure2.5: Protonation profiles of AGMA1, in which each curve represent relative abundance of different 
protonation profiles of the repeating units. pH scale is from 1 to 11.  
 
Agmatine containing amphoteric polymers have been tested as carriers for drug delivery and as 
transfection promoters. In vitro assays demonstrated the polymer ability to interact with cell 
membranes in a non disruptive way and to effectively protect DNA by enzymatic degradation in 
biological environment and to promote stable gene transfection in living cells. In vivo assays 
demonstrated a stealth like behavior with passive accumulation in tumour by EPR effect. Agmatine 
containing PAAs’ hydrogels, easily obtained using a polyfunctional amine monomer, are fully 
cytocompatible and showed also remarkable properties adhesion and proliferation promoters 
towards several cell lines (Ferruti, Piras et al, 2005). 
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CHAPTER 3 
 
Kinetic study of PAAs synthesis 
in organic solvents 
 
 
3.1 AIM AND RATIONALE OF THE WORK 
 
PAAs are a family of polymers obtained by Michael type polyaddition reaction in which amine 
and amide groups are regularly arranged along the main chain. Several different fuctional groups 
are compatible with Michael reaction, such as carboxyl, hydroxyl, allyl, amide or ether groups. This 
fact represent a clear advantage in PAAs synthesis, since PAAs containing chemical functions as 
side-substituents can be easily obtained using suitable functionalized monomers. In fact, only a few 
groups are able to interfere in the polyaddition reaction and, in principle, nearly every aliphatic 
amine and bisacrylamide can be used as a monomer (Ferruti et al., 2002). 
For special purposes, such as hydrophilic-hydrophobic block co-polymer or compatibilisers for 
drug formulations, PAAs containing hydrophobic moieties can be obtained. This involves the use of 
water insoluble monomers and, therefore, organic reaction solvents are needed (Malgesini et al, 
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2003). Pioneering studies previously performed showed that high molecular weight polymers can 
only be obtained in organic solvents bearing mobile hydrogens, such as alcohols; indeed aprotic 
solvents give always poor results irrespective of their polarity (Danusso, Ferruti, 1970). In fact, 
mobile hydrogens play a key role in reaction mechanism of Michael addition, and hydrogen 
mobility strongly influenced reaction kinetics.  
 
Since systematic comparison studies of the polymerization kinetics of PAAs in water and 
alcohols were lacking, we performed a comparative study of the kinetics in water, methanol and 
ethylene glycol of a typical polyaddition reaction, namely that of 2-methylpiperazine (MP) to 1,4-
bisacryloylpiperazine (BP). Formamide, was also studied, together with a typical dipolar aprotic 
solvent, dimethylformamide. With this solvents choice a wide range of several common solvents, 
often used also in biological field, are taken into account; moreover they represent almost all 
commonly used solvent classes with respect with their polarity and acid-base properties. 
 
3.2 EXPERIMENTAL PART 
3.2.1 Materials. 
1,4-Bis(acryloyl)piperazine (BP) was prepared as previously described (Ferrutim 1985); 2,5-
dimethylpiperazine (DMP) was commercially available (Aldrich) and was used without further 
purification. The 2-methylpiperazine (MP) was purchased from Fluka and recrystallized from n-
heptane (1 g MP in 20 mL solvent) before use. Its purity was checked just before use by 
potentiometric titration. The organic solvents were anhydrous analytical grade freshly purchased 
from Fluka. They were transferred under dry nitrogen by means of syringes. The bottles were 
opened just before use and their content left over molecular sieve. 0.1M hydrochloric acid solution 
was purchased from Riedel-de Haen. Water was doubly distilled. 
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3.2.2 Measurements 
UV-VIS spectra were run on a Perkin-Elmer Lambda EZ210 spectrometer connected to a PC for 
data transfer. For all measurements, quartz cells with a 1 cm path length were used. The calibration 
curves were obtained for each solvent in the analysis of 1,4-bis(acryloyl)piperazine at nine different 
concentrations; the absorbance at 250 nm fell within the range 0.04-0.9. The solutions were 
prepared using as solvent 0.1M hydrochloric acid containing 0.05% v/v of the organic solvent used. 
The data were processed by means of the least square fitting.   
 
3.2.3 Model polymerization reactions 
A 0.4 M solution of 1,4-bis(acryloyl)piperazine in the appropriate solvent (25 mL) and a 0.4 M 
solution of 2-methylpiperazine (or 2,5-dimethylpiperazine) in the same solvent (25 mL) were 
introduced, by means of syringes into a 100 mL one-necked flask, equipped with a silicon rubber 
stopper and thermostated at 25°C. The reaction mixture was flushed with dry nitrogen and then kept 
at 25°C without stirring. Aliquots (10 μL) were withdrawn at specific reaction times and the final 
volume of each adjusted to 20 mL with 0.1 M hydrochloric acid. The UV absorption of each 
solution was measured against the appropriate blank solution, that is, 0.1 M hydrochloric acid 
containing 0.05% v/v of organic solvent; the experiments were performed in duplicate. 
 
3.3RESULTS AND DISCUSSION 
The aim of this work was the study of the kinetics in different solvents (water, methanol, ethylene 
glycol, formamide, and dimethyl formamide) of a typical polyaddition reaction leading to a PAA. 
The model reaction adopted in this study was the polyaddition of MP to BP (Scheme 3.1): 
N N
O O
NH NH N N N N
O O
*
*
n
 
+
 
 
 
Scheme 3.1. Polyaddition reaction of BP to MP. 
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This reaction was chosen as model PAA preparation because both the monomers involved, as 
well as the resultant polymer, are easily soluble in water, lower alcohols and formamide. Perhaps 
plain piperazine would have been an even better model because it bears two perfectly identical 
amino groups. Piperazine, however, was discarded because its polymer with BP is soluble only in 
water and, therefore, in organic solvents precipitation would occur after a short reaction time. 
Moreover, MP is the amine used as the monomer in the PAAs with particular biomedical interest, 
some of which, also employ BP as a co-monomer. In addition, in the case of water, also DMP was 
used in comparison to MP, in order to investigate the effect of the different steric hindrance of the 
substituents in the α−position to the reactive secondary amine groups on the polyaddition reaction 
with bisacrylamides. 
The reactions were carried out at 25°C (close to the room temperature for the PAA syntheses). 
The reaction progress was monitored by UV spectroscopy, chosen for its sensitivity, fastness and 
cheapness, measuring the decrease of the intensity of the absorption band of the conjugated double 
bonds of BP. The following procedure was invariably adopted. The polymerization reactions were 
carried out at a 0.2 M concentration in the selected solvent (see Experimental), that is, 
approximately 1/10 of the reaction concentrations commonly adopted in PAA syntheses. Aliquots 
(10 μL) of the polymerization solutions were taken at specific time intervals and diluted in 20 mL 
0.1 M aqueous hydrochloric acid in order to stop the polymerization reaction and to reach a suitable 
concentration for UV measurements. The UV spectra of MP, BP and their polyaddition product 
were, therefore, preliminarily studied in 0.1 M aqueous hydrochloric acid containing 0.05% v/v of 
organic solvent, in order to verify the influence of the residual solvent on the absorption spectra of 
reagents and products. The absorption spectra in 0.1 M aqueous hydrochloric acid  + 0.05% (v/v) 
methanol are shown in Figure 3.1.  
In all the aqueous mixtures, the absorption spectrum of BP showed a peculiar absorption band 
with a maximum at 240 nm due to the π-π* transition of the BP conjugate double bond. In this 
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range, BP spectrum partially interferes with the tail of polymer absorption bands. For this reason, a 
different wavelength, 250 nm, was chosen for measuring the decrease in BP concentration. 
 
Figure 3.1. Absorption spectra of BP (---), MP (·-·) and the the polyaddition products (···) in 0.1 M aqueous 
hydrochloric acid + 0.05% (v/v) methanol. 
 
The molar extinction coefficients curves obtained in the different aqueous hydrochloric 
acid/solvent mixtures, ε, are reported in Table 3.1. The experimentally determined values of ε show 
slight differences in different aqueous/solvent mixtures, reflecting the different interactions between 
solvent and BP. 
 
Table 3.1. Molar extinction coefficients ε for bis-acryloylpiperazinea
Solvent 
Molar extinction coefficient 
(M-1cm-1) 
Water 10600 
Ethylene glycol 12200 
Methanol 11400 
Formamide 11700 
Dimethyl formamide 12400 
a)  In 0.1 M Hydrochloric acid  with 0.05% of different organic 
solvents at 250 nm 
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3.3.1 Determination of the rate constants: steric hindrance effect. 
The conversion curves obtained in the polyaddition reaction of BP with MP in the series of 
solvents listed in Table 1 are shown in Figure 3.2. The reaction proceeds much faster in water and 
glycol than in methanol, formamide in dimethylformamide, the latter solvents gave the poorest 
performance.  
 
Figure 3.2. Conversion curves of the polyaddition reaction of BP with MP in different solvents [(?) water, (?) glycol, 
(?) methanol, (?) formamide, (?) dimethyl formamide]. Best fitting curves were obtained using equation (3) and for 
dimethylformamide equation (4). 
 
We referred to our Previous studies demonstrated that polyaddition reactions involving 
acrylamides, bis-acrylamides and/or bis-acrylic esters, proceed with a pseudo-second order kinetics 
(Ranucci, Ferruti, 1991; Ferruti et al, 1998; Emilitri et al., 2005) with the kinetic constants that 
included the concentration of the catalytic protonic species, when performed in the presence of 
hydroxyl solvents. Thus, to investigate the kinetic features of the polymerization reactions of BP 
with MP in different protic solvents, data obtained were substituted in the following equation: 
 
[ ] [ ][MPBPk
dt
BPd −= ]     Eq (3.1) 
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on integration, if the initial reagent concentrations, [BP]o and [MP]o, are equal, equation (3.2) is 
obtained: 
[ ] [ ] ktBPBP o +=
11       Eq (3.2) 
 
The results obtained from the experimental data using equation (3.2), are reported in Figure 3.3 
(a-d).  
 
Figure 3.3. Calculated kinetic data using equation (2). Panels (a)-(d): polyaddition reaction of MP to BP in (a) water, 
(b) methanol, (c) ethylene glycol and (d) formamide. Best fitting curves were obtained  using equation (3). 
 
Unexpectedly, the 1/[BP] versus t curves obtained were not linear, but they all diverged at 
approximately 50% conversion. These facts suggested that the amine groups on MP may not be  
equivalent, due to the different steric hindrances by the neighbouring groups. To confirm this 
hypothesis, polymerization reactions were performed in water using  2,5-dimethylpiperazine (DMP) 
with two equivalent amine groups. A typical conversion curve was obtained (Figure 3.4).  
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Figure 3.4. Conversion curves of the polyaddition reaction of BP with MP (?) and DMP (?) in water. 
 
The results obtained from these experimental data using equation (3.2), are reported in Figure 3.5. 
In this case, the relationship 1/[BP] versus t curve was approximately linear with some deviation in 
the lower conversion region.  
 
Figure 3.5. Calculated kinetic data using equation (2) for the polyaddition reaction of BP with DMP in water. Best 
fitting curve were obtained using equation (3). 
 
This was ascribed to a small decrease in reactivity affecting the second amino group of DMP 
after the first addition step had occurred. The pseudo-second order kinetic constants, kDMP, are 
reported in Table 3.2. 
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Table 3.2. Kinetic constants for the polyaddition reactiona with 2,5-dimethylpiperazine (DMP) 
Solvent 
k1
(min-1M-1) 
k2
(min-1M-1) 
Water 0,804 0,0961 
Methanol 0,143 0,0158 
Etylene glycol 1,013 0,0946 
Formamide 0,042 0,0030 
Water - DMP / 0,0972 
a) In 0.1 M Hydrochloric acid  with 0.05% of different organic    solvents at 250 nm. 
 
These findings suggest that the polyaddition reaction of MP with BP proceeds through two 
distinct reaction steps, each characterized by a different rate. The first relatively fast step 
corresponds to the addition of the least hindered amine, while the second to the addition of the most 
hindered amine.  
 
3.3.2 Determination of the rate constants: solvent effect. 
For protic solvents, the kinetics constants of the two reaction steps were obtained by determining 
the slopes of the very initial and the very final segments of the 1/[BP] versus t curves (Figure 3.3), 
with the assumption that in either regions the reaction of one amino group of MP prevails over the 
other. Specifically, the faster step, with kinetic constant k1, occurs in the initial phase of the reaction, 
while the slower step, with kinetic constant k2, occurs in the final reaction phase.  
The values of the k1 and k2 kinetic constants obtained for the different protic solvents are reported 
in Table 3.2. These values were used to simulate the theoretical conversion curves by numerically 
integrating the differential equation (3.3) 
 
[ ] [ ][ ] [ ][ 2211 MPBPkMPBPkdt
BPd −−= ]  Eq (3.3) 
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where [MP1] = concentration of the least hindered amino group and [MP2] = concentration of the 
most hindered amino group. The results, reported in Figure 3.3, well fit the experimental data. 
Moreover, as reported in Table 3.2, the k2 value calculated for the MP reaction in water (0.0961 
min-1 M-1) is very close to the kDMP value (0.0961 min-1M-1) in the same solvent thus confirming that 
steric hindrance influences the second MP reaction step.  
The case of dimethylformamide was quite different. In this case, the best fitting curve was 
obtained by assuming a third order kinetics (Eq. (3.4)), which accounts for the autocatalytic effect 
of the aminic protons, being the solvent proton catalysis effect negligible. Due to the fact that the 
reaction rate in dimethylformamide under the conditions adopted is very slow, it was not possible to 
reach more than 50% conversion and, consequently, to determine the kinetics of the second step. 
The  kinetic constant determined was 0.0142 min-1M-2.  
 
[ ] [ ][ ]2MPBPk
dt
BPd −=    Eq (3.4) 
 
A comparison of the kinetic constants obtained in the different solvent systems allowed us to 
confirm that the proton concentration and solvent polarity are the main factors affecting the 
reactivity of the system. The pKa and dipole moment, μ, values for all solvents employed are 
reported in Table 3.3.  
 
Table 3.3: Pka and the dipole moment, (μ) of the solvents used in the BP/MP polyaddition reactiona). 
Solvent pKa μ (D) 
Water 14.00 1.85 
Ethylene glycol 15.84 2.2 b)
Methanol 16.71 2.87 
Formamide 16.80 3.37 
Dimethyl formamide >30 3.24 
a) Kosuke, 2002; b) Li et al., 2002. 
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It was observed that, in general, the reactivity increased with increasing proton concentration and 
decreasing solvent polarity. In the case of formamide, a dipolar solvent with an autoprotolysis 
constant (pKa = 16.80) which is similar to that for methanol (pKa = 16.71), the reaction rate is 
remarkably low. It appears that in the case of formamide, which has a very high dipole moment, the 
establishing of dipole-dipole interactions between solvent and reactants largely overshadowed the 
positive effect of proton availability on the reaction rate. In particular, the polarizable acrylic moiety 
of BP, stabilized by the dipolar solvent, showed a decrease in addition reactivity. The same 
stabilizing effect may be responsible for the very low reaction rate observed in dimethylformamide, 
a classical aprotic dipolar solvent, which also had a very low autoprotolysis constant (pKa >30). 
 
3.4 CONCLUSIONS. 
A kinetic study of Michael type polyaddition reaction was performed in different protic and 
aprotic solvents. It was found that solvent nature play a key role in the behaviour of this reaction, 
being its kinetic strongly depending on protonation constant and polar dipole of the solvent. In 
particular the reaction rate increase with increasing the autoprotolisis constant, taking into account 
the proton catalytic effect, and decrease with increasing the dipole moment, taking into account the 
stabilization of reactants for dipole-dipole interaction.  
Water demonstrated overall the best solvent for Michael type polyaddition reactions, even if 
alcohols or ethylene glycol appear to be suitable alternatives as reaction media, when water 
insoluble bisacrylamids or amines are used in PAA synthesis.  
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CHAPTER 4 
 
Synthesis of new polymeric precursors of  
PAA-drug or PAA-protein conjugate by disulfide bond 
 
 
4.1 INTRODUCTION 
In recent years a large number of research work is focusing on products in which disulfide bonds 
are involved. Disulfide bonds represent an important functional group in organic and also inorganic 
chemistry. They are being largely used for their properties to easily undergo reduction and 
oxidation and to interact with metal surfaces or complex metal ions. When different disulfides are 
mixed together, direct disulfide-disulfide exchange reaction occurred until redox equilibrium was 
reached, and for this property they have been recently considered in molecular dynamic library 
synthesis (Danieli et al., 2006). 
Disulfide bonds play also a key role in biological field. A very wide range of metabolic processes 
involved disulfide bond formation or reduction, from sugar and lipid metabolism and oxidative 
phosphorilation, to protein folding and stabilisation, cell signalling, aging, apoptosys, and so on, the 
major part of which have probably to be discovered (Appfel, 1976; Jordan, Gibbins, 2006). 
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Moreover, many diseases have been recently associated with redox imbalances, such as AIDS and 
other immune diseases, Parkinson and Alzheimer syndromes, cancer and many others (Reynolds et 
al, 2007; Bonomini et al., 2008; Huber, Parzefall, 2007; Wu et al, 2004). 
Recent researches demonstrated that cytoplasmic fluids are quite strongly reducing compared to 
extracellular fluids, such as plasma and other body fluids. As a consequence, disulfide bonds are 
stable in bloodstream but undergo reduction inside cells and therefore can be regarded as “smart” 
stimuli-responsive linkages in polymer therapeutic design for intravenous administration (Arpicco 
et al, 1997; Masuho et al., 1982; Miyata et al., 2005). Several publications reports on disulfides 
used as cleavable linkers in drug or gene delivery systems (Saito et al., 2003; Lin et al., 2007; Kwok 
et al., 2003). For these reasons, we decided to synthesise novel linear PAAs bearing pendant 2-
ethenyldithiopyridine moieties (PAA-SSPy) as intermediates for the synthesis of new bioactive 
macromolecular conjugates sensitive to electric stimuli by exchange reaction with thiol-containing 
active molecules. The strategy adopted consist of a two step synthesis: first a cystamine cross-
linked PAA was synthesised, in fact, having cystamine two primiary amine groups, react in 
polyaddition reaction as tetra-functional monomer, thus generating a hydrophilic tri-dimensional 
network; second, the hydrogel obtained was de-reticulated by direct disulfide exchange reaction 
with dipyridyl disulfide (Scheme 4.1).  
A linear and soluble PAA with 2-Ethenyldithiopyridine pendants was obtained, that can be 
regarded as a precursor for thiol containing bioactive molecules conjugates. Ethenyl-dithiopyridine 
group is in fact extremely reactive towards these reactions for which the driving force is provided 
by the production of 2-mercaptopyridine that, mostly turning into the tautomeric 2-thiopyridone 
form, is an excellent leaving group (Bulmus et al., 2003).  
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Scheme 4.1: general synthesis of PAAs containing 2-ethenyl dithiopyridine pendants. 
 
 
4.2 EXPERIMENTAL PART 
4.2.1 BAC20-PDEA. In a two necked flask, equipped with nitrogen inlet and stirring bar, BAC 
(0.134 g, 0.68 mmol), lithium hydroxide (0.034 g, 0.812 mmol) and pyridyl disulfide ethane amine 
(PDEA, 0.030 mg, 0.135 mmol) were dissolved in water (0.075 ml) under nitrogen. After 24 hours 
MP (0.054 g, 54.1 mmol) was added and the reactive solution maintained under stirring for 72 
hours and then diluted to 50 ml. The solution pH was adjusted to 2.5 by addition of a 1M 
hydrochloric acid aqueous solution and ultrafiltered over a 3000 nominal cut-off membrane. The 
product was eventually liophilized. Yield = 60.6%. nM  = 7500, wM  = 18000, d = 2.4.  
NMR of BAC30-SSPy hydrochloride: 1H NMR (D2O): δ (ppm) =  8.29, 7.71, 7-36, 7.19 (m, 
mercaptopyridine group, pattern A), 7.98, 7.56, 7.45, 6.92, (m, mercaptopyridine group, pattern B) 
5.56 (m, br, NH-CH-NH), 2.85-3.62 (m, br, N-CH, N-CH2, S-CH2), 2.70-2.74 (m, br, CO-CH2), 
1.37 (skeleton, CHCH3). UV spectrum (0.6 mg/ml): maxima 252 (0.32), 278 (0.39), 317 (0.41), 350 
(shoulder, 0.27). For comparison: PDEA (0.05 mM): 236 (0.29), 310 (0.35); Mercaptopyridine: 
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(0.06 mM): 272 (0.54), 343 (0.38). After addition of reducing agents no variations occurred in UV 
absorbance spectrum. 
 
4.2.2 HG-BP30. In a two-necked flask, BP (1.960 g, 10.0 mmol), cystamine di-hydrochloride 
(0.338 g, 1.5 mmol) and lithium hydroxide monohydrate (0.126 g, 3.0 mmol) were dissolved in 
water (3.5 mL) under nitrogen. 2-Methylpiperazine (0.701 g, 7.0 mmol) was added under stirring 
until a homogeneous solution was obtained. After 120 hours the gel obtained was finely ground, 
extensively washed with water, estracted with acetone, and dried at 30° C and 0.1 tor. Yield = 84%. 
Swelling: 2.7 (H2O); 1.8 (EtOH); 2.4 (CH2Cl2). (C15H26N4O2)0.7·n(C12H20N3O2S)0.3·n 
(294.4)0.7·n(270.38)0.3·n: Calcd. C 59.97, H 8.49, N 18.05, O 11.14; S 3.34; Found = C 58.53, H 8.78, 
N 16.45, O 12.84. 
HG-BP20, HG-BP10, HG-BAC30, HG-BAC20 and HG-BAC10 were prepared following the 
same procedure described for HG-BP30 (see Table 4.1 for reagents’ amounts). The HG-BAC series 
was treated with ethanol in place of acetone before drying. In all cases, the yields were 
approximately 85% and the elemental analyses agreed with the theoretical. The swelling degrees 
were: HG-BP20: 3.7 (H2O); 2.3 (EtOH); 3.9 (CH2Cl2); HG-BP10: 4.2 (H2O); 3.1 (EtOH); 6.6 
(CH2Cl2); HG-BAC30: 10.5 (H2O); HG-BAC20: 21.4 (H2O); HG-BAC10: 41.8 (H2O).  
 
Table 4.1: Preparation of cystamine cross-linked PAA hydrogels a)
Code BP (mmol) 
BAC 
(mmol) 
Cystamine .2HCl 
(mmol) 
LiOH.H2O 
(mmol) 
2-methylpiperazine 
(mmol) 
HG-BP10 10.0 - 0.5 1.0 9.0 
HG-BP20 10.0 - 1.0 2.0 8.0 
HG-BP30 10.0 - 1.5 3.0 7.0 
HG-BAC10 - 10.0 0.5 11.0 9.0 
HG-BAC20 - 10.0 1.0 12.0 8.0 
HG-BAC30 - 10.0 1.5 13.0 7.0 
           a) All hydrogels were prepared in 3.5 mL water. 
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4.2.3 BP30-SSPy. HG-BP30 (5.00 g, 1.13 mmol disulfide) was soaked in ethanol (30 mL) and 
2,2’-dipyridyldisulfide (0.750 g, 3.4 mmol) with catalytic 2-mercaptopyridine were added. The 
PAA gel dissolved within 5 hours. The reaction mixture was stirred for further 24 hours at r.t. and 
then diluted to 100 mL with water. Excess 2,2’-dipyridyldisulfide precipitated and was filtered out. 
The solution pH was then adjusted to 2.5 (HCl) , ultrafiltered through a membrane with nominal 
cut-off 3000 and liophilized.  
BP20-SSPy and BP10-SSPy were prepared as BP30-SSPY, using a three-fold molar excess of 
2,2’-dipyridyldisulfide with respect to disulfide units.  
BP30-SSPy: Yield = 70.4%. Yield of the exchange reaction (from NMR data) = 71.9%. nM  = 
9500, wM  = 32000, d = 3.3.  
BP20-SSPy: Yield = 64.9%. Yield of the exchange reaction (from NMR data) = 67.8%. nM  = 
47000, wM  = 190000, d = 4.0.  
BP10-SSPy: Yield = 83.4%. Yield of the exchange reaction (from NMR data) = 77.5%. nM  = 
40000, wM  = 130000, d = 3.2. 
Polymers of the BP series, as hydrochlorides, were soluble in water, methanol, DMSO, DMF, but 
insoluble in chloroform, acetone and most organic solvents; as free bases, soluble in DMSO, DMF 
chloroform and methanol, but insoluble in water, acetone, toluene, ether and ethylacetate.  
Complete 1H and 13C NMR characterization in reported in Table 2. The spectra of all samples 
equally confirmed the proposed structures. UV-Vis absorption spectra: 302, 235 
 
BAC10-SSPy, BAC20-SSPy and BAC30-SSPy were prepared by the same procedure, using a 2:1 
(v/v) water/ethanol mixture as reaction medium.  
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BAC30-SSPy: Yield = 69.2%. Yield of the exchange reaction (from NMR data) = 62.7%. nM  = 
25000, wM  = 47000, d = 1.8.  
BAC20-SSPy: Yield = 68%. Yield of the exchange reaction (from NMR data) = 66.1%. nM  = 
44000, wM  = 93000, d = 2.1.  
BAC10-SSPy: Yield = 85.6%. Yield of the exchange reaction (from NMR data) = 65.3%. nM  = 
26000, wM  = 52000, d = 2.0.  
All polymers of the BAC series were in all cases soluble in water, but insoluble in most organic 
solvents. 
NMR of BAC30-SSPy hydrochloride: Complete 1H and 13C NMR characterization in reported in 
Table 4.2. The spectra of all samples equally confirmed the proposed structures. 
 
Table 4.2. Relevant 1H and 13C chemical shifts (δ) of BP-SSPy and  
BAC-SSPy hydrochlorides in D2O. * 
BP-SSPy: R= -CH2-CH2- ; R'= -CH2-
BAC-SSPy: R= -CH(COOH) ; R'= -H
1 2
3
4
5
6
12
11n
m
1' 2'
8
9
10
7
13
14
N N
R
N N N
R
NN
O OH3C O O
R' R' R' R'
S
S
N
15
19
18
17
16
 
BP-SSPy 1H
13C
BAC-SSPy 1H
13C
2a
2.85;3.40
55.4
8
170.6
9
2.89
27.7
27.8
7/7'
-3.75
41.3
41.6
6/6'
3.65
44.6
44.8
1
3.42
56.35
1' a
3.15;3.65
48.85
2' a
3.00;3.42
49.6
Me-1
1.35
14.1
3
3.18
52.6
12
3.00
26.9
11
2.70;3.58a
51.9
10
2.18;3.57
48.5
13
3.48
50.7
2.90;3.46
55.1
2.73
29.8
172.8
172.9
5.15
58.0
58.15
3.46
56.25
3.19;3.62
48.3
3.10;3.46
49.3
1.33
13.9
3.14
52.5
2.83
28.7
3.51
51.5
3.22;3.62
48.5
3.20
50.1
4
2.86
28.2
2.70
30.3
14
2.98
26.8
2.70
31.7
15
156.6
156.8
5
170.9
171.6
5'
170.5
8'
170.3
 
a for 1H resonance: AB system 
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4.2.4 BAC10-SSNBA was prepared by the same procedure described for BAC10-SSPy but 
replacing 2,2’-dipyridyldisulfife with 5,5’-dithiobis(2-nitrobenzoic) acid (Ellman’s reagent, 0.5g). 
NMR of BAC30-SSPy hydrochloride: 1H NMR (D2O): δ (ppm) = 8.03 (broad, nitrobenzoic 
residue, -C(NO2)-CH-), 7.67 (broad, nitrobenzoic residue, -C(CO2H)-CH-C(S-)-), 7.60 (m, 
pyridine, -C(S-)CH-CH), 5.56 (m, br, NH-CH-NH), 2.85-3.62 (m, br, N-CH, N-CH2, S-CH2), 2.70-
2.74 (m, br, CO-CH2), 1.37 (skeleton, CHCH3). 
 
4.2.5 BP30-SSG. BP30-SSPy hydrochloride (0.3 g, 0.149 mmol SSPy units) was dissolved in 20 
mL TRIS buffer under nitrogen pH 8.50 and the solution purged with nitrogen. L-Glutathione 
reduced (0.0458 g, 0.149 mmol) was added. The solution turned immediately intensely yellow. 
After 30m a 1 M HCl aqueous solution was addet until pH 2.5 was reached, the solution was diluted 
with water (300 mL), ultrafiltered and isolated as in the previous cases. Yield = 82.8 %. Reaction 
yield ≃100%.  
nM =28 000 wM =51 000, d = 1.82. α[ ]D25= -7.4 deg·dm-1·g-1·cm3, (c=1 in H2O). For comparison 
purposes, L-glutathione reduced = –17.2 deg·dmα[ ]D25 -1·g -1·cm3, (c=2 in H2O). 
1H NMR (D2O): δ (ppm) = 8.43 (m, pyridine, N-CH-CH), 7.84-7-87 (m, pyridine, N-C-CH-CH), 
7.35 (m, pyridine, N-CH-CH), 3.77 (glycine residue, HO-CO-CH2-NH), 2.88-3.65 (m, br, CO-CH2, 
N-CH, N-CH2, S-CH2), 2.15 (glutamic acid residue, H2N-CH-CH2-CH2), 2.09 (glutamic acid 
residue, H2N-CH-CH2), 1.38 (d, CHCH3). 13C NMR (D2O): δ (ppm) = 170.59-171.11 (, C=O), 
156.86 (pyridine, N-C), 149.76 (pyridine, N-CH), 139.24 (pyridine, N-C-CH-CH), 122.82 (m, 
pyridine, N-CH-CH), 122.14 (pyridine, N-C-CH), 43.33 (glycine residue, HO-CO-CH2-NH), 
41.46-56.48 (C-N, C-S), 31.59 (glutamic acid residues, H2N-CH-CH2-CH2), 26.94-28.34 (C-CO), 
26.28 (glutamic acid residue, H2N-CH-CH2), 14.18 (, CHCH3).  
BAC30-SSG was prepared by a similar procedure. Yield = 78.2 %. Reaction yield ≃100%.  
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nM  = 24 900, wM  = 42 000, d = 1.69. α[ ]D25= -5.4 deg·dm-1·g-1·cm3, (c=1 in H2O). The NMR 
spectra were as expected. 
 
4.2.6 BAC30-SSG-UV: BAC30-SSPy hydrochloride (20.0 mg, 12.0 μmol SSPy units) was 
dissolved in 50 mL 0.1M TRIS buffer pH 8.50 and the solution purged with nitrogen. A quartz 
cuvette was loaded with a 2 ml aliquot of the polymer solution and closed with a rubber stopper. A 
L-glutathione reduced solution, obtained dissolving L-glutathione reduced (2.5 mg, 8.1*10-3 mmol) 
in purged TRIS buffer (2 ml), was added in 10,0 μl aliquots with a Hamilton gastight syringe. After 
each addition, the solution was allowed to equilibrate for 5 minutes and a UV-spectrum was 
recorded.  
 
4.3 RESULTS AND DISCUSSION 
The rationale of this work was to obtain a new family of functionalized PAAs bearing pendant 2-
ethenyldithiopyridine moieties, to be used as intermediates in the preparation of smart soluble 
polymer conjugates sensitive to reductive cleavage.  
The first and most logic strategy was the direct co-polymerization of bis(acrylamido)acetic acid 
(BAC) with 2-methylpiperazine (2MP) and pyridyl disulfide ethane amine (PDEA), that in a single 
step would lead to the desired product. Following this route, a polymer was obtained as shown by 
SEC traces, but 1H NMR spectra showed two different signal patterns due to the presence of 
aromatic rings (confirmed by COSY experiments) and different form the typical pattern of 
ethenylditiopyridin groups. UV-Vis absorption spectrum again confirmed what shown by NMR 
spectrum. Moreover, after addition of glutathione reduced, no change in the spectrum occurred, thus 
indicating an important decomposition of ethenyldithiopyridine groups during the reaction, 
probably due to the strong basicity, and affecting final product reactivity.  
 
 
43 
CHAPTER 4 – Synthesis of new polymeric precursors of  PAA-drug or PAA-protein conjugate by disulfide bond. 
For this reason a different synthetic route was chosen, consisting in two synthetic steps: 
cystamine cross-linked PAA networks were first prepared (Scheme 4.1a) and then converted into 
linear soluble PAAs bearing activated disulfide pendants by exchange reaction of the cross-linking 
cystamine moieties with 2,2’-dithiodipyridine (Scheme 4.1b).  
Six different cross-linked PAA samples were obtained by reacting bis(acryloyl)piperazine BP 
(HG-BP10, HG-BP20 and HG-BP30) or BAC (HG-BAC10, HG-BAC20 and HG-BAC30) with 2-
methylpiperazine as co-monomer and three different amounts of cystamine as cross-linker. More 
precisely, in HG-BP10 and HG-BAC10 the amount of the amine hydrogens of cystamine over the 
total number of amine hydrogens was 10%, whereas in HG-BP20 and HG-BAC20 this amount was 
20%, and in HG-BP30 and HG-BAC30 30%. The molar ratios of the reagents used in each 
preparation are reported in Table 4.1. The choice of the two different bisacryl amides lead us to 
obtain two PAA families with different ionic behaviour, a purely polycationic (BP series) and an 
amphoteric PAA (BAC series). 
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Figure4.1: general structure of PAAs containing reactive pendants towards thiol exchange reaction; a) BAC-SSPy; b) 
BP-SSPy; c) BAC-SSNBA. For n:m ratio see text. 
 
The exchange reactions were performed on finely ground PAA networks swollen in ethanol (HG-
BP series) or in 2:1 (v/v) water/ethanol mixture (HG-BAC series) under slightly alkaline conditions 
(pH 8.5-9 after dilution with water) and in the presence of a catalytic amount of 2-mercaptopyridine. 
A 3:1 excess 2,2’-dipirydyldisulfide with respect to cystamine moieties was employed in all cases. 
The reaction mixture turned to a clear homogeneous solution in few hours, the dissolution time 
largely depending on the particle size of the hydrogels. The reaction was then allowed to proceed 
for further 24 hours. The final products were purified by ultrafiltration and recovered by 
lyophilization, invariably leading to linear soluble polymers (Figure 4.1, a and b).  
Similar results were obtained by substituting 5,5’-dithiobis(2-nitrobenzoic acid) (Ellman’s 
reagent) for 2,2’-dipyridyldisulfide (Figure 4.1, c). The properties of the resultant products were on 
the most the same.  
 
The molecular weights of the linear PAAs obtained, BP10-SSPy, BP20-SSPy, BP30-SSPy 
BAC10-SSPy BAC20-SSPy and BAC30-SSPy, were of the same order as those of most 
“traditional” PAAs. This chemically proves that all the four hydrogens of cystamine participate in 
the polyaddition reaction notwhistanding the chemical constrains of a cross-linked network.  
Solubility tests showed that the solubility properties of dithiopyridyl-functionalized PAAs based 
on BAC are similar to those of the un-functionalized polymer. By contrast, functionalized BP-based 
PAAs are insoluble in water whereas still soluble in aqueous acids.  
All dithiopyridyl-containing PAAs were fully characterized by NMR spectroscopy. Disulfide 
exchange reaction yields were calculated by the integral ratio of the signals at 1-1.5 ppm (assigned 
to the methyl group of 2-methylpiperazine residue) and at 7.3 ppm (referred to the proton β to the 
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nitrogen of pyridyl disulfide moiety). The 1H spectrum of BP10-SSPy is reported in Figure 4.2 as 
typical example. 
 
Figure 4.2: 1H spectrum of BP10-SSPy. Integral ratio between 2MP methyl signal (1.17 ppm) and pyridyl moieties 
signals (8.36, 7.80, 7.28 ppm) is used to calculate reaction yield and degree of functionalisation for each PAA-SSPy 
product. 
 
The number of pyridyl groups found in the polymers was always somewhat lower than expected; 
the figures reported in the Experimental part as “yield of the exchange reaction” refer to the ratio 
between the found and the expected dithiopyridyl content. However, it is unlikely that the exchange 
reaction was really incomplete, since the starting hydrogels were in all cases completely solubilized 
long before the reaction was stopped. This behaviour could be ascribed, instead, to possible 
elimination of some highly functionalized low molecular weight fractions during ultrafiltration. In 
all cases, for simplify reading, the soluble exchange products are labelled according to the 
functionalization degree of the parent hydrogels. 
Ethenyl dithiopyridine groups reactivity was ascertained by means of reaction with a model oligo 
peptide containing a thiol group, namely glutathione reduced. The reaction was performed in 
deoxygenated aqueous solution, with a slight basic catalysis, with an equimolar amount of the 
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peptide with respect to the molar amount of polymer pendants (Scheme 4.2). After addition of 
glutathione reactive solution turned immediately to a yellow colour, due to the presence of 
mercaptopyridine, and the reaction was allowed to proceed for 30 minutes. After purification, the 
NMR spectra of the resultant products (BP30-SSG and BAC30-SSG) showed the presence of L-
glutathione diagnostic carbon atom resonance peaks at 26.13, 53.87, 59.84, 172.44, 173.59 and 
174.80 ppm and, in parallel, the disappearance of the aromatic protons of pyridine. As expected, 
both BAC30-SSG and its BP-deriving counterpart BP30-SSG showed optical rotation power.  
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Scheme 4.2: exchange reaction between grutathione reduced and PAAs ethenyl dithiopyridine pendants. 
 
A special reaction was monitored by UV-Vis spectroscopy. Spectra were recorded after the 
addition of small aliquots of glutathione reduced to the polymer solution and their superimposition 
is reported in Figure 3. The dark blue line represents the spectrum of the polymer solution at the 
beginning of the reaction: the peak at 302 nm and the shoulder at 235 nm are ascribed to the linked 
mercapto-pyridine, beeing polymer backbone absorbing at 220 nm.  
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During the exchange reaction, a strong bathochromic effect is observed due to the formation of 
free mercapto-pyridine. The reaction was very fast and quantitative, non further changes occurring 
after the 5 minutes necessary to obtain a homogeneous solution. This finding confirmed that 
ethenyldithiopyridinegroups reactivity is not affected by insertion in the PAAs chain.  
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Figure 4.3: Overlap of UV-Vis absorption spectra collected during ehchange reation between glutathione reduced 
and BAC30-SSPy. Dark blue line represents the spectrum registered at the beginning of the reaction, red line the one 
registered at the end 
 
When an equimolar amount of glutathione reduced was added, the typical absorption spectrum of 
mercapto-pyridine, with maxima at 343 and 265 nm, (red line) was observed and no further change 
occurred to the absorption spectrum if more reducing agent was added. UV determined final 
concentration of mercaptopyridine was in good agreement with the expected. 
 
4.4 CONCLUSIONS 
In this work, cystamine was used as cross-linking agent for obtaining families of PAA hydrogels 
with different structure and various amount of disulfide containing cross-linkers. These hydrogels 
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react with symmetrical activated aromatic disulfides, such as 2,2’-dipyridyl disulfide, yielding 
linear PAA carrying as side substituents activated disulfides. This functional groups can enter under 
mild conditions into exchange reactions with thiols, including thiol-containing peptides such as L-
glutathione reduced, producing conjugates with disulfide bonds, that are stable in bloodstream and 
easily reduced inside cells. For these reasons PAA-SSPy can be regarded as important synthetic 
intermediates for “smart” PAA conjugates of biologically active molecules, peptides or proteins 
containing either original or artificially introduced SH groups.  
Applications of this polymeric precursor and synthetic strategy are reported in the following 
chapters. 
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CHAPTER 5 
 
Synthesis of nano-structured  
PAA-Cholesterol conjugates 
 
 
5.1 INTRODUCTION 
In the last years, increasing attention have been paid by chemistry and pharmacology research in 
the field of drug delivery systems. Poor solubility of drug is one of the most limiting problem in 
new drugs application. Hydrophilic-hydrophobic compounds, among which block co-polymer or 
polymer conjugates, are regarded as promising structure in view of their use in drug delivery. In 
fact, in aqueous environment these molecules self assemble into nano- or micro-particles in which 
the lipophilic part tend to segregate into domains, capable of remarkable payloads of hydrophobic 
molecules which solubility resulted enhanced of several times. A general review concerning 
polymeric nanoparticles is reported in Chapter 1.  
 
Among amphiphilic polymers, increasing attention has been recently paid to cholesterol 
conjugates of hydrophilic polymers; cholesterol is one of the most common membrane sterols and 
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plays a relevant role in living organism metabolism and in particular in self-association of 
molecules in biological environments. A wide range of hydrophilic polymers, such as natural or 
modified polysaccharides, poly(ester-amine), poly-l-lysine, polyethyleneimine, acryl and vinyl 
polymers, have been used to obtain hydrophilic-hydrophobic conjugates that exhibit a strong 
tendency to self-association even at low cholesterol contents and have been studied as gene 
transfection agents, promoters of intracellular delivery of proteins, carriers of lipophilic anticancer 
drugs and scaffolds for tissue engineering (Yusa et al., 2000; Xu et al., 2005; Sugimoto et al., 2005; 
Wang et al., 2006; Iwasaki et al., 2006; Wang et al., 2007; Matsusaki et al., 2005; Akiyiama et al., 
2007; Morimoto et al., 2005; Akiyoshi et al., 1997; Akiyoshi et al., 1997). 
 
In the present part of this work, we report on preparation, NMR and morphological 
characterization and preliminary cytotoxicity evaluation of new PAA-cholesterol conjugates, in 
which the cholesterol pendants are linked to the polymer backbone through redox-sensitive 
disulphide bonds. These PAA-cholesterol conjugates have been obtained using the polymeric 
precursors which synthesis is reported in the previous chapter, and are expected to self assemble in 
aqueous media into hydrophilic/hydrophobic nanoaggregates or nanogels, characterized by strong 
hydration of the outer shell due to the highly hydrophilic nature of the PAA portion and endowed 
with a significant loading capability of lipophilic drugs in the hydrophobic domains. They are also 
expected to retain the same behavior of the parent polymers in the biological environment, as low 
cytotoxicity, ability to promote intracellular trafficking of bioactive molecules, and, in the case, 
stealth-like properties, since in the biological fluids only the hydrophilic polymer chain is exposed. 
The linkage between cholesterol and PAA chain is obtained by means of redox sensitive disulfide 
bonds. After internalization, these PAA-cholesterol conjugates are expected to be rapidly dissolve, 
releasing a drug payload, if present.  
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5.2 EXPERIMENTAL PART 
5.2.1 Instruments.  
All NMR experiments were performed on a Bruker Avance 500 spectrometer, operating at 
500.13 MHz (
1
H) and at 125.62 MHz (
13
C). All deuterated solvents were purchased from Aldrich. 
For all other instruments see Appendix 2: Common materials and methods. 
 
5.2.2 Materials 
Cell line 3T3/BALB-c Clone A31 mouse embryo fibroblasts (CCL163) was obtained from the 
American Type Culture Collection (ATCC) and propagated as indicated by the supplier. Dulbecco’s 
Modified Eagles Medium (DMEM), 0.01 M pH 7.4 phosphate buffer saline without Ca2+ and Mg2+ 
(PBS), Calf serum (CS), trypsine/EDTA, glutamine, and antibiotics (penicillin/streptomycin) were 
purchased from GIBCO Brl. Cell proliferation reagent WST-1 was purchased from Roche 
Diagnostic. Tissue culture grade disposable plastics were obtained from Corning Costar. 
 
5.2.3 Synthesis of PAA-SSChol.  
All polyamidoamine-cholesterol conjugates were prepared according to a similar procedure. As 
model reaction, only BP-SSChol2 synthesis is reported. Parent polymers used in PAA-SSChol 
syntheses, namely BP-SSPy1, BP-SSPy2, BAC-SSPy1, BAC-SSPy2, were prepared following the 
procedure described in Chapter 4. Two different compositions for each polymer series in term of 
initial cystamine content were investigated, leading to the final polymers structures described 
below.  
BP-SSPy2 hydrochloride (1.005 g, 2.6 mmol repeating units, 0.43 mmol SSPy units) and 
thiocholesterol (0.191 g, 0.47 mmol) were introduced in a two necked flask, equipped with 
magnetic stirring, and purged with nitrogen. De-oxygenated chloroform/methanol=9/1 mixture (60 
mL) and triethylamine (0.3 mL, 2.6 mmol) were added and the solids allowed to dissolve under 
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nitrogen. The solution turned yellow in few minutes, the reaction mixture was allowed to react for 
further 15 hours, then the organic solution was poured in water (50 ml). The solution pH was 
adjusted to 2.5 adding 1M HCl aqueous solution and a emulsion was obtained. The suspension was 
concentrated to 40 mL by evaporation in vacuo, then water (50 mL) was added. The final aqueous 
suspension was extracted with diethylether (2 x 200 mL) and then dialyzed with a 12,000 nominal 
cut-off tube against a 80/20 v/v water/methanol mixture till complete disappearance of 
mercaptopyridine (UV monitored). The ultrafiltered suspension was eventually lyophilized.  
BP-SSChol1 was prepared following the procedure described above. BAC-SSChol1 and BAC-
SSChol2 were prepared following the same procedure but using 1/1 water/chloroform emulsion as 
reaction medium in place of methanol/chloroform mixture. Reagent thiocholesterol amount was 
always 1.1 mol per mol of ethenyl dithiopyridine units of the starting polymer.  
 
BP-SSChol1: yield = 60%. Cholesterol content: 7.8% w/w (calculated on the basis of the parent 
polymer functionalization, BP-SSPy1). Elemental analysis: found = C 52.3, H 10.1, N 14.9, S 1.35; 
calculated = C 58.4, H 8.0, N 14.5, S 1.3. IR (cm-1): 3422 (amide N-H stretching), 2928-2858 (C-H 
stretching), 1637, broad (amide C=O stretching), 1439-1385 (CH2 (bending), 1221 (amine C-N 
stretching), 1016 (CH bending). = -1.4 deg·dmα[ ]D25 -1·g-1·cm3 (for comparison, thiocholesterol 
= -23 deg·dmα[ ]D25 -1·g-1·cm3). As free base: soluble in chloroform, dichloromethane, methanol, 
dimethylsulfoxide, insoluble in water. As hydrochloride salt: insoluble in organic solvents, in 
aqueous solution formed suspensions.  
BP-SSChol2: yield = 62%. Cholesterol content: 16.4% w/w. Elemental analysis: found = C 51.7, 
H 9.4, N 13.4, S 3.16; calculated = C 62.2, H 7.9, N 12.1, S 2.6. α[ ]D25 = -2.7 deg·dm-1·g-1·cm3. 
Solubility as BP-SSChol1. As for the PAA bearing ethenyldithiocholesterol pendants, only BP-
SSChol2 was considered, performing the integration between the methyl carbon of the 
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methylpiperazine ring and one of methyl signals of the cholesterol moiety; the observed values 
confirmed the n:m ratios of the starting material.  
 
BAC-SSChol1: yield = 61%. Cholesterol content: 7.3% w/w. Elemental analysis: found = C 50.6 
H 8.2, N 16.7, S 0.9; calculated = C 48.2, H 7.1, N 15.7, S 0.9. IR (cm-1): 3416 (amide NH 
stretching), 3281 (carboxylic acid OH stretching), 2967-2828 (CH stretching), 1650-1621, broad 
(amide and carboxylic C=O stretching), 1519 (amide NH bending), 1454-1385 (CH2 bending), 
1129 (amine C-N stretching), 1134 (CH bending). Solubility: insoluble in water and in organic 
solvents; in aqueous solution formed suspensions.  
BAC-SSChol2: yield = 62%. Cholesterol content: 13.1% w/w. Elemental analysis: found = C 
50.7, H 8.2, N 17.1, S 2.2; calculated = C 50.2, H 7.3, N 14.3, S 2.0. Solubility as BAC-SSChol1.  
Complete 1H and 13CNMR characterization of the two series of polymers is reported in Table 5.1. 
 
Table 5.1. Relevant 1H and 13C chemical shifts (δ) of PAA-cholesterol derivatives.* 
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*BP-SSChol in CDCl3/CD3OD ( 95:5 ratio) as solvent (HR NMR),BAC-SSChol hydrochloride in D2O ( HR NMR )  
and BAC-SSChol swelled in CDCl3 (HRMAS NMR).  See the text for major explications 
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5.2.4 Loading capacity.  
The uptake ability towards hydrophobic substances was estimated by measuring the amount of 
azobenzene and estradiol dissolved into the hydrophobic core of the PAA-SSChol nanoparticles 
samples. The hydrophobic substance (1.5 mg) was added to the polymer solution (1.5 mg polymer 
in 1.5 mL of water), adjusted to pH 7.4 in PBS 0.01N, in presence of a small amount of methanol 
(15 μL). After 48 hours the volume was firstly reduced under vacuum to remove methanol, then 
restored to 1.5 mL with water and the suspension filtered with a 0.45 μm pore size filter to remove 
the undissolved hydrophobic molecule. Methanol was added to the filtered solution in an equal 
volume and absorption intensity was measured by UV-Vis spectroscopy at 430 nm for azobenzene 
and 280 nm for estradiol. A similar sample without polymer was prepared as a blank and the 
hydrophobic molecule absorption subtracted to the polymer sample ones. The amount of 
hydrophobic substance was determined with a pre-prepared analytical curve.  
 
5.2.5 Biological evaluations. 
Cell Line. Cytoxocity evaluations of the investigated materials were carried out using the 
3T3/BALB-c Clone A31 cell line. Cells were grown in DMEM containing 10% CS, 4 mM of 
glutamine, and 100 U/mL:100 íg/mL penicillin:streptomycin (complete DMEM). 
Subculturing. A 25 mL flask containing exponentially growing 3T3 cells was observed under and 
inverted microscope for cell confluence. The complete DMEM media was then removed, and cells 
were rinsed for a few min with PBS. The buffer solution was removed, and cells were incubated 
with 0.5 mL of trypsin/EDTA solution at 37 °C in 5% CO2 incubator for 5 min or until the 
monolayer started to detach from the flask. Cells were suspended in an appropriate volume of 
DMEM and plated at a split ratio of 1:6 or 1:10 in a 75 mL flask. 
For routine culturing and evaluation of morphology, cells were analyzed under an inverted 
microscope Nikon Eclipse TE2000-U. 
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Determination of IC50 of Polymeric Materials. The IC50 (50% inhibitory concentration, that is 
the material concentration at which 50% of cell death in respect to the control is observed) of the 
investigated polymers was evaluated by exposing cells for 24 h to DMEM containing different 
polymer concentrations (1 to 10 mg/ml). At the end of the exposure time, cells were incubated with 
WST-1 cell proliferation reagent for the quantitative evaluation of cell proliferation. 
Cell Proliferation Assay. Quantitative proliferation was assayed by using the cell proliferation 
reagent WST-1 and by following the protocol indicated by the manufacturer. Briefly, cells were 
allowed to proliferate in DMEM containing different concentration of polymeric materials and then 
incubated or 4 h with an appropriate volume of WST-1 tetrazolium salts. Formazan production was 
detected at 450 nm, with 620 nm as reference wavelength using an ELISA microplate reader 
(Biorad). 
 
5.3 RESULTS AND DISCUSSION 
The new PAA-cholesterol conjugates were obtained by thiol-exchange reaction of thiocholesterol 
with PAA precursors bearing ethenyldithiopyridyl pendants (PAA-SSPy). Four PAAs where chosen 
as precursors, two purely cationic (BP-SSPy1 and BP-SSPy2) and two amphoteric (BAC-SSPy1 
and BAC-SSPy2). They were prepared by employing 1,4-bisacryloylpiperazine (BP) and 2,2-
bisacrylamidaocetic acid (BAC), respectively, as bisacrylamide monomers.  
 
5.3.1 Synthesis of PAA-SSChol.  
Different PAA-cholesterol conjugates were obtained by thiol exchange reaction of thiocholesterol 
with the ethenyl dithiopyridine units of BP-SSPy and BAC-SSPy precursors, which syntheses an 
characterization have been previously developed and studied. Full discussion is reported in Chapter 
4: “Synthesis of new polymeric precursors of PAA-drug or PAA-protein conjugate by disulfide 
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bond”. We decided to use both polymer series in order to have a comparison between cholesterol 
conjugates of both cationic and amphoteric PAAs. 
In the case of BP-SSPy polymers (Scheme 5.1), the thiol exchange reaction was performed in a 
1:9 (v/v) methanol/chloroform, where both reactants were soluble, whereas in the case of BAC-
SSPy (Scheme 5.2) the reaction was performed in a chloroform/water slurry, thiocholesterol 
residing in the former solvent and BAC-SSPy in the latter.  
The thiol exchange reactions went to high yields in the presence of triethylamine as basic 
catalyst. Stronger inorganic bases lead invariably to undesired side reactions and were therefore 
discarded as catalysts. When the reaction was complete, water was added to the reaction mixtures 
and the raw products were acidified to pH 3.5 with dilute hydrochloric acid. The organic solvents 
were then stripped under vacuum, the resultant suspension extracted with diethyl ether to eliminate 
excess thiocholesterol, and eventually dialyzed against an 80:20 water:methanol mixture until the 
complete disappearance of the 2-mercaptopyridine byproduct (UV monitoring). Purified products 
were obtained in yields higher than 60%. 
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Scheme 5.1: BP-SSChol syntesis. 
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Scheme 5.2: BAC-SSChol syntesis. 
 
All product formed stable cloudy suspensions in water. The polymers of the BP series, as 
hydrochlorides, were insoluble in chloroform, dichloromethane, methanol and dimethylsulfoxide, 
whereas, as free bases, showed good solubility in some organic solvents, such as methanol and 
chloroform. As a consequence, it was possible to perform Specific Optical Rotation measurements 
and NMR analyses of these products in solution. Indeed, these products showed Specific Optical 
Rotation ability revealing the presence of chiral moieties linked to the otherwise non-chiral polymer 
chain. The conjugates of the BAC series were insoluble in organic solvents in all conditions. 
The IR spectra of all products showed the presence of carbonyl, amino and amido groups. The 
absence of peaks due to aromatic compounds confirmed that reaction proceeded to completeness 
and 2-mercaptopyridine was completely eliminated. Elemental analyses were as expected. In 
particular the agreement between the found and calculated nitrogen and sulfur percentage was 
excellent. 
 
5.3.2 NMR characterization 
BP-SSChol NMR characterization of this amphiphilic polymers represented an interesting 
challenge. 1H and 13C NMR spectra of BP series polymer, soluble in organic solvents as free base, 
were first recorded in DCl3/CD3OD 9/1 and the chemical shift assignments were reported in Table 
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5.1. The assignments relative to the cholesteryl moieties were obtained by comparison with the 
spectral data of the starting thiocholesterol. All proton and carbon resonances were very similar to 
the thiocholesterol’s ones with the exception of those belonging to the A ring, in which the thiol 
group was replaced by a disulphide function. In particular, the C-15, C-16, and C-20 resonances, 
observed in the 13C spectrum of thiocholesterol, at 39.7, 44.2 and 34.0 ppm, respectively, were 
shifted at 49.9, 38.4 and 28.9 ppm, respectively (Figure 1,a). These chemical shift changes 
suggested the presence of cholesteryl moieties bound to the main backbone with a disulphide 
linkage. Remarkably, the lines of cholesterol resonances were sharp in both 1H and 13C spectra in 
CDCl3 (Figure5.1,a and 5.2,a) whereas those of the PAA backbone much broader. This behavior, 
never observed in the case of the BP-SSPy parents, was ascribed to the tendency of BP-SSChol to 
undergo phase association. The hypothesis is that in CDCl3 the hydrophilic PAA portion of the 
conjugates partially segregates giving rise to a reversed-micellar structure. This reduces mobility 
giving rise to line broadening. 
 
Figure 5.1: 13C spectra of BP-SSChol2 in a) CDCl3 an b) D2O. 
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This hypothesis was confirmed by the observation of an analogous, but exactly reversed behavior 
in D2O, in which both proton (Figure 5.2,b) and carbon (Figure 5.1,b)spectra of BP-SSChol 
hydrochloride revealed only PAA backbone’s signals, thus indicating the complete loss of mobility 
of cholesteryl residues.  
 
Figure 5.2 1H spectra of BP-SSChol2 in a) CDCl3 an b) D2O. ?Impurity (TEA) 
 
The obvious explanantion is that BP-SSChol conjugates undergo phase segregation of insoluble 
cholesteryl domains while water soluble PAA segments completely dissolve in D2O.  
 
BAC-SSChol. Since these conjugates are not soluble in organic solvents, but only swell in CDCl3, 
the HRMAS technique was used to perform the NMR study. Interestingly, the resulting NMR 
spectra showed exclusively signals ascribable to the cholesterol residues and the ethylendithionyl 
bridges. The 
1
H and 
13
C assignments reported in Table 1 were indeed in agreement with the 
chemical shift values previously found for the cholesteryl moiety of BP-SSChol. In addition, it was 
possible to recognize the C-11 and C-12 signals of the ethylendithionyl segment at 44.2 and 29.7 
ppm, respectively. ( Figure 5.3,a). 
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Figure 5.3: 13C spectra of BAC-SSChol2 in a) CDCl3 an b) D2O. 
 
In contrast, the spectra of BAC-SSChol hydrochloride conjugates, which give stable dispersions 
in D2O, revealed only PAA backbone’s resonances, in agreement with the previously reported 
BAC-SSPy’s assignments (Figure 5.3,b and 5.4,b). Therefore, the chemical shifts reported in Table 
5.1 are referred to the spectra of BAC-SSChol swelled in CDCl3 (HRMAS), for the cholesterol 
residue, and to BAC-SSChol hydrochloride in D2O, for the polymer the backbone.  
This result points to the conclusion that, as in the case of BP-SSChol conjugates, even in BAC-
SSChol ones hydrophobic cholesteryl units segregate from D2O into insoluble lipophilic domains, 
which completely lose their mobility and are therefore not revealed by NMR spectroscopy.  
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Figure 5.4: 1H spectra of BAC-SSChol2 in a) CDCl3 an b) D2O. 
 
 
5.3.3 Morphological characterization.  
The dimensions of PAA-cholesterol nanoaggregates in aqueous media were determined by 
Dynamic Light Scattering (DLS) and their morphological analyses performed by Transmission 
Electron Microscopy (TEM).  
Each sample was routinely filtered through 1 and 0.45 μm porosity filters, prior to DLS and TEM 
analyses respectively. Filtrate solutions invariably showed, upon drying, a nearly quantitative 
recovery of the initial sample.  
Since PAAs carry ionizable groups, DLS analyses were performed at two different pHs, namely 
pH 3 and 7.4, in order to evaluate pH-mediated conformational changes. Data obtained, averaged 
over measurements performed in triplicate are reported in Table 5.2.  
All PAA-cholesterol conjugates were found to self-assemble in nanoparticles with narrow 
monomodal diameter distributions ranging between 100 and 300 nm. It may be observed that BP-
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based nanoparticles exhibited invariably larger dimensions than BAC-based nanoparticles with 
similar cholesterol content, probably due to the lower hydrophilicity of the BP-based PAA 
backbone, which reduces dispersion ability and leads to a larger aggregates. Moreover, BP-based 
nanoparticles undergo a considerable increase in diameter as the solution pH increases. This result 
may also be ascribed to the larger nanoparticle aggregation related to the decrease in the net positive 
charge, hence in hydrophilicity, occurring in the polymer backbone of BP-based PAAs.  
 
Table 5.2: DLS Analyses of PAA-SSChol conjugates. 
Sample pH 3 pH 7.4 
 Da (nm) SDb (nm) D (nm) SD (nm) 
BP-SSChol1 157 2.8 241 15.9 
BP-SSChol2 186 6.5 261 21.4 
BAC-SSChol2 106 3.7 122 6.5 
BAC-SSChol1 109 3.1 117 6.4 
a D = diameter of the most frequent particle fraction. 
b SD = standard deviation from D value. 
 
TEM imaging experiments, performed on dried samples prepared by means of a negative staining 
technique, lead invariably to results similar to those reported in Figure 5.5, referring to a BAC-
SSChol2 sample.  
 
Figure 5.5: TEM image of BAC-SSChol2 nanoparticles obtained with negative staining technique. 
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Homogeneous round-shaped nanoparticles were revealed, characterized by a quite regular 
diameter distribution centered around 40 nm. As expected, nanoparticles’ diameter determined by 
TEM in the dry state was invariably approximately 3 times smaller than those obtained by DLS in 
aqueous media. This finding confirms the large water absorption ability of PAA-cholesterol 
conjugates, ascribed to their amphiphilic nature. These may be therefore defined as true 
nanohydrogels, characterized by a water absorbing PAA matrix and insoluble cholesteryl domains 
as physical cross-links.  
 
5.3.4 Evaluation of uptake ability of PAA-cholesterol conjugates towards hydrophobic 
substances. 
The uptake ability of PAA-cholesterol towards two different hydrophobic probes, namely 
azobenzene and estradiol, was estimated by measuring the amount of probe “solubilized” by the 
conjugates by means of UV measurements, in comparison with the amount solubilized by plain 
water and aqueous PAA solutions. Azobenzene was chosen due to its high lipophilicity and its 
strong absorbance of UV light, that made it easy to detect its concentration even in very dilute 
solutions. Estradiol was instead chosen for its structure affinity with cholesterol, which was 
expected to increase the uptake ability. The amount of azobenzene and estradiol uptaken by each 
PAA-cholesterol sample is reported in Table 5.3.  
The uptake ability ranged between 9 and 20% of the polymer conjugates on a weight to weight 
basis. It may be observed that a good proportional relationship exists between the amount of 
hydrophobic probes “solubilized” and the amount of cholesterol moieties in the conjugate. This 
gives clear indication that lipophilic probes were absorbed in the hydrophobic cholesterol domains. 
Moreover, the observed uptake ability of the PAA-cholesterol conjugates was comparable to what 
 
 
64 
CHAPTER 5 – Synthesis of nano-structured PAA-cholesterol conjugates 
elsewhere reported with other amphiphilic polymers, even if with different lipophilic probes (wang, 
et al., 2005; Iwasaki, Akiyoshi, 2006; Wang et al., 2007). 
 
Table 5.3: Evaluation of uptake ability of hydrophobic substances for PAA-SSChol conjugates. 
a weight ratio of the lipophilic probe versus cholesterol contained in the polymer conjugate. 
Sample 
Azobenzene/ 
PAA-SSChol 
(mg/g) 
Azobenzene/ 
cholesterola
(w/w) 
Estradiol/ 
PAA-SSChol 
(mg/g) 
Estradiol/ 
cholesterola
(w/w) 
BAC-SSChol1 131 1.8 90 1.3 
BAC-SSChol2 288 1.8 124 0.8 
BP-SSChol1 94 1.1 129 1.5 
BP-SSChol2 210 1.3 189 1.1 
 
 
5.3.5 Biological evaluations 
The cytoxocity (cellular compatibility) of PAA-cholesterol conjugates was assessed by in vitro 
cytotoxicity assays performed against 3T3/BALB-c Clone A31 cell lines. Cells were incubated for 
24 hours with the polymer solutions and then analyzed for viability with WST-1 tetrazolium salt, 
which allows for the quantitative evaluation of metabolically active cells. The resulting IC50 values, 
namely BP-SSChol1: 1.5, BP-SSChol2: 3, BAC-SSChol1: >10; BAC-SSChol2: 3 mg/ml, point to 
the conclusion that all PAA-cholesterol conjugates exhibit, on the whole, low cytotoxicity, 
especially in the case of BAC-SSChol1 (IC50>10). Apparently, in the two series of polymers, the 
cholesterol content acts in the opposite way, in that higher contents decrease cytotoxicty of BP-
based conjugates, whereas decreases that of  the BAC-based ones. However, it is not possible to 
draw straightforward conclusions regarding the effect of cholesterol content on cytotoxicitiy, since 
it affects the polymers’ state in aqueous systems and it was not possible to screen out this factor.  
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5.4 CONCLUSIONS 
This present chapter reports on a particular application of the research line concerning disulfide 
based PAAs conjugates, opened with the previous reported work. Thiocholesterol was successfully 
linked to PAA through ethenyl dithiopyridine pendants and two different families of PAAs, one 
cationic and one amphoteric were obtained. Both polymer showed remarkable amphiphlic 
properties and in water formed stable nanoparticles suspensions. Preliminary test on dimensional 
pH sensitive changes ,suggest for these nanoparticles a inner structure similar to physically cross-
linked nano-hydrogels. Hydrophobic cholesterol domains demonstrate capable of considerable 
lypophilic molecules payloads; moreover preliminary cytotoxicity assays demonstrate a good 
cytocompatibility. Further studies are ongoing to confirm preliminary results shown and to 
demonstrate, as we expect, a massive release of drug in presence of reducing agents, after cleavage 
of disulfide links between cholesterol and polymer, and consequent nanoparticle dissolution. At 
present, these novel PAA-cholesterol conjugates appear very promising for applications in the field 
of polymer therapeutics.  
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CHAPTER 6 
 
Synthesis of cross linked polyplexes  
for applications in gene delivery  
 
 
6.1 INTRODUCTION 
Gene therapy strategies have been proposed for a vast and diverse range of disorders for which 
current available treatments are deemed unsatisfactory. Such a research interest to explore a variety 
of methodologies for the achievement of effective DNA delivery and subsequent expression. A 
major branch of investigation has focussed on a pharmaceutical approach through the development 
of nonviral vectors. Within this field, cationic polymers, such as poly(L-lysine) (PLL), have 
demonstrated efficient condensation of DNA (Kwoh et al., 1999). Systems based on 
poly(ethylenimine) (PEI) (Boussif et al., 1995), poly(amidoamine) (PAMAM) dendrimers 
(Kukowska-Latallo et al., 1996), linear PAAs (Jones et al, 2000; Richardson et al., 2001; Ferruti, 
Franchini et al., 2007) and polymethacrylate-based systems (Van de Weitering et al., 1997), have 
shown significant promise. Non-viral vectors hold several advantages over modified viruses 
employed for gene delivery purposes, such as of improved and more predictable safety, higher 
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DNA carrying capacity and, therefore, increased versatility, more straightforward production and 
better quality control. Nevertheless, their efficiency is currently lagging far behind that of viral 
systems. This perhaps should not surprise when taking into account the barriers that exist to the 
successful delivery of an exogenous sequence of DNA to the nucleus of a target cell and that 
viruses have evolved to perform such a role (Pouton, Seymour, 1998). It seems that, in all 
likelihood, a successful nonviral system will require a number of distinct elements, each with a 
specialist role in the realisation of this goal. Having identified a number of promising cationic 
polymer candidates, attention has now shifted to their incorporation in multicomponent systems in 
order to improve their efficacy (Wu et al, 1994; Zhou et al., 1994; Dashg et al., 2000). 
The stability of the polymer/DNA complex in serum is a key area of investigation. Particulate 
systems are rapidly cleared from the circulation by the reticuloendothelial system following 
parenteral administration, resulting from a range of interactions with serum components, including 
the complement system (Stolnik et al., 1994) and subsequent phagocytosis. Moreover, the 
interaction with serum components, together with high dilution, can also affect particle stability and 
contribute to polyplexes disruption. Thus, the delivery system can be eliminated before it reaches its 
intended target cell population. A potential solution to this problem is the formation of a steric 
barrier around particles, as it has been demonstrated with nanoparticulate drug delivery systems by 
the inclusion of hydrophilic polymers, such as poly(ethylene glycol) (PEG). This PEG layer greatly 
reduces the adsorption of serum components to the particle surfaces, reducing uptake by the 
mononuclear phagocytes thus increasing the circulating life of the delivery system (Gref et al., 
1994). Furthermore, these hydrophilic polymers can also prevent interparticulate aggregation, 
improving the colloidal stability of systems. This approach can also be applied to DNA vectors, and 
a number of researchers have explored the formation and polyfection performance of DNA 
complexes with co-polymers of varying architecture formed from cationic and hydrophilic polymer 
segments (Choi et al., 1999; Toncheva et al., 1998; Nguyen et al., 2000). 
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On the other hand, the major barriers for non-viral gene delivery are believed to be inefficiencies 
in endosomal escape of the polyplexes that avoid the lysosomal degradation pathway, or in 
unpacking of DNA from the polyplexes that can enable transcription (Shaffer et al., 2000; Hill et al., 
1999).  
In past years several linear PAAs have been studied as cationic polymers for DNA delivery. 
Previous findings established a number of structures that exhibited favourable biocompatibility, in 
vitro polyfection performance and DNA-condensing properties (Danusso, Ferruti, 1970; Ferruti, 
Ranucci, 1991). In particular the PAA obtained by reaction of methylene-bis(acrylamide) and N,N’- 
dimethyl ethylenediamine was identified as the best transfection promoter. In further studies a tri-
block co-polymer has been synthesised by addition of two PEG chains on both PAA ends and 
several formulations have been tested to identify the best ratio between the polycationic polymer 
and the hydrophilic one, in order to obtain less cytotoxic nanoparticles with increased colloidal 
stability and retained transfection efficiency in vitro (Bignotti et al., 1994; Rackstraw et al., 2002).  
Recently much attention is focusing on disulphide linkages for their importance in biological 
fields. The presence of the disulphide linkages could increase stability of polyplexes in bloodstream 
increseang also the biodegradability of the polymers by reductive cleavage in the intracellular 
environment. Polyplexes obtained resulted more prone to release DNA once internalized inside 
cells, and enhanced gene expression, as well as a lower cytotoxicity profile of the polymers are 
obtained (Miyata et al., 2004; Oupicky et al., 2002; Read et al., 2005; Gosselin et al., 2001 and 
2002). In recent research it has been demonstrated that disulphide containing PAAs behave as 
powerful transfection promoters with a very low toxicity (Lin et al, 2006; Christensen et al., 2006; 
Lin et al., 2007; Lin et al., 2008).  
The aim of this work was to increase polyplexes stability using novel PEG-PAA based block co-
polymers, capable to form, during polyplexes formation, smart disulphide bridges between different 
polymer chains. The particles obtained are expected to be resistant to enzymatic degradation as well 
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as to high dilution and high salt concentration, such as in the bloodstream, but undergo reduction 
and consequent loss of stability in presence of reducing agents, such as inside cells, thus favouring, 
in principle, DNA endosomal escape and full explotation of transfection ability. 
 
6.2 EXPERIMENTAL PART 
6.2.1 Materials 
Homo poly(MBA-DMEDA), 30K, amino terminated.(CP1) 
MBA ( 1.54 g, 10.0 mmol) was added in small portions to an aqueous solution of DMEDA (0.88 
g, 10.0 mmol in 3.5 ml of water) under nitrogen. The mixture was allowed to react for three days 
under stirring. Subsequently the solution pH was adjusted to 2.5 with a 1 M aqueous HCl, the 
solution was ultrafiltered through a membrane with a molecular weight cut off 3000 and eventually 
freeze dried. Product was characterized by SEC and NMR spectroscopy. nM : 27000, wM : 42000; 
Yield: 2.6 g, 93%. 1H NMR (d6-DMSO): 2.25 (s, 6H, CH3N); 2.39 (t, 4H, CO-CH2-CH2-N); 2.51 (s, 
4H, N-CH2-CH2-N), 2.66 (t, CO-CH2-, 4H); 4.56 (m, broad, NH-CH2-NH, 2H), 8.82 (t, broad, NH, 
2H). 
 
Trityl-DMEDA31 (1) 
N,N’-Dimethylethylenediamine (19.37 ml, 0.18 mol) was dissolved in dichloromethane (DCM, 
75 ml) under stirring in nitrogen atmosphere and the solution cooled to 5°C. Triphenylmethyl 
chloride (5 g, 0.018 mol) was added in small portions. After the addition was completed, the 
solution was allowed to react at room temperature for 4 hours. During this time the reaction was 
monitored by TLC (eluent chloroform:ethanol=8:2), then another aliquot of DCM (50 ml) was 
added and the solution washed several times with water (50 ml) until neutral pH of the aqueous 
phase was reached. The organic layer was dried over anhydrous sodium sulphate and the solvent 
evaporated under reduced pressure. A pale yellow viscous oil was obtained in an almost 
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quantitative yield. TLC of the product showed a single spot (R.f. 0.54). 1H NMR (CD3OD): 7.52 (t, 
benzene ring, 3H), 7.28 (t, benzene ring, 6H), 7.18 (t, benzene ring, 3H), 2.85 (t, CH3-NH-CH2-, 
2H), 2.39 (s, CH3-NH-CH2, 3H), 2.31 (t, CH3-N(Trit)-CH2, 2H), 2.10 (s, CH3-N-Trit, 3H). 
 
Trityl DMEDA-MBA adduct (2) 
MBA (55.0 g, 0.35 mmol) was dissolved in methanol (400 ml), (1) (5.9 g, 0.017 mol) was added 
in portions and the mixture was allowed to react for 20 hours at room temperature in the dark. The 
completion of the reaction was monitored by TLC (eluent CHCl3/MeOH=9:1), then methanol was 
removed under reduced pressure, the crude product dissolved in chloroform (500 ml) and the 
organic solution washed several times with water until complete disappearance of MBA trace, as 
revealed by TLC. The organic layer was dried over anhydrous sodium sulphate and the solvent 
evaporated under reduced pressure. A pale yellow solid was obtained in an almost quantitative yield. 
TLC of the product showed a single spot (R.f. 0.7; for comparison MBA R.f. 0.5, Trityl-DMEDA 
R.f. 0.61). 1H NMR (CDCl3): 7.51 (t, benzene ring, 3H), 7.29 (t, benzene ring, 6H), 7.18 (t, 
benzene ring, 3H), 6.25, 6.02, 5.68 (m, terminus double bond, 3H), 4.53 (t, broad, -NH-CH2-NH-, 
2H), 2.77, 2.62, 2.36, 2.31 (m, CH2-N(CH3)-CH2-, 8H), 2.39 (s, CH3-NH-CH2, 3H), 2.23 (s, CH3-
N-(CH2-)2, 3H), 2.10 (s, CH3-N(Trit)-CH2, 3H). 
 
MBA-DMEDA adduct (3) 
(2) was added in portions to a 1 M HCl aqueous solution (100 ml). The thick suspension formed 
was left stirring for 1 hour, diluted with water (50 ml) and subsequently washed several times with 
DCM (6 x 50 ml) to eliminate triphenylcarbinol from the aqueous phase. The organic phase was 
separated, extracted with water (4 x 50 ml) and the combined aqueous phases eventually freeze 
dried. A white solid was obtained in an almost quantitative yield (5.6 g, 96 %). 1H NMR (D2O):  
 
N-tert-Butyloxycarbonyl Cystamine Hydrochloride32 (4)  
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TEA (19.8 g, 0.190 mol) was added to a dry methanol solution (250 ml) of cystamine bis-
hydrochloride (15.0 g, 0.066 mol), and the solution stirred for 15 min at room temperature. Di-tert-
butyldicarbonate (14.5 g, 0.066 mmol) was added and the stirring maintained for an additional 3 h, 
monitoring the reaction progress by TLC (eluent: chloroform/ isopropyl alcohol 1:1, Rf product: 
0.25). The solvent was then evaporated, and a 1 M KH2PO4 aqueous solution (350 ml, pH 4.2) was 
added. The aqueous phase was extracted with diethyl ether (3 x 100 ml) to remove N,N’-di-tert-
butyloxycarbonyl cystamine, then brought to pH 9 with 3 M NaOH, and extracted with ethyl acetate 
(6 x 150 ml). The combined organic phases were dried over anhydrous sodium sulphate and 
evaporated to dryness. The residue was dissolved in water (150 ml) at pH 4 (HCl). The clear 
solution obtained was freeze-dried and N-tert-butyloxycarbonyl-cystamine isolated as 
hydrochloride (9.6 g, 75%). 
1H NMR (D2O): 1.30 (s, Boc CH3, 9H), 2.72 (t, CH2-S, 2H), 2.83 (t, CH2-S, 2H), 3.21–3.31 (m, 
4H, NH3+-CH2 and CONH-CH2). 
 
Mono-piperazine terminated mono-methoxy-PEG75033 (5) 
Mono-methoxy-PEG750 (20 mmol, 15g) was introduced in two necked round bottom flask 
equipped with stirring bar, vacuum/nitrogen inlet and a glass stopper. PEG was melted under gentle 
warming, purged and kept under nitrogen. Chloroform (50 ml) was added and PEG allowed to 
dissolve. A three fold excess CDI (9.72 g, 60 mmol) was subsequently added in small portions, 
after 1 hour, unreacted CDI was quenched by addition of water (5 ml) and the organic phase was 
washed with brine (4 x 30 ml). The organic layer was dried over anhydrous sodium sulphate, a three 
fold excess piperazine (5.17 g, 60 mmol) was added and the solution maintained under stirring for 1 
hour. The organic solution was washed again with brine until neutral pH of the washing liquor was 
reached. It was subsequently dried over anhydrous sodium sulphate and the solvent evaporated 
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under reduced pressure. The crude pale yellow oily product was kept under vacuum for several days 
until a waxy substance was obtained in quantitative yield.  
1H NMR (D2O): 2.71 (t, broad, 4H, CH2-NH-CH2, piperazine), 3.30 (s, 3H, O-CH3, PEG 
terminus), 3.38 (broad, 4H, CH2-N(CO)-CH2, piperazine), 3.5-3.8 (m, broad, 60 H, CH2O-CH2, 
PEG chain), 4.17 (broad, 2H, CO-O-CH2, PEG). 
 
MBA terminated PEG750 (6) 
In a two necked flask, MBA (4,52 g, 0.029 mol) was dissolved under nitrogen in methanol (50 ml) 
at 40° C. (5) (2.6 g, 0.003 mol) was dissolved in methanol (5 ml) and added to the MBA solution. 
The reactive mixture was allowed to react for 2 days. The solution was cooled to r.t., water (40 ml) 
was added and the organic solvent evaporated under reduced pressure. The aqueous phase was 
extracted with chloroform (3 x 25 ml). The organic phases were collected and washed with water (3 
x 25 ml) and dried over anhydrous sodium sulphate. The solvent was eventually evaporated under 
reduced pressure to obtain a waxy solid in almost quantitative yield. 1H NMR (D2O): 6.21, 5.77 
(vinyl terminus, 3H), 4.61 (-NH-CH2-NH-, 2H), 3.67 (-O-CH2-PEG chain, 60 H), 3.35 (CH3-O- 
PEG terminus, 3H), 2.46 (-N-CH2-CH2-CO-, 4H). 
 
PEG-MBA-(cyst-m-Boc) (7) 
In a two necked flask, (4) (6.2 g, 24.5 mmol) was dissolved under nitrogen in water/methanol 7/3 
mixture (40 ml) at r.t and lithium hydroxide monohydrate was added up to pH 10. (6) (5.0 g,  4.9 
mmol) was dissolved in the same solvent (20 ml) and added. The reactive mixture was allowed to 
react for 4 days. Then water (50 ml) was added and the organic solvent evaporated under reduced 
pressure. The aqueous phase was washed with ethyl acetate (1 x 40 ml, then 4 x 25 ml) and 
eventually freeze dried. A white waxy solid was obtained in an almost quantitative yield. No trace 
of unreacted cystamine-m-Boc could be detected in TLC. 1H NMR (D2O): 6.18, 5.72 (vinyl 
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terminus, 0.4 H), 4.61, 4.48 (-NH-CH2-NH-,α to vinyl 0.26 H, γ to cystamine residue 1.74 H), 3.67 
(-O-CH2-PEG chain, 60 H), 3.35 (CH3-O- PEG terminus, 3H), 2.81-2.41 (-N-CH2-CH2-CO-, N-
CH2-CH2-S-, 14.5 H), 1.36 (CH3- t-Boc, 7.5 H). Trace of residual double bonds (13%) could be 
observed in 1H NMR spectrum. Reaction yield: 87% 
 
PEG-(MBA-(Cyst-m-Boc))2 (8) 
(8) was obtained through a two step procedure;  
Step1). The same procedure to obtain compound (6) was followed but using (7) (5.0 g, 3.9 mmol) 
instead of (5) and MBA (6.0 g, 39.0 mmol) and solvent in proportion. Product was purified as 
described. No trace of residual MBA was detected in the final product that was used in the 
following step. 
Step 2). The same procedure to obtain compound (7) was followed but using the product obtained 
in the previous step instead of (6) and (4) (5.6 g, 19.5 mmol) and solvent in proportion. Product was 
purified as described. 
(8) was obtained in a 91% overall yield (6.0 g). 1H NMR (D2O): 4.48 (reacted -NH-CH2-NH-, 3 
H), 3.62 (-O-CH2-PEG chain, 60 H), 3.35 (CH3-O- PEG terminus, 3H),2.81-2.41 (-N-CH2-CH2-
CO-, N-CH2-CH2-S-, 25 H), 1.36 (CH3- t-Boc, 13.5 H). No trace of residual double bonds could be 
observed in 1H NMR spectrum, even if the ratio between integrals was not completely in 
accordance with the expected. 
 
PEG-(SH)2-poly(MBA-DMEDA) (9) 
(3) (2.5 g, 7.9 mmol) was dissolved under nitrogen in water (3 ml) and lithium hydroxide mono 
hydrate was added until pH 10 was reached. (8) (0.13 g, 0.079 mmol) was then added and the 
reaction left under stirring for 120 hours. A 1M HCl aqueous solution was subsequently added until 
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pH 4 was reached, the solution was ultrafiltered through 5000 nominal cut-off membrane and 
eventually freeze dried. A white solid was obtained in 74% yield (1.9 g).  
 
 
CP02 
(9) (1 g, 0.08 mmol of cystamine pendants) was dissolved in water (10 ml) and pH adjusted to 8.5 
with 1M NaOH solution. The polymer solution was deoxygenated with bubbling nitrogen for 2 
hours, then DTT (36 mg, 0.24 mmol) was added and the solution left under nitrogen for two hours. 
Then 1M aqueous HCl was added to reach pH 2, and the solution was ultrafiltered through a 5000 
nominal cut off membrane with deoxygenated water. The product was eventually freeze dried. 
 
Mono-piperazine terminated mono-methoxy-PEG200033 (10) 
The same procedure to obtain (5) but using mono-methoxy-PEG2000 (10g, 5 mmol) instead of 
mono-methoxy-PEG750. The product was purified according to the procedure described and a 
waxy solid was obtained in quantitative yield.  
1H NMR (D2O): 2.71 (t, broad, CH2-NH-CH2, piperazine, 4H), 3.30 (s, O-CH3, PEG terminus, 
3H), 3.38 (broad, CH2-N(CO)-CH2, piperazine, 4H), 3.5-3.8 (m, broad, CH2O-CH2, PEG chain, 
120 H), 4.17 (broad, CO-O-CH2, PEG, 2H). 
 
Poly(MBA-DMEDA), 10K, amino terminated. (11) 
MBA (1.54 g, 10.0 mmol) was added in small portions to an aqueous solution of DMEDA (0.902 
g, 10.25 mmol in 3.5 ml of water) under nitrogen. The mixture was allowed to react for three days. 
Subsequently the solution pH was adjusted to 2.5 with a 1 M aqueous HCl and the solution was 
eventually freeze dried without any further purification. Product was characterized by SEC and 
NMR spectroscopy. 
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Yield: quantitative. nM : 11600; wM : 28000. 1H NMR (d6-DMSO): 2.25 (s, 6H, CH3N); 2.39 (t, 
4H, CO-CH2-CH2-N); 2.51 (s, 4H, N-CH2-CH2-N), 2.66 (t, 4H, CO-CH2-); 4.56 (m, broad, 2H, 
NH-CH2-NH), 8.82 (t, broad, 2H, NH). 
 
(PEG-(SH)4)2-poly(MBA-DMEDA) (13) 
In a two-necked flask, MBA (0.308 g, 2.0 mmol), cystamine-m-Boc (0.460 g, 1.6 mmol) and 
TEA (0.160 g, 0.220 ml, 1.6 mmol) were dissolved in ethylene glycol (2 ml) under nitrogen flow. 
The reaction was monitored by TLC (eluent: chloroform/ isopropyl alcohol 1:1, Cyst-mBoc Rf: 
0.25). After the reaction was complete the crude (12) obtained was diluted with ethylene glycol (4 
ml), (10) (0.42 g, 0.2 mmol) and (11) (1.2 g, 0.2 mmol) were added. The mixture was allowed to 
react for 7 days, then diluted in water (100 ml). A 1 M HCl aqueous solution was added until pH 4 
was reached and the final solution dialysed against water (5 x 1L) in a 3500 nominal cut off dialysis 
tube. The purified product was eventually lyophilized. Yield: 1.25 g, 52%. 
1H NMR (D2O): 1,41 (s, O-C-(CH3)3, cyst-m-Boc), 2,57 (s, N-CH3, PAA-block), 2,61 (m, CO-
CH2-CH2-N, PAA-block), 3,07 (s, N-CH2-CH2-N, PAA-block), 3.11 (m, CO-CH2-CH2-N, PAA-
block), 3,67 (s, O-CH2-CH2-O, PEG-block), 4.57 (s, NH-CH2-NH, PAA-block), 6.22 (d, CH=CH2, 
terminus) 
Integral ratios between different signals are as expected. A reaction yield of 72 % is calculated on 
the basis of the signal referred to the unreacted double bond (6.22 ppm).  
 
CP03 
(13) (1 g, 0.5 mmol of cystamine pendants) was dissolved in water (10 ml) and pH adjusted to 8 
with 1M NaOH solution. The polymer solution was deoxygenated with bubbling nitrogen for 2 
hours, then DTT (0.385 g, 2.5 mmol) was added and the solution left under nitrogen for two hours. 
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Then 1M aqueous HCl was added to reach pH 2, and the solution was ultrafiltered through a 5000 
Mw nominal cut off membrane with deoxygenated water. Product was eventually freeze dried. 
 
Poly(MBA-DMEDA-co-ethenyl-dithio pyridine) (XLP) 
In a two-necked flask cystamine di-hydrochloride (1.22 g, 5.4 mmol), lithium hydroxide 
monohydrate (0.45 g, 10.8 mmol) and DMEDA (2.00 g, 22.7 mmol) were dissolved in water (11 ml) 
under nitrogen flow. MBA (5.00 g, 32.4 mmol), was then added under stirring until a homogeneous 
solution was obtained. Stirring was stopped and the solution allowed to react for 120 hours. The 
transparent gel obtained was finely ground and soaked in ethanol solution (35 ml), and 2,2’-
dipyridyldisulphide (3.60 g, 16.0 mmol) with few milligrams of 2-mercaptopyridine were added. 
The reaction mixture, completely dissolved within few hours, was maintained under stirring at room 
temperature for overall 24 hours, then diluted to 150 ml with water to precipitate the excess 2,2’-
dipyridyldisulphide, which was filtered off. The pH of the filtered solution was adjusted to 2.5 with 
a 1 M aqueous HCl. The polymer was fractioned by ultrafiltration between 10000 and 5000 nominal 
cutoff membranes and eventually freeze dried. 
Yield: 0.73 g.  1H NMR (D2O): 2,71 (m, CO-CH2-CH2-N, 4H), 2.77 (s, N-CH3, 6H), 3.35 (m, 
CO-CH2-CH2-N, 4H), 3.46 (s, N-CH2-CH2-N, 4H), 4.57 (s, NH-CH2-NH, 2H), 7.27 (m, pyridine, 
N-CH-CH, 1H), 7.67-7-77 (m, pyridine, N-C-CH-CH, 2H), 8.38 (m, pyridine, N-CH-CH, 1H).  
 
DNA  
For electrophoretic retardation, plasmid gWIZLuc, containing the firefly luciferase gene was 
supplied as a 5mg/ml solution by Aldevron (South Fargo, ND) and diluted with water without any 
further purification to obtain a working solution of 1 mg/ml. 
77 
CHAPTER 6 – Synthesis  of cross linked polyplexes for applications in gene delivery 
 
 
 
For DLS analyses and polyplexes formation with semi-automatic mixing apparatus, single 
stranded salmon sperm DNA was supplied by Aldrich and dissolved in water without any further 
purification to obtain a working solution of 1 mg/ml. 
 
6.2.2  Methods 
Preparation of complexes 
Complexes were routinely prepared by the addition of a single aliquot of polymer or polymers 
mixture solution to a 0.05 mg/ml DNA solution, in the required amounts to produce complexes of 
the desired polymer repeating unit/DNA nucleotide ratio (RU/DNA ratio). The amount of polymer 
required to produce complexes of a given polymer RU/DNA ratio was calculated according to the 
following: 
Polymer amount 
MwRUDNA
MwRUPolymer
__
__=  x RU/DNA ratio x DNA amount Eq. (6.1) 
The DNA RU molecular weight was taken as 308, for the mean Mr of a DNA nucleotide. The RU 
molecular weight of the p(MBA-DMEDA) cationic homopolymer was 315 for the dihydrochloride 
salts; for polymers containing PEG chains or ethenyldithiopyridine units, only MBA-DMEDA RU 
were taken into account as DNA complexing.  
More details on polymer mixture composition and addition order to DNA solution are reported in 
the results and discussion section. 
 
Hydrodynamic particle size determination 
Samples were prepared according to the procedure described above. The z-average particle sizes, 
polydispersity and light scattering intensity were determined by dynamic light scattering using a 
Viscotek 802 DLS at 25°C, data analized with Omnisize 2.0 software, Correlator resolution 256 
channel. 
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Transmission Electron Microscopy 
Samples were prepared according to the procedure described above. One drop of each sample 
was placed onto copper grids coated with Pioloform resin (Taab Laboratory Equipment, Reading, 
UK) and excess liquid blotted using filter paper. After air drying grids were floated on a drop of 
uranyl acetate staining solution (4% w/v in 50/50 v/v EtOH/H2O) for 15 min, after which they were 
washed once in 50% v/v EtOH and twice in purified water, followed by air drying. Grids were 
analyzed using a JEOL JEM-1010 transmission electron microscope (Jeol, Welwyn Garden City, 
UK) operating at a voltage of 80 kV. Micrographs were taken at various magnifications with a 
Kodak Megaplus digital camera 1.6i using the Analysis 3.0 software package.  
 
Gel electrophoresis 
Gel electrophoresis was used to observe complex stability and protection from nuclease 
degradation. Complexes were formed adding the required amounts of polymer to plasmid (2 μg) in 
PBS with 5 mM MgCl2 (16 μl), followed by incubation at room temperature for 30 min. A DNase I 
solution (1 μl of 10 μg/ml, containing 4.4 activity units) was added and samples were incubated for 
60 min and then cooled to 0°C. A solution of poly(4-styrenesulfonic acid-co-maleic acid) sodium 
salt solution (1 μl of 10 mg/ml) was added to displace polycation. Gel loading buffer consisting of a 
solution of bromophenol blue (0.25% w/v) in 40% (w/v) sucrose (2 μl) was added. Then samples (9 
μl) were loaded onto a 0.8% agarose gel in TAE buffer containing 1 μg/ml ethidium bromide, and 
developed electrophoretically over 60 min at 70 V, with TAE as running buffer. The gels were 
photographed on a UV transilluminator to visualise DNA, prior to polymer detection. Gels were 
stained for polymer using a solution of brilliant blue R250 (1% w/v) in a 50:10:40 mixture of 
methanol/glacial acetic acid/water for 1 hour. Destaining was achieved using a 10:10:80 
methanol/glacial acetic acid/water mixture overnight. 
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Diluted Bovine pancreatic RNase-Free Deoxyribonuclease I (DNase I), FPLC pure, 1000units 
were purchased from GE Healthcare Life sciences; agarose was purchased from VWR International 
Ltd. (Lutterworth, Leicestershire). 
 
Ultrafiltration tests 
Polyplexes stability to dilution was proved by ultrafiltration tests. Samples (40 μl) were prepared 
according to the procedure described, loaded into centrifugal filter Microcon YM-100 with a 
nominal cut off of 100 k, diluted with water (360 μl) and centrifuged (500 G). The dilution-
centrifugation procedure was repeated twice; retained and filtrate solutions were recovered and 
eventually analyzed with TEM and DLS.  
 
6.3 RESULTS 
In this work a novel formulation to obtain suitable DNA-PAA complexes for gene delivery 
applications has been studied. Two different PAA based block co-polymers (labelled CP2 and CP3) 
were synthesised and subsequently formulated with another PAA based polymer in which ethenyl 
dithiopyridine pendants were present (labelled XLP).  
The PAA main structure was obtained by polyaddition reaction of MBA and DMEDA, leading to 
a polymer that demonstrated remarkable DNA complexing properties even if with a non negligible 
cytotoxicity. According to previous findings and publications, a PEG chain was bound to one or 
both ends of PAA macromolecule in order to increase colloidal stability of the polyplexes.  
A short PAA block containing 2 or 4 sulphidryl pendants was inserted between poly(MBA-
DMEDA) and PEG chains in order to further increase polyplexes stability in case of high dilution or 
elevated ionic strength. Thiol pendants are supposed to react with XLP during the formulation of 
polyplexes, in order to create a stabilizing network between the PAA-DNA complex and the 
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surrounding PEG shell. Polyplexes obtained with a homo poly(MBA-DMEDA) (CP1) were used in 
all case for comparison. 
 
6.3.1 Synthesis. 
The PAA homopolymer methylene-bis(scrylamide) co-N,N’-dimethylethylenediamine (CP1) was 
synthesised according to a well established procedure. 
XLP polymer synthesis has been performed according to a procedure developed during the first 
two years of this PhD course and reported in Chapter 3. XLP structure is reported in Figure 6.1.  
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Figure 6.1: structure of XLP 
CP2 and CP3 instead were obtained following two different reaction strategies: CP2 was 
synthesised by a stepwise procedure, to better control the polymer architecture; CP3 was obtained 
by a tri-block addition procedure. In the CP2 synthesis (Scheme 6.1), a piperazine terminated PEG 
(5) was synthesised, followed by addition of first MBA (6)and second mono-protected cystamine 
(7), each step followed by extraction in order to obtain a pure product. Both reactions was 
performed with a large excess of MBA and m-Boc-Ccystamine respectively in order to limit double 
PEG chains coupling reaction. The entire MBA and m-Boc-cystamine addition procedure was 
repeated twice. The amino terminating product (8) was eventually used as terminator in a 
polyaddition reaction with a purposely synthesised mono-adduct of MBA to DMEDA (3).  
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Scheme 6.1: Synthesis of (9). reaction conditions: c) methylene-bis(acrylamide) (excess), methanol, r.t, 48h; d) N-
Boc-cystamine (excess), water/methanol 7/3, r.t., 100 h; e) (3), water, 120 h. 
 
Intermediate (3) have been obtained by addition of MBA to a mono-N-trityl protected DMEDA 
(1), followed by deprotection in HCl solution (Scheme 6.2). 
Despite the careful synthetic procedure, the final product showed a reduced amount of cystamine 
residues compared to the expected one, probably because of  a non complete addition reaction of m-
Boc-cystamine. 
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Scheme 6.2: synthesis of AB type MBA-DMEDA monomer. Reaction conditions: a) MBA (excess), methanol, r.t., 
20 h; b) 1M HCl 
 
In the preparation of CP3, each block was synthesised separately. Amine-terminating PEG with 
2k nM  (10) and poly MBA-DMEDA terminating with secondary amine groups (11) after synthesis 
were isolated and subsequently added to a oligo MBA-(N-Boc-cystamine) terminating with 
acrylamido groups. Since N-Boc-cystamine was scarcely soluble in water, ethylene glycol was used 
as solvent in order not to reduce reaction rate. In fact in previous research we have demonstrated the 
effectiveness of ethylene glycol in Michael polyaddition reaction (see Chapter 3 for more details) 
The three blocks were allowed to react for several days because of the relatively low concentration of 
reactive functions. The polymer obtained was ultrafiltered and eventually freeze dried (Scheme 6.3). 
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Scheme 6.3: synthesis of CP3 
SEC traces and NMR spectra confirmed the expected mean structures. PEG 750 and 2000 block 
were coupled with a 25000 and 10000 nM  PAA ones in the syntheses of CP2 and CP3 respectively, 
in order to test two different ratios between PEG and cationic polymer.  
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6.3.2 CP1 based polyplexes 
DLS analyses, gel electrophoresis retardation and DNA enzymatic degradation tests were 
performed on 0.5:1, 1:1, 5:1 polymer:DNA comlpexes, in order to have a reliable comparison with 
modified polyplexes. Each formulation was prepared in NaCl 0.15, 0.3 or 0.6 mM solutions to 
evaluate the complex stability and behaviour in the presence of high salt concentration.  
Gel electrophoresis retardation showed that CP1 was very effective in DNA complexation 
(Figure 6.2). Even with the lowest polymer:DNA ratio (0.5:1) a complete DNA compexation 
occurred and no traces of free DNA or of free polymer were detectable. For every other 
composition excess CP1 was observed in the stained gel. A certain increase of brightness in the 
holes could be observed with the increase of NaCl concentration. This was probably due to 
complexes loosening as a consequence of increased ionic strength that allowed a stronger 
interaction between ethidium bromide and double stranded DNA.  
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Figure 6.2: Gel electrophoretic retardation of gWIZLuc plasmid by CP1. The lower halves of the gel image shows 
DNA migration as viewed under UV light; the upper halves are stained for polymer. The anode and cathode are marked 
+ and -, respectively.  
 
A similar result was obtained by DLS analyses: a slight decrease in size is observed with the 
increase of CP1:DNA ratio while large increase in size was observed with increasing salt 
concentration, in particular between 0.15 and 0.3 mM salt concentrations. As expected, an increase 
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in the ionic strength of the solution produced a weakening of the interaction between anionic DNA 
and cationic CP1, thus leading to an increase of complexes dimension (Figure 6.3).  
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Figure 6.3: DLS analyses of polyplexes obtained by salmon sperm DNA and CP1, in solution with different 
concentration of NaCl. 
 
This phenomenon was confirmed by the enzymatic degradation test, performed only on 
polyplexes with CP1:DNA 5:1 ratio: in 10 minutes of incubation with DNase I only DNA was 
degraded, differently from complexes (Figure 6.4). Only after 60 minutes some degradation 
occurred to complexed DNA, and complete degradation only in the presence of 0.6 M NaCl. 
(Figure 6.5) 
Plasmid CP1:DNA = 5:1
Time  0      10      0      10       0      10      0      10   0      10      0      10 min
NaCl 0.15            0.3              0.6             0.15       0.3              0.6      M
-
+
 
Figure 6.4. Gel electrophoretic retardation of gWIZLuc plasmid by CP1 in solutions with different concentrations of 
NaCl. The anode and cathode are marked + and -, respectively.  
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Time  0      60      0      60     60 60 60 60 min
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Figure 6.5. Gel electrophoretic retardation of gWIZLuc plasmid by CP1 in solutions with different concentrations of 
NaCl. The anode and cathode are marked + and -, respectively.  
 
6.3.3 CP2 based polyplexes 
This second group of polyplexes was obtained by formulation of CP2 and XLP with DNA. Four 
different ratios between CP2 and XLP were used, namely 0.2:1, 0.6:1, 0.8:1, 1:1 and 1.4:1, defined 
on the basis of previous findings [Hill et al., 1999]. Each CP2-XLP composition was combined with 
DNA according to the same ratios used with CP1.  
DLS data obtained for each sample are reported in Table 6.1.  
 
Table 6.1. Salmon sperm DNA and CP2 polyplexes dimensions 
0
50
100
150
CP2/XLP ratio
R
ad
iu
s 
(n
m
)
PAA:DNA 1 145,6 125,3 65,8 99,7 59,8
PAA:DNA 1,25 130,7 127,3 58,8 113,2 75,4
PAA:DNA 1,5 146,7 120,2 37,0 82,9 63,9
PAA:DNA 1,75 140,8 116,7 41,1 56,8 54,7
PAA:DNA 151,9 110,0 49,8 71,4 51,6
0,2 0,6 0,8 1,0 1,4
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They showed a general decrease in size with increasing the amount of XLP in the formulation, 
with a minimum around 0.8:1 CP2:XLP ratio. No relevant differences were observed varying the 
ratio between polymer and DNA in formulations with the lowest amount of XLP, while for 1:1 and 
1.4:1 CP2:XLP ratios polyplexes undergo relevant variations, in both cases with a maximum around 
1.25:1 polymer: DNA ratio.  
 
TEM images of the two samples with PAA/DNA ratio 1.75:1, and  0.6:1 and 0.8:1 CP2:XLP 
ratio, as they appeared to be more promising,. Round shaped nanoparticles are shown in Figure 6.6, 
with a mean diameter around 35 nm. No relevant differences between the two samples were noticed.  
 
 
200 nm 200 nm 
Figure 6.6. TEM images of salmon sperm DNA-CP2 polyplexes, with 1.75 PAA:DNA ratio. On the left: 0.6:1 
XLP:CP2; on the right: 0.8:1 XLP:CP2 
 
When the samples are treated with Na2SO4 (that was demonstrated to be more effective in 
polyplexes destabilization than NaCl even at low concentrations), the best result in term of 
dimension stability was obtained with 0.6:1 XLP:CP2 ratio, at any PAA:DNA ratio (Figure 6.7).  
DNA enzimatic degradation test was performed again on samples with 0.6:1 and 0.8:1 ratio 
between XLP and CP2, followed by gel retardation. DNA and complex with CP1 were added for 
comparison. While after 10 minutes incubation with DNase I, DNA was completely degraded and 
no degradation was detectable for CP1 complexes, all the other samples showed some extent of 
DNA degradation (Figure 6.8). It has to point out that while CP1 was in large excess with respect to 
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DNA, in CP2-XLP formulations DNA was in stoichiometric amount. Anyway, the fact that DNA 
was displaced from the complexes by the presence of poly(styrene-4-sulfonic-co-maleic)acid, 
clearly indicate that no effective cross-linking was achieved with this formulation. 
 
0
100
200
300
1:1 1:25 1:5
Formulation
R
ad
iu
s 
si
ze
 (n
m
)
water
1 mM
4 mM
0
100
200
300
400
500
1:1 1:25 1:5
Formulation
R
ad
iu
s 
si
ze
 (n
m
)
water
1 mM
4 mM
0
100
200
300
400
1:1 1:25 1:5
Formulation
R
ad
iu
s 
si
ze
 (n
m
)
water
1 mM
4 mM
0
100
200
300
400
1:1 1:25 1:5
Formulation
R
ad
iu
s 
si
ze
 (n
m
)
water
1 mM
4 mM
R
ad
iu
s 
si
ze
 (n
m
)
R
ad
iu
s 
si
ze
 (n
m
)
R
ad
iu
s 
si
ze
 (n
m
)
R
ad
iu
s 
si
ze
 (n
m
)
 
Figure 6.7: DLS analyses of salmon sperm DNA -CP1polyplexes, in solution with different concentration of Na2SO4. 
For each panel: on x axis DNA:PAA ratio; on top left: XLP:CP2=0.2:1; on top right: XLP:CP2= 0.6:1; on bottom left: 
XLP:CP2=0.8:1; on bottom right: XLP:CP2= 1.4:1. 
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Figure 6.8. Gel electrophoretic retardation of gWIZLuc plasmid by CP1 in solutions with different concentrations of 
NaCl. The anode and cathode are marked + and -, respectively.  
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6.3.4 CP3 based polyplexes 
On the basis of the results obtained with CP2, a new polymer with longer PEG chains, shorter 
PAA chain, and increased number of sulfidryl pendants was synthesised to enhance complexes 
resistance to dilution at high salt concentration. Complexes were formed with higher XLP:CP ratios, 
namely 2:1 and 3:1, in order to achieve suitable SH:SSPy groups and PEG:PAA ratios. PAA:DNA 
ratios were maintained. Two different addition orders of the components were followed: in 
formulation 1 (F1) XLP was added to DNA, then CP3 to the complexes; in formulation 2 (F2) XLP 
was added to CP, then polymer mixture to DNA solution. Both formulations gave rise to suitable 
polyplexes with diameters ranging from 65 to 95 nm, with the exception of F1 formulations when 
using  1:1 PAA:DNA ratio. DLS analyses of the polyplexes are reported in Table 6.2.  
No relevant differences between the samples were evidenced by TEM imaging, as shown in 
Figure 6.9.  
Table 6.2. DLS analyses of salmon sperm DNA and CP3 polyplexes. 
0
20
40
60
80
100
120
Formulation
R
ad
iu
s 
(n
m
)
F1 106,0 48,6 36,4 35,0 48,7 73,4 46,7 42,1 56,3 44,1
F2 34,8 37,7 35,1 34,2 32,3 37,3 38,0 34,7 33,3 37,3
2:1 
(1:1)
2:1 
(1.25:1)
2:1 
(1.5:1)
2:1 
(1.75:1)
2:1 
(2:1)
3:1 
(1:1)
3:1 
(1.25:1)
3:1 
(1.5:1)
3:1 
(1.75:1)
3:1 
(2:1)
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200 nm 200 nm 
Figure 6.9. TEM images of salmon sperm DNA-CP3 polyplexes, with 1.25 PAA:DNA ratio. On the left: 2:1 
XLP:CP3 ratio; on the right: 3:1 XLP:CP3 
 
When sodium sulphate was added to the samples up to 4 and 10 mM concentrations, invariably 
large increase in size was observed, about three fold ratio. Anyway, samples produced with 
formulation 2 showed the smaller increase in size. Results of DLS analyses were reported in Table 
6.3 and 6.4. 
 
Table 6.3. DLS analyses of salmon sperm DNA and CP3 polyplexes in solution with different 
sodium sulfate concentrations. PAA:DNA ratio=2:1 
0
50
100
150
200
250
PAA:DNA=2:1
R
ad
iu
s 
(n
m
)
Na2SO4 0 mM 106 49 36 35 49 35 38 35 34 32
Na2SO4 1 mM 111 113 133 67 76 67 68 38 42 39
Na2SO4 10 mM 155 155 139 203 197 124 116 134 114 104
 F1   
1:1
F1 
1.25:1
F1 
1.5:1
F1 
1.75:1
 F1   
2:1
 F2   
1:1
F2 
1.25:1
F2 
1.5:1
F2 
1.75:1
 F2   
2:1
 
a) b) 
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Table 6.4. DLS analyses of salmon sperm DNA and CP3 polyplexes in solution with different 
sodium sulfate concentrations. PAA:DNA ratio=3:1. 
0
50
100
150
200
250
PAA:DNA=3:1
R
ad
iu
s 
(n
m
)
Na2SO4 0 mM 73 47 42 56 44 37 38 35 33 37
Na2SO4 1 mM 135 151 130 112 93 129 113 61 45 55
Na2SO4 10 mM 178 180 205 114 213 148 173 136 140 130
 F1   
1:1
F1 
1.25:1
F1 
1.5:1
F1 
1.75:1
 F1   
2:1
 F2   
1:1
F2 
1.25:1
F2 
1.5:1
F2 
1.75:1
 F2   
2:1
 
b) 
 
DNA enzimatic degradation tests were initially performed only on the formulation with 3:1 
XLP:CP3 ratio and 1.25:1 PAA:DNA ratio, in comparison with a non-cross linked formulation in 
which CP1 was used instead of XLP (Figure 6.10). DNA was visible only in non degraded sample, 
with the exception of XLP based polyplexes in which DNA was always not detectable. This could 
suggest that no DNA displacement occurred to this samples even in the presence of poly(styrene-4-
sulfonic-co-maleic)acid, proving cross-linking effectiveness.  
A slight DNA trace was revealed in the case of XLP based sample – F1, probably due to a non 
complete complex stabilization. Moreover, fluorescence in the wells could be ascribed to interaction 
between still complexed DNA and ethidium bromide due to a more loosened PAA-DNA interaction 
compared to F2 sample, therefore appearing as the best sample. Several different gel electrophoresis 
retardation tests were performed in different conditions but no definitive proof was obtained about 
complexes stability. 
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Figure 6.10. Gel electrophoretic retardation of gWIZLuc plasmid by PAA polymers, with 1.25 PAA:DNA, 3:1 
XLP:CP3 or CP1:CP3 ratio. The anode and cathode are marked + and -, respectively. 
 
On the bases of previous results and according to the best PEG-PAA ratio defined in previous 
research, our attention was focused on the following formulatons: 2:1 XLP:CP3 - 1.5 PAA:DNA 
and 3:1 XLP:CP3 - 1.25 PAA:DNA..  
To obtain more reliable and reproducible results and to test complex formation procedure 
scalability, a semi-automatic mixing system was set up, in which polymer and/or DNA solutions 
were mixed in a small mixing chamber at a constant flow rate controlled by two peristaltic pumps, 
according to the different dilutions and compositions.  
A small amount of NaCl was added to polymer and DNA solutions, up to a 5 mM final 
concentration, in order to increase chains mobility and to obtain more tight complexes with a better 
defined architecture. Nanoparticles formed in water were invariably smaller in size according to 
DLS analyses (e.g. complexes formed in water: 15-20 nm radius; NaCl 5mM solution: 20-30 nm 
radius), TEM images showed surprisingly very interesting differences. While round shaped 
polyplexes were formed in distilled water, in 5mM NaCl solution very regular rods or toroids were 
obtained (Figure 6.11) 
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200 nm 200 nm 
 
Figure 6.11. TEM images of salmon sperm DNA-CP3 polyplexes, with 1.25 PAA:DNA ratio, 2:1 XLP:CP3 ratio. 
obtained with a semi automatic mixing system, in distilled water (on the left) or in 5 mM NaCl solution.(right) 
 
To definitely prove the stability of complexes in high dilution conditions, ultrafiltration tests were 
performed. Microcon centrifugal filters were used with a nominal cut off of 100 k, allowing free 
polymer and/or DNA to pass through the filter while retaining the complexe. DLS showed the 
presence of nanoparticles in the retained solution for both compositions, with a certain increase in 
nanoparticle size; anyway a slight better behaviour was observed in 2:1 XLP:CP3 - 1.5 PAA:DNA 
formulation, in term of size increasing and of sample recovery (see Table 6.5) 
 
Table 6.5. DLS analyses of salmon sperm DNA and CP3 polyplexes  
before and after ultrafiltration 
0
20
40
60
80
100
120
140
Formulation
D
ia
m
et
er
 (n
m
)
before filtration 88,83 44,00 89,30 50,10
after filtration 90,20 59,40 130,50 96,00
2:1 (1,5:1) 
water
2:1 (1,5:1) 
NaCl
3:1 (1,25:1) 
water
3:1 (1,25:1) 
NaCl
 
a) b) 
93 
CHAPTER 6 – Synthesis  of cross linked polyplexes for applications in gene delivery 
 
 
 
TEM images were taken on 2:1 XLP:CP3 - 1.5 PAA:DNA sample before and after ultrafiltration 
to observe polyplexes presence and shape. A formulation in which XLP have been substituted with 
CP1 was analyzed for comparison. Results are reported in Figure 6.12. 
 
200 nm 200 nm 
Figure 6.12. TEM images of salmon sperm DNA-CP1 polyplexes, with 5:1 PAA:DNA ratio, obtained with a semi 
automatic mixing system after ultrafiltration test. On the left side the retained solution, on the right the filtrate solution. 
 
No trace of non-cross linked complexes remained in the retained solution while in the filtrate a 
disorganized solid mass was present almost everywhere in the sample.  
On the contrary, complexes were present in the formulations with the cross linker (XLP), both  in 
distilled water and in NaCl 5 mM solution. Moreover both samples retained the initial polyplexes 
shape, as discussed above. Filtrate solutions appeared both clear and free of solutes (Figure 6.13)  
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200 nm 200 nm 
200 nm 200 nm 
Figure 6.13. TEM images of salmon sperm DNA-CP3 polyplexes, with 1.25 PAA:DNA ratio, 2:1 XLP:CP3 ratio. 
obtained with a semi automatic mixing system, in distilled water (on top) or in 5 mM NaCl solution.(on bottom) after 
ultrafiltration test. On the left side the retained solution, on the right the filtrate solution 
 
 
6.4 DISCUSSION 
Cationic polymers and DNA complexes have been studied in these years as non viral vectors for 
gene delivery. Stability of complexes in various conditions is still one of the problematic aspect 
affecting in vivo application of gene therapy. For this reason we decided to perform this preliminary 
study on multi-components polyplexes based on PAA. The aim was to stabilize the DNA-PAA 
complexes by means of two strategies: creating a hydrophilic shell of PEG, well known to be 
stealth-like and non interactive with proteins or other biological media, and cross-linking the 
polyplexes through disulphide linkages, widely adopted in recent years for their stability in serum 
and blood but susceptible to be reduced in the cytoplasmic environment.  
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Previous researches, performed in Nottingham University, demonstrated the stability 
enhancement of polyplexes combining PEG and cationic PAA, the best PAA:PEG ratio for 
preventing particle coalescence being between 10:1 and 5:1. 
According to this research we synthesised two different PAA-based polymers. In the first one 
(CP2) a semi-thelechelic approach was used and a mono-PEG functionalised polymer was obtained. 
A stepwise strategy was adopted to control polymer architecture, but the entire procedure was very 
time consuming, due to the numerous synthetic and purification steps, and results were not as 
expected. In fact only 2/3 of the expected thiol pendants were detected in the final product. This is 
probably due to incomplete MBA or cystamine-m-Boc addition to functionalised PEG chains and/or 
coupling reaction between two PEG chains occurring during MBA or cystamine-m-Boc addition. 
As a result, also the PAA:PEG ratio resulted to be higher than the one previously found (around 
20:1).  
Different XLP:CP2 polymer blend ratios were investigated in DNA complexing ability. The 
ratios were chosen as a function of the number of CP2 pending sulphydryl groups. In all cases 
round shaped nanoparticles with good diameters were obtained, in particular when 0.6:1 and 0.8:1 
XLP:CP2 ratios were used, but all formulations showed less DNA protecting ability to enzymatic 
degradation than the corresponding non-cross linked polyplexes.  
On the basis of these results a different polymer was synthesised with a lower PAA:PEG ratio 
and a higher number of sulphidryl pendants. Also the synthetic strategy was modified from a step-
by-step to a block addition one, the latter not involving large excess of reagents, therefore not 
requiring extensive purifications.  
Also in this case different XLP:CP3 blends were investigated in DNA complexing ability. 
XLP:CP3 ratios were higher than the previously used ones, namely 2:1 and 3:1, leading to final 
PAA:PEG ratios of 6.5 and 8.5 respectively. Both blends were formulated with DNA using  
PAA:DNA ratios between 1:1 and 2:1 and almost all formulations showed good DNA complexing 
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properties. Polymer addition order to DNA was also varied and some differences were found. It was 
already known that better performances were obtained when polymer solution was added to DNA 
solution in a single addition. The best approach resulted to be mixing polymers together and adding 
the polymer solution to DNA solution, according to a commonly adopted protocol. According to 
this strategy better results were obtained, not only in term of particles size (polyplexes obtained 
according to F2 were invariably smaller than the ones obtained with F1) but also in term of stability 
in the presence of salt (a smaller increase in size was observed in the case of F2 polyplexes). In gel 
retardation assays, CP3 based complexes formed stable complexes with DNA that were not affected 
by the interaction with poly(styrene sulfonic-co-maleic)acid, a polyanion used to disrupt polyplexes, 
thus evidencing the efficacy of cross linking. Moreover, F2 complexes resulted so tight that no 
interaction between ethidium bromide and DNA occurred (as evidenced by the absence of 
fluorescence in the loading wells).  
More difficulties were encountered in finding the best composition, because electrophoresis gel 
retardation assays resulted to be not completely reliable. Therefore, ultrafiltration tests have been 
performed on the formulations that showed better results, in particular, 2:1 XLP:CP3 - 1.5 
PAA:DNA and 3:1 XLP:CP3 - 1.25 PAA:DNA ratios, obtained according to F2 protocol.  
Using a semi-automatic mixing system and NaCl 5mM solution as the solvent for complexes 
formation, we obtained very reproducible results on nanoparticles formation in terms of shape and 
dimensions. These sample were used in ultrafiltration test and the results obtained definitely 
confirmed that 2:1 XLP:CP and 1.5 PAA:DNA was the formulation with the higher stability.  
 
6.5 CONCLUSIONS 
In the present work novel PAA based multi-component polyplexes with increased stability for 
gene transfection purposes have been studied. The polymer mixture, combined two cross-linkable 
polymers: a PEG-PAA polymer bearing sulfidryl pendants and a PAA containing 
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ethenyldithiopyridine residues. Two different synthetic strategies were adopted and a wide 
screening of different compositions and formulations were performed. The composition identified 
as the most stable presented a very low polymer/DNA ratio compared to the commonly adopted 
polycationic transfection agents. The polyplexes obtained showed a remarkable stability in dilute 
solution even in presence of high concentration of salt; colloidal stability of polyplexes solution has 
also been demonstrated. Cytotoxicity and transfection assays are ongoing to definitely demonstrate 
the potential of these polyplexes as transfection promoters.  
Moreover, this system are currently tested by a private company for applications in the field of 
environmental analyses, ground water tracing and pollution source recovery.  
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CHAPTER 7 
 
Glass surface functionalization for AFM imaging  
of lipid systems 
 
 
7.1 INTRODUCTION 
Atomic force microscopy is one the most powerful techniques used not only for studying drugs 
morphology but also to better understand physicochemical properties of drugs, in particular 
nanostructured drug and gene delivery systems, since they are increasingly considered as the real 
key improvement to enhance therapies efficacy.  
On the other hand, comprehension of internalization mechanisms of such kind of drug delivery 
systems by cells is strongly related to understanding cell membranes morphology and behaviour. 
Several studies have been performed in vitro on real or simulated cellular membranes constituted by 
lipid bilayers 1-5.  
In collaboration with CIMaINa, Nanostructured Materials and Interfaces Interdisciplinary Center, 
we focused our attention on lipid based architecture, both small lipoproteins and lipid surfaces, 
within an extensive research concerning AFM characterization of reconstructed high-density 
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lipoproteins, used as model systems for the study of fat-hunting proteins involved in prevention of 
cardiovascular diseases 6-8. 
In order to better understand lipid-surface interactions, different surfaces have been employed by 
virtue of their different interfacial chemical properties and wettability: mica (hydrophilic, negatively 
charged), SiO2 and glass (hydrophilic, negative OH- groups), Highly Oriented Pyrolitic Graphite 
(HOPG-hydrophobic). However, these few surfaces were not sufficient to investigate thoroughly 
the effect of different surface chemistries on the formation mechanisms of liposome patterns or 
even lipid bilayer. Surface functionalization was the natural choice to succeed in investigate 
different conditions with greater elasticity.  
Several studies are reported about engineering of surfaces in order to provide specific binding 
sites for lipid particles and layers 9-12. Cholesterol is often chosen as functional group, being a 
omnipresent hydrophobic molecule in living organism, involved in several biological processes and 
naturally present in cell membranes 13. Surface linked cholesterol proved to act as molecular 
binding sites for lipid layers and particles, providing a stable and specific link 9,12,14.  
Based on this premises, in this part of the work the preparation of functionalized glass surfaces 
able to selectively bind phospholipids systems, small liposomes or extended bilayers, with tunable 
binding efficiency was reported. Cholesterol was chosen as functional binding molecule and a short 
PEG chain was inserted as hydrophilic spacer between glass and cholesterol.  
In order to test the properties of this novel surface, an extensive AFM study of the interaction 
between phospholipid 1,2-Diphytanoyl-sn-Glycero-3-Phosphocholine (Diph-PC) with cholesterol-
functionalized surfaces was carried out. Freshly cleaved mica, HOPG and PEG functionalized glass 
coverslips were also used in comparison to better understand the mechanism of phospholipids 
bilayer formation. 
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7.2 EXPERIMENTAL PART 
7.2.1 Materials 
Glass coverslips (12 mm diameter) and mica disks (10 mm diameter) were purchased from Ted 
Pella; HOPG square pieces (10 mm x 10 mm) were purchased from MikroMasch; PEG-1000, 1,1’-
carbonyldiimidazole (CDI) (>97%) were purchased from Fluka and used as received, 
cholesterylchloroformate (97%) was purchased from Aldrich and used as received, (3-
Aminopropyl)triethoxysilane (APTES), ethylenediamine (EDA) and triethylamine (TEA) were 
purchased from Fluka and distilled before use, hydrochloric acid (37%) and nitric acid (67%) were 
purchased from Carlo Erba Reagents and used as received, ACS grade acetone and chloroform were 
purchased from Fluka and used as received, water was MilliQ grade. All functionalisation and 
washing steps were performed in a Sonorex RK510H ultrasonic bath operating at 640W/35kHz at 
room temperature. Diph-PC (1,2-Diphytanoyl-sn-Glycero-3-Phosphocholine) (Avanti Polar Lipids) 
was a kind gift from Markus Paulmichl and Silvia Dopinto, Department of Biomolecular Sciences 
and Biotechnologies of the University of Milan. DiPH-PC is a synthetic lipid commonly used for 
reconstituting ion channels (since this lipid is not found in native membranes). 
 
Synthesis of di-imidazolyl terminated PEG (PEG-Im2) 
PEG (5 g, 5 mmol,) was put in a two-necked round bottom flask equipped with a stirring bar, 
vacuum/nitrogen inlet and a glass stopper. PEG was molten under gentle warming and the 
equipment purged with nitrogen. After cooling down to room temperature, chloroform (15 mL) was 
added under nitrogen, PEG allowed dissolving and CDI (4.8 g 30 mmol) subsequently added in 
small portions. After 1 hour, unreacted CDI was quenched by addition of water (5 mL) and the 
organic phase extracted with a saturated sodium chloride aqueous solution (4 x 15 mL). The organic 
phase was then dried over anhydrous sodium sulphate and the solvent evaporated under reduced 
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pressure. A pale yellow oil was obtained almost quantitatively, with purity > 95%, according to 
NMR and IR analyses. 
 
Glass coverslips functionalization  
Glass coverslips were treated before functionalization with aqua regia to increase the hydroxyl 
group content on the surface (5 washings, 1 min each). The functionalization procedure consisted of 
four steps. In the first step, the glass surface was functionalized with amino groups by reaction with 
(3-Aminopropyl)triethoxysilane (APTES). We used a freshly prepared 5% water/acetone solution 
of APTES 1% v/v for 3 min and rinsed with acetone. In the second step, PEG spacers were linked 
to the amino groups on the surface by reaction with an imidazolyl activated PEG 15. A large excess 
of di-functionalized PEG was used to link only one chain end to the surface. A 5% w/v PEG-Im2 
acetone solution was allowed to react for 15 min and rinsed with acetone. In the third step, an amino 
function was added to the free imidazolyl PEG terminus by reaction with a large excess of EDA, 
obtaining the EDA-PEG intermediate. To this purpose, coverslips were put in a 5% v/v EDA 
acetone solution, allowed to react for 15 min and rinsed with acetone. Finally, cholesterol was 
linked to the amino terminus of the PEG spacer by substitution reaction with cholestryl 
chloroformate. Coverslips were put in a 5% w/v cholesteryl chloroformate chloroform solution with 
3% TEA v/v, allowed to react for 15 min and finally rinsed with chloroform and acetone. TEA was 
used as scavenger of the HCl formed during the reaction. 
All functionalisation and washing steps were performed in ultrasonic bath at 30° C. Rinsing 
procedure consisted in three washings of 1 min in the solvent used in the previous reaction, 
followed by rinsing with 3 mL of running solvent. 
 
7.2.2 Methods 
Vesicles suspension preparation 
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50 μl of a solution of Diph-PC at 2% in chloroform were prepared. The solvent was then 
evaporated under a stream of nitrogen gas. The lipids were resuspended overnight in 400 μl of 
MilliQ water and the mixture was vortexed for 3 minutes in order to produce multilamellar vesicles.  
 
Atomic Force Microscopy 
The investigation of morphology of the samples was carried out in air using a Bioscope II AFM 
equipped with a Nanoscope V controller (Veeco Instruments, USA). All images were acquired in 
Tapping Mode using single crystal silicon tips with nominal radius of curvature of 5-10 nm and 
cantilever resonance frequency in the range 200-300 kHz. Scan areas were typically 5μm x 2.5μm 
and 50μm x 25μm, with scan rates of 1.5 Hz and 0.5 Hz, accordingly. Phase maps were recorded 
simultaneously to topographic maps. Phase maps report the phase lag between the cantilever free 
end and the driving oscillation 16. Topographic and Phase maps at higher magnification were 
collected with resolution of typically 1-2 nm/pixel. 
 
Sample preparation for AFM analysis. 
The supported lipid bilayers were prepared by vesicles fusion: 10-70 µl of the vesicles solution 
were deposited on the substrate (mica, HOPG, amino-terminated PEG-functionalized coverslips, 
cholesterol-functionalized coverslips) and incubated for 5-90 minutes at room temperature. 
Subsequently 50 µl of HBS (150 mM KCl, 5 mM Hepes, pH 8) were added for 3 minutes to remove 
of weakly bound phospholipids 18. The samples were rinsed with 3 ml of MilliQ water in order to 
remove the excess of vesicles, gently dried with nitrogen and eventually analyzed. 
 
Contact angle measurements. 
Advancing contact angles of water on different substrates have been measured using a FTA 1000 
instrument. Droplet volume was approximately 3 microliters. Shape analysis of the droplet in 
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equilibrium on the surfaces has been performed using Fta32 Video v2.0 software. For each drop we 
have estimated the contact angle as the average of left and right contact angles. Measures was 
performed in triplicate and final value was calculated as average of the three results. 
 
7.3 RESULTS AND DISCUSSION 
In this work, a novel protocol to obtain cholesterol-functionalized glass surfaces suitable for 
AFM imaging was reported. Wettability and morphological properties of this novel substrate have 
been studied by advancing contact angle and AFM imaging, in comparison to other surfaces having 
different physical and chemical properties. Moreover, a thoroughly study concerning interaction 
mechanism and structure of phospholipid patches after different incubation times on the different 
surfaces have been performed.  
 
7.3.1 Surface functionalization and morphology of substrates 
The aim of the work was to design a new tethered binding site for lipid based systems, satisfying 
several requirements: specificity against lipids, high mobility in aqueous solutions, ability to stay 
sufficiently far-away from the substrate (about 1 nm).  
We chose to modify glass surfaces for several reasons: glass coverslips are easily available and 
functionalizable, they satisfy smoothness requirements for AFM imaging and, due to their 
transparency, they can be also used for optical microscope imaging applications.  
Cholesterol was chosen as binding molecule, being an omnipresent compound of biological 
membranes and naturally inserting into phospholipid double layers. A short PEG chain was chosen 
as linker between cholesterol and glass due to its amphiphilic properties and its ability not to 
interact with proteins 18-20. PEG high hydration provides the desired separation of the binding site 
from the substrate, and keeps it from collapsing onto it. 
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Glass coverslips have been functionalized following an original four-step protocol described in 
Scheme 7.1.  
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Scheme 7.1. Functionalization strategy of glass coverslips. 
 
The protocol aims to firmly attach cholesterol groups to elastic PEG spacers, covalently attached 
to the glass surface. According to Scheme 1, imidazolyl-terminated PEG, obtained through an 
original procedure as shown in Scheme 7.2, is allowed to react with a previously amine-terminated 
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glass surface in order to bind PEG. Imidazolyl-terminated PEG is very reactive towards exchange 
with primary or secondary amines, and is also stable enough to be isolated and stored in the cool 15.  
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Scheme 7.2. synthesis of bis-imidazolyl PEG. 
 
The addition of an amino function to the end of PEG chains provides the EDA-PEG intermediate 
surface that has been investigated in this study. Eventually, cholesterol is added. Figure 2 shows an 
AFM image of a cholesterol-functionalized glass coverslip (the last step of the functionalization 
procedure). The surface of cholesterol-functionalized glass coverslips shows the typical nano-
porous, textured morphology of untreated glass coverslips (not shown). In particular, the typical 
nanometer-sized holes observed in clean untreated glass coverslips appear in Figure 7.1 as dark 
spots. These holes do not get filled upon surface functionalization, because the latter acts at the 
molecular level, and the functionalization density is relatively low.  
 
Figure 7.1. AFM topography of cholesterol functionalized glass coverslip. 
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The typical rms-roughness of clean glass coverslips is 0.3 nm; it remains well below 1 nm after 
functionalization with EDA-PEG and cholesterol. Mica and HOPG substrate were used fresh after 
cleavage. These substrates are atomically smooth.  
Several expedients were adopted in order to obtain very clean surfaces satisfying the standard for 
AFM imaging of small nanoparticles. Only freshly prepared reagents were utilized and much 
attention was paid to materials purity grade. Reaction times were kept short, and concentrations 
were kept low, in order to avoid deposition of excess materials on the surface and preserve its 
smoothness. Each reaction and rinsing step was performed in an ultrasonic bath at 30° C, in order to 
improve the spatial homogeneity of the functionalization, enhance the reaction kinetics, and 
minimize re-deposition of desorbed excess material on the surface.  
 
7.3.2 Contact angle measurements 
Table 7.1 summarizes the advancing contact angles of water measured on cholesterol-
functionlized and EDA-PEG-functionalized glass coverslips, glass coverslips freshly cleaned in 
aqua-regia for 15’, HOPG and mica. Freshly cleaved mica is highly hydrophilic.  
 
Table 7.1. advancing contact angles of water upon different surfaces 
Surface Contact Angle (°) 
Mica < 5 
Glass coverslip (aqua regia cleaned) 32 ± 2 
Amino-terminated PEG 69 ± 3 
HOPG 85 ± 2 
Cholesterol-functionalized 91 ± 6 
 
We measured a contact angle of less than 5°, corresponding to complete wetting. As reference, 
we have measured the contact angle of a clean glass coverslip surface (32 ± 2°), because this is the 
basic substrate for all the functionalized surfaces considered in this study. Amino-termination of 
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PEG molecules led to a surface with a contact angle of 69 ± 3°. On cholesterol-functionalized 
coverslips we measured a contact angle of 91 ± 6°, while that measured on HOPG is 85 ± 2°. 
According to these values, cholesterol functionalized glass appear as the most hydrophobic surface.  
 
We can estimate approximately the effective coverage of amino and cholesterol groups on glass 
coverslips. The binding efficiency of imidazolyl-PEG to silane is very high, and the incubation 
times allow for a complete saturation of silane sites by PEG. This is also true for the binding 
affinity of EDA to imidazolyl-PEG and of cholesterol to EDA terminals. We assume therefore that 
all the sites where silane attached are also successfully functionalized with EDA and/or cholesterol. 
As a consequence, the glass/PEG/cholesterol surfaces consist in uncovered glass domains and in 
cholesterol- or EDA-PEG-functionalized regions. According to Cassie & Baxter 21,22, the relation 
between the measured contact angle cosθGlass/Chol and those of homogeneous glass and cholesterol 
surfaces is: 
CholCholGlassCholCholGlass ff θθθ coscos)1(cos / +−=      Eq(7.1) 
where fChol is the fraction of the surface occupied by the cholesterol molecules. From the plot of 
cosθ vs. cholesterol coverage shown in Figure 2 of ref. 14, assuming that the maximum effective 
coverage of cholesterol on a gold surface is 65% 24, and recalibrating the curve accordingly, we 
calculate a value of θChol = 141° for a surface with a 100% cholesterol coverage. Using our data for 
θGlass/Chol and θGlass, we obtain fChol ≈ 55%. According to our hypotheses, this value represents also 
the fractional degree of functionalization of EDA-PEG on glass coverslips. Sheikh et al. found a 
similar functionalization density of cholesterol on self-assembled monolayers on gold 12. 
 
7.3.3 AFM imaging of phospholipids layers. 
Diph-PC multilamellar vescicles preparation and deposition onto the different surfaces were 
performed according to standard procedures. Lipid patches, both layers and particles, are firmly 
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attached to all the substrates. Despite the fact that samples are (gently) washed with water and a 
liposolvent agent, HBS, and dried before AFM imaging, lipid domains neither detach, nor loose 
their structural order, when present. Images of each sample are collected after different incubation 
times, from 10 to 90 minutes in order to appreciate deposition kinetics. Anyway after only ten 
minutes from deposition, relevant differences among the different samples are revealed.  
On mica phospholipids tend to form circular islands with a quite regular shape (Figure 7.3). 
These circular islands have different heights, all consistent with an integer multiple of the bilayer 
basic thickness (around 6 nm) and very steep sidewalls, even when their thickness is more than that 
of a single bilayer. The almost perfect circular shape suggests that the bilayers, generated by 
adhesion and flattening of lipid vescicles, have high lateral mobility and can easily undergo changes 
of shape on mica in order to minimize the line tension. Moreover, The growth of lipid patches 
seemed to be more three-dimensional (up to 15 stacked bilayers are observed) than two-
dimensional, suggesting that phospholipids interact more likely among themselves that with mica 
surface. After time, surface covering increase and wider lipid patches formed as a consequence of 
island coalescence.  
 
 
Figure 7.3: AFM topographic (left) and phase (right) maps of supported phospholipid bilayers on mica after an incubation time of 
10 minutes (vertical scale 50 nm) 
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HOPG showed not surprisingly a completely different behavior. Only small lipids domains can 
form on the surface, with a thickness around 2 nm, compatible with single Diph-PC layer (Figure 
7.4). In the case of hydrophobic HOPG, in fact, liposomes can interact only after a severe structure 
modification, since hydrophilic phospholipids head is initially exposed in the aqueous solution. 
Once the liposome is disrupted, small mono-layers initially form, in which interaction between 
phospholipids hydrophobic tails and the surface occurred.  
 
 
Figure 7.4: AFM topographic (left) and phase (right) maps of supported phospholipid bilayers on HOPG after an incubation time 
of 10 minutes (vertical scale 50 nm) 
 
The behavior of liposomes upon glass surface functionalized with amino terminating PEG chains 
was also analyzed, in order to better understand the behavior of liposomes on cholesterol 
functionalized glass obtained by reaction of cholesteryl chloroformate with EDA-PEG glass. 
The morphology is similar to that of mica after a much longer time. Regular, extended bilayers 
are already formed after only 10 minutes, although less stratification is observed with respect to 
mica and no circular islands are visible (Figure 7.5). EDA-PEG terminated surfaces evidently favor 
the rapid adsorption of negatively charged vesicles and the binding of phospholipids, thus 
accelerating the formation of extended bilayers  
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Bilayers appear to be less thick than on mica (around 5 nm). This behavior is not well 
understood. It can be possibly ascribed to a direct interaction between weakly basic amine PEG 
terminus with the anionic part of Diph-PC, causing a distortion in phospholipids arrangement 
and/or to a thinner water interlayer between glass and lipid bilayer induced by a backdrawing PEG 
effect. EDA-PEG terminated surfaces favor the rapid adsorption of negatively charged vesicles and 
the binding of phospholipids, thus accelerating the formation of extended bilayers.  
 
 
Figure 7.5: AFM topographic (left) and phase (right) maps of supported phospholipid bilayers on EDA-PEG fuctionalized glass 
surface after an incubation time of 10 minutes (vertical scale 50 nm) 
 
The case of cholesterol-PEG functionalized glass surface is, as expected, much different. Despite 
the hydrophobicity was very similar to (or even higher than) HOPG, only after 10 minutes from 
deposition, very uniform and extended bilayers was formed, covering almost completely the surface 
with a few exceptions (Figure 7.6).  
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Figure 7.6: AFM topographic (left) and phase (right) maps of supported phospholipid bilayers on cholesterol fuctionalized glass 
surface after an incubation time of 10 minutes (vertical scale 50 nm) 
 
Small lipid particles are decorating the top of the first bilayer. Rare second and third bilayer can 
also be seen, representing the early stages of the formation of a second bilayer. The measured 
thickness of the first bilayer appeared to be smaller than on mica and EDA-PEG coverslip (around 
4.5 nm). We though that cholesterol mobile residues tethered by PEG to the glass surface can 
intercalate lipids bilayers disrupting the regularly phospholipids arrangement, thus accelerating 
single bilayer assembly on top of the surface. A schematic representations of the already discussed 
different lipids-surfaces interaction is reported in Figure 7.7.  
HOPG
- - - - - - - -
MICA
++
Phospholipid molecule
Water molecules
EDA-PEG chains
Cholesterol unit
+ + +
EDA-PEG 
functionalized glass
CHOLESTEROL-PEG
functionalized glass  
Figure 7.7: Schematic representation of the first phospholipid layers on different surfaces considered in this study. HOPG: DiPH-
PC forms a phospholipid monolayer by the hydrophobic interaction of the lipophilic chains with HOPG surface. Mica: several water 
layers arrange between the negatively charged surface and the phospholipid bilayer. EDA-PEG: positively charged EDA-PEG 
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macromolecules grafted on the glass surface directly interact with the negative charges of DiPh-PC molecules, inducing a bending on 
the double layer assembly. In this case only the PEG-solvating water molecules are positioned between the double layer and the 
surface. Cholesterol-PEG: when cholesterol is bound to a PEG chain, lipophilic interactions between cholesterol and liposomes take 
place, causing cholesterol intercalation in the double layer. The presence of a small water layer solvating PEG chains prevents from 
the direct interaction of the lipophilic tails of DiPh-PC with the substrate’s surface. 
 
As already stated, a cholesterol coverage around 55 % can be estimated for the cholesterol-
functionalized glass studied in this work. It is noticeable that the degree of functionalization can be 
easily modified by tuning of the first glass functionalization step, for example controlling 
silanization reaction time or silane concentration.. We expect that a lower density of cholesterol 
group allows to obtain single lipid nanoparticles binding instead of extended bilayers, as suggested 
by preliminary studies.  
 
7.4 CONCLUSIONS 
Structure and morphology of DiPh-PC phospholipid domains on different surfaces have been  
thoroughly investigated by atomic force microscopy. In particular, a new functionalization strategy 
based on the attachment of cholesterol residues to glass coverslips surface for the firm binding of 
phospholipid layers and nanoparticles have been developed, providing ultra-clean, smooth substrate 
suitable for single-particle studies by AFM. Modified glass surfaces obtained according the stated 
protocol can be also useful in optical microscopy studies, being glass transparency not affected by 
the functionalization. In particular by AFM –fluoresecnce microscopy coupling, further possibilities 
of studying proteins interaction with lipid bilayers are opened. 
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Common materials and methods 
 
Materials.  
1,4-Dithio-DL-threitol (DTT) (99%),  carbonyl di-imidazole (>97%), cystamine dihydrochloride 
(>98%), lithium hydroxide monohydrate (>98%), morpholine (>99%), N,N’-
dimethylethylenediamine (>98%) (DMEDA), piperazine (>99%), poly(ethylene glycol) (PEG) 
1000, poly(ethylene glycol) methyl ether 750, poly(ethylene glycol) methyl ether 2000, tri-etyl 
amine (TEA),  tris(hydroxymethyl)aminomethane (TRIS) (>99.8%), were purchased from Fluka 
and used as received;  2,2’-dipyridyl disulfide (98%),  2-mercaptopyridine (>95%), azobenzene 
(>98%), cholesteryl chloroformate (97%), di-tert-butyl-dicarbonate (>98%), estradiol (97%), N,N’-
methylenebis(acrylamide) (MBA) (>98%),  thiocholesterol (98%), were purchased from Aldrich 
and used as received; ethylene diamine (EDA) was purchased from Fluka and distilled before use, 
2-Methylpiperazine were purchased from Fluka and used after sublimation, purity controlled by 
acidimetric titration; 2,2-Bis(acrylamido)acetic acid (BAC) (Ferruti, Ranucci et al., 1999) and 
bis(acryloyl)piperazine (BP) (Ferruti, 1985) were synthesized according to a procedure reported 
elsewhere. CDCl3 (99.8%) stabilized over silver coil, D2O (99.9%), d6-DMSO (99.8%), MeOD 
(99.8), DCl 35% in D2O solution and NaOD 30% in D2O solution  were purchased from Aldrich. 
Organic solvents used were all analytical grade and were purchased from Fluka. Water was 
bidistilled.  
 
Instruments and Methods.  
(a) 1H and 13C NMR spectra were run on a Brüker Advance 400 spectrometer operating at 
400.132 MHz (1H) and 100.623 (13C).  
(b) Size exclusion chromatography (SEC) traces of polymers soluble in organic solvents 
(polystyrene standards) were obtained with Phenomenex Phenogel 500, 103, and 104 A columns, 
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connected in series, UV detector operating at 254 nm, mobile phase 9/1 (v/v) CHCl3/CH3OH. SEC 
traces of water soluble polymer (pullulan standards) were obtained using a WATERS 515 HPLC 
PUMP instrument, with Toso-Haas 486 columns, using 0.1 M TRIS buffer pH 8.0 ± 0.1 as mobile 
phase, UV detector operating at 230 nm.  
(c) UV-VIS spectra were run on a Perkin-Elmer Lambda EZ210 spectrometer. For all 
measurements, quartz cells with a 1 cm path length were used.  
(d) IR spectra were recorded with a Jasco FT/IR-4100 spectrometer. 
(e) Elemental analyses were performed with a Fison EA 1108 CHNS apparatus. 
(f) Specific optical rotations were measured with a Jasco P-1030 polarimeter. 
(g) Transmission electron microscopy analyses were performed with Zeiss LEO 912AB 
(EFTEM). One drop of 0.1 mg/mL nanoparticle dispersion was placed on a polymer coated sample 
grid after filtration on 0.45 μm HPLC syringe filter, the excess dried out and the sample stained 
with uranyl acetate. 
(h) Particle size distributions were measured using a Viscotek 802 Dynamic Light Scattering 
analyzer. Samples were prepared dispersing 1 mg of lyophilized nanoparticles in 1 mL of distilled 
water in ultrasonic bath for 15 min, then diluting with a three fold amount of water or phosphate 
buffer solution and filtering on 1 μm HPLC syringe filter. Samples were analyzed with a Viscotek 
802 DLS, data analized with Omnisize 2.0 software, Correlator resolution 256 channel. 
(i) AFM imaging was performed using a Bioscope II AFM equipped with a Nanoscope V 
controller (Veeco Instruments, USA). All images were acquired in Tapping Mode using single 
crystal silicon tips with nominal radius of curvature of 5-10 nm and cantilever resonance frequency 
in the range 200-300 kHz. Scan areas were typically 5μm x 2.5μm and 50μm x 25μm, with scan 
rates of 1.5 Hz and 0.5 Hz, accordingly. 
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Poster and oral presentations: 
 
EPF 3rd Summer School 
22-27 May 2005 - Saint Die des Vosges, France 
 
Poster:  
1.  Marco Suardi, Amedea Manfredi, Jade Wu, Elisabetta Ranucci, Paolo Ferruti. 
Kinetic analysis of polymerization of poly(amidoamine)s in organic solvents. 
2.  Marco Suardi*, Sabrina Bianchi*, Federica Chiellini**, Elisabetta Ranucci*, Paolo Ferruti*. 
Novel poly(amidoamine)-based hydrogels as scaffold for tissue engineering. 
 
 
33rd Annual Meeting of the Controlled Release Society 
July 22-26, 2006 - Wien, Austria 
 
Poster:  
Suardi Marco, Franchini Jacopo, Cavalli Roberta, Ranucci Elisabetta, Ferruti Paolo 
Transfection efficiency and preliminary pharmacokinetics study of amphoteric 
agmatine-based poly(amidoamine) 
 
 
1° Forum Nazionale dei Giovani Ricercatori su Materiali Polimerici e Biomteriali 
September 18-20, 2006 - Modena, Italy 
Member of the scientific committee. 
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7th International Symposium on Frontiers in Biomedical Polymers 
June 24-27, 2007 - Ghent, Belgium 
 
Oral presentation: 
Marco A. Suardi, Elisabetta Ranucci, Paolo Ferruti 
New stimuli-responsive polymeric nanoparticles based on cholesterol-poly(amidoamine) 
conjugates. 
 
 
3rd IUPAC International Symposium on Novel Materials and their Synthesis (NMS-III) & 17th 
International Symposium on Fine Chemistry and Functional Polymers (FCFP-XVIII) 
October 17-21, 2007- Shanghai, China 
 
Oral presentation: 
M.A. Suardi, E. Ranucci P. Ferruti, E. Emilitri, F. Martello, E. Lattanzio, F. Fenili. 
Biocompatible and Bioeliminable Hydrophilic Polymers 
 
 
International Congress on Biohydrogels 
November 14-18, 2007- Viareggio, Italy 
 
Oral Presentation: 
Marco Suardi, Elisabetta Ranucci, Paolo Ferruti, Federica Chiellini. 
Novel poly(amidoamine)-based hydrogels as scaffold for tissue engineering. 
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Polymerization Kinetics 
of Poly(amidoamine)s 
in Different Solvents
AMEDEA MANFREDI, ELISABETTA RANUCCI*, MARCO SUARDI, 
AND PAOLO FERRUTI
Dipartimento di Chimica Organica e Industriale, Università di Milano,
via Venezian 21, 20133 Milano, Italy and CIMAINA, Centro
Interdisciplinare Materiali e Interfacce Nanostrutturate, via Golgi 19,
20133 Milano, Italy
ABSTRACT: The polyaddition kinetics of 2-methylpiperazine to 1,4-bis-
acryloylpiperazine was determined in water, methanol, ethylene glycol, for-
mamide, and dimethylformamide, respectively. In the protic solvents, the
polyaddition proceeded through a two-step mechanism, each step involved one
of the two different secondary amino groups; the difference in amine reactiv-
ity was ascribed to the different steric hindrance by the neighbouring groups.
Each step followed pseudo-second-order kinetics; the kinetic constants
included the catalytic protonic species. In the case of dimethylformamide, the
polyaddition proceeded through third-order kinetics; this accounted for the
autocatalytic activity of the amino groups. The apparent kinetic constants in
the protic solvents increased with the increase in the autoprotolysis constant
values and decreased with the increase of the dipole moment.
KEY WORDS: poly(amidoamine)s, polymerization kinetics, stepwise polyad-
dition in organic solvents.
INTRODUCTION
Poly(amidoamine)s (PAAs) are biodegradable and biocompatiblesynthetic polymers characterized by the presence of tert-amino
Q1
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groups in the main chain [1–5]. Besides being endowed with interest-
ing properties as polymeric bases and metal ion complexing agents
[6–9], PAAs have important biomedical properties, such as heparin-
complexing ability [9,10]. Water-soluble PAAs have been extensively
studied by Duncan et al. as drug carriers and endosomolytic polymers
[11–16]. In cross-linked form, hydrophilic PAAs give rise to hydrogels,
some of which exhibit excellent biocompatibility and are currently being
studied as scaffolds for tissue engineering [17,18].
PAAs are usually obtained by hydrogen-transfer polyaddition of
primary or secondary amines to bis-acrylamides (Scheme 1). The reac-
tion conditions involve room temperature (15–30°C) conditions with no
added catalysts.
One of the advantages of PAAs as specialty polymers is that they
are amenable to further functionalization. PAAs containing other
chemical functions as side-substituents can be obtained by using suit-
ably functionalized monomers. In fact, only a few groups are able to
interfere in the polyaddition reaction and, in principle, nearly every
aliphatic amine and bis-acrylamide can be used as a monomer.
For some purposes, PAAs containing hydrophobic moieties can be
obtained. This involves the use of water-insoluble monomers and,
therefore, organic reaction solvents are needed [19]. Pioneering stud-
ies performed by the authors showed, not surprisingly, that high
molecular weight polymers can only be obtained in organic solvents
bearing mobile hydrogens, such as alcohols. Aprotic solvents gave poor
results irrespective of their polarity [1].
Since systematic comparison studies of the polymerization kinetics
of PAAs in water and alcohols were lacking, a comparative study of the
kinetics was performed in water, methanol, and ethylene glycol of a
typical polyaddition reaction, namely that of 2-methylpiperazine (MP)
to 1,4-bis-acryloylpiperazine (BP). Formamide, was also studied,
together with a typical dipolar aprotic solvent, dimethylformamide.
Scheme 1. Synthesis and genera molecular structure of PAAs.
EXPERIMENTAL
Materials and Methods
BP was prepared as previously described [20]; 2,5-dimethylpiperazine
(DMP) was commercially available (Aldrich) and was used without
further purification. The MP was purchased from Fluka and recrystal-
lized from n-heptane (1 g MP in 20 mL solvent) before use. Its purity
was checked just before use by potentiometric titration. The organic
solvents were anhydrous analytical grade, freshly purchased from
Fluka. They were transferred under dry nitrogen by means of
syringes. The bottles were opened just before use and their content
leftover molecular sieve. 0.1 M hydrochloric acid solution was
purchased from Riedel-de Haen. Water was doubly distilled.
Measurements
UV-VIS spectra were run on a Perkin-Elmer Lambda EZ210 spectrom-
eter connected to a PC for data transfer. For all measurements, quartz
cells with a 1 cm path length were used. The calibration curves were
obtained for each solvent in the analysis of BP at nine different con-
centrations; the absorbance at 250 nm fell within the range 0.04–0.9.
The solutions were prepared using as solvent 0.1 M hydrochloric acid
containing 0.05% v/v of the organic solvent used. The data were
processed by means of the least square fitting.
Model Polymerization Reactions
A 0.4 M solution of BP in the appropriate solvent (25 mL) and a 0.4 M
solution of MP (or DMP) in the same solvent (25 mL) were introduced
by means of syringes into a 100 mL one-necked flask, equipped with a
silicon rubber stopper and thermostated at 25°C. The reaction mixture
was flushed with dry nitrogen and then kept at 25°C without stirring.
Aliquots (10 L) were withdrawn at specific reaction times, and 
the final volume of each was adjusted to 20 mL with 0.1 M hydrochlo-
ric acid. The UV absorption of each solution was measured against 
the appropriate blank solution, that is, 0.1 M hydrochloric acid con-
taining 0.05% v/v of organic solvent; the experiments were performed
in duplicate.
RESULTS AND DISCUSSION
The aim of this work was to study the kinetics in different solvents
(water, methanol, ethylene glycol, formamide, and dimethylformamide)
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of a typical polyaddition reaction leading to a PAA. The model reaction
adopted in this study was the polyaddition of MP to BP (Scheme 2).
This reaction was chosen as model PAA preparation, because both
the monomers involved, as well as the resultant polymer, are easily
soluble in water, lower alcohols, and formamide. Perhaps plain
piperazine would have been an even better model, because it bears two
perfectly identical amino groups. Piperazine, however, was discarded
because its polymer with BP is soluble only in water [2–4] and,
therefore, in organic solvents precipitation would occur after a short
reaction time. Moreover, MP is the amine used as the monomer in the
PAAs with particular biomedical interest, some of which also employ
BP as a co-monomer (4). In addition, to investigate the effect of the dif-
ferent steric hindrance of the substituents in the -position to the reac-
tive secondary amine groups on the polyaddition reaction with
bis-acrylamides, MP and, in the case of aqueous solutions, DMP were
chosen as monomers.
The reactions were carried out at 25°C (close to the room tempera-
ture for the PAA syntheses). The reaction progress was monitored by
UV spectroscopy, preferred to other methods for its sensitivity, fast-
ness, and cheapness, measuring the decrease in the intensity of the
absorption band of the conjugated double bonds of BP. The following
procedure was invariably adopted. The polymerization reactions were
carried out at a 0.2 M concentration in the selected solvent (see
Experimental Section), that is, approximately 1/10 of the reaction con-
centrations commonly adopted in PAA syntheses. Aliquots (10 L) of
the polymerization solutions were taken at specific time intervals and
diluted in 20 mL 0.1 M aqueous hydrochloric acid, in order to stop the
polymerization reaction and to reach a suitable concentration for UV
measurements. The UV spectra of MP, BP and their polyaddition
product were, therefore, preliminarily studied in 0.1 M aqueous
hydrochloric acid containing 0.05% v/v of organic solvent, in order to
verify the influence of the residual solvent on the absorption spectra of
reagents and products. The absorption spectra in 0.1 M aqueous
hydrochloric acid  0.05% (v/v) methanol are shown in Figure 1. In all
the aqueous mixtures, the absorption spectrum of BP showed a pecu-
liar absorption band with a maximum at 240 nm due to the –*
A. MANFREDI ET AL.4
Scheme 2. Polyaddition reaction of BP to MP.
transition of the BP conjugate double bond. In this range, BP spectrum
partially interferes with the tail of polymer absorption bands. For this
reason, a different wavelength, 250 nm, was chosen for measuring the
decrease in BP concentration. The molar extinction coefficients curves
obtained in the different aqueous hydrochloric acid/solvent mixtures,
ε, are reported in Table 1. The experimentally determined values of ε
show slight differences in different aqueous/solvent mixtures, reflect-
ing the different interactions between solvent and BP.
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Table 1. Molar extinction coefficients ε for 
bis-acryloylpiperaizine.*
Solvent Molar Extinction Coefficient (1/M cm)
Water 10 600
Ethylene glycol 12 200
Methanol 11 400
Formamide 11 700
Dimethylformamide 12 400
*In 0.1 M hydrochloric acid with 0.05% of different organic solvents at 250 nm.
Figure 1. Absorption spectra of BP (—), MP (—..—) and the the polyaddition products
(- - -) in 0.1 M aqueous hydrochloric acid  0.05% (v/v) methanol.
Kinetic Features and Determination of Rate Constants
The conversion curves obtained in the polyaddition reaction of BP with
MP in the series of solvents listed in Table 1 are shown in Figure 2. It
is apparent that the reaction proceeds much faster in water and glycol
than in methanol, formamide, and dimethylformamide, the latter
solvents gave the poorest performance.
To investigate the kinetic features of the polymerization reactions
of BP with MP in different protic solvents, we referred to our previous
studies on hydrogen transfer addition and polyaddition reactions
involving acrylamides, bis-acrylamides, and/or bis-acrylic esters
[21–23]. These reactions exhibited pseudo-second-order kinetics, with
the kinetic constants that included the concentration of the catalytic
protonic species, when performed in the presence of hydroxyl solvents.
On the basis of this premise, the current data was substituted in the
following equation:
(1)
d BP
d
BP MP
⎡⎣ ⎤⎦
= − ⎡⎣ ⎤⎦ ⎡⎣ ⎤⎦t k
A. MANFREDI ET AL.6
Figure 2. Conversion curves of the polyaddition reaction of BP with MP in different sol-
vents: water ( ), glycol ( ), methanol ( ), formamide () and dimethylformamide ( )
[the best fitting curves were obtained using Equation (3) and for dimethylformamide
Equation (4)].
Q3
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on integration, if the initial reagent concentrations, [BP]o and [MP]o,
are equal, Equation (2) is obtained:
(2)
The results obtained from the experimental data using Equation (2) are
reported in Figure 3(a)–(d). Unexpectedly, the 1/[BP] versus t curves
obtained were not linear, but they all diverged at ~50% conversion.
These facts suggested that the amine groups on MP may not be equiv-
alent, due to the different steric hindrances by the neighbouring
groups. To confirm this hypothesis, polymerization reactions were per-
formed in water using DMP with two equivalent amine groups. A typi-
cal conversion curve was obtained (Figure 4). The results obtained from
these experimental data using Equation (2) are reported in Figure 5. In
this case, the relationship of 1/[BP] versus t curve was approximately
linear with some deviation in the lower conversion region. This was
ascribed to a small decrease in reactivity, affecting the second amino
group of DMP after the first addition step had occurred. The pseudo-
second-order kinetic constants, kDMP, are reported in Table 2.
These findings indicate that the polyaddition reaction of MP with
BP proceeds through two distinct reaction steps, each characterized by
a different rate. The first relatively fast step corresponds to the addi-
tion of the least hindered amine, whereas the second to the addition of
the most hindered amine.
In the case of protic solvents, the kinetic constants of the two reac-
tion steps were obtained by determining the slopes of the very initial
and the very final segments of the 1/[BP] versus t curves (Figure 3),
with the assumption that in either regions the reaction of one amino
group of MP prevails over the other. Specifically, the faster step, with
kinetic constant k1, occurs in the initial phase of the reaction, whereas
the slower step, with kinetic constant k2, occurs in the final reaction
phase.
The values of the k1 and k2 kinetic constants obtained for the differ-
ent protic solvents are reported in Table 2. These values were used to
simulate the theoretical conversion curves by numerically integrating
the differential Equation (3),
(3)
d BP
d
BP MP BP MP
⎡⎣ ⎤⎦
= − ⎡⎣ ⎤⎦ ⎡⎣ ⎤⎦ − ⎡⎣ ⎤⎦ ⎡⎣ ⎤⎦t k k1 1 2 2
1 1
BP BP
o
⎡⎣ ⎤⎦
= ⎡⎣ ⎤⎦
+ kt
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].
where [MP1] is the concentration of the least hindered amino group
and [MP2] the concentration of the most hindered amino group. The
results, reported in Figure 3, fit the experimental data. Moreover, a
comparison of the k2-value relative to the MP reaction in water with
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Figure 4. Conversion curves of the polyaddition reaction of BP with MP (O) and DMP
() in water.
Figure 5. Calculated kinetic data using Equation (2) for the polyaddition reaction of BP
with DMP in water [the best fitting curve was obtained using Equation (3)].
Q3
the kDMP, value (Table 2) in the same solvent shows that they are very
close to each other, thus confirming that steric hindrance influences
the second MP reaction step.
A different case was represented by MP reaction in dimethylfor-
mamide, where the best fitting curve was obtained by assuming a
third-order kinetics (Equation 4), which accounts for the autocatalytic
effect of the aminic functions in aprotic solvents. Because the reaction
rate in dimethylformamide under the conditions adopted is very slow,
it was not possible to reach more than 50% conversion and, conse-
quently, to determine the kinetics of the second step. The kinetic 
constant determined was 0.0142 min/M2.
(4)
A comparison of the kinetic constants obtained in the different sol-
vent systems allowed us to confirm that the proton concentration and
solvent polarity are the main factors affecting the reactivity of the
system. The pKa and dipole moment, , values for all solvents employed
are reported in Table 3. It was observed that, in general, the reactivity
increased with increasing proton concentration and decreasing solvent
polarity. In the case of formamide, a dipolar solvent with an autoprotol-
ysis constant (pKa  16.80), which is similar to that for methanol
(16.71), the reaction rate is remarkably low. It appears that in the case
of formamide, which has a very high dipole moment, the establishing of
dipole–dipole interactions between solvents and reactants largely over-
shadowed the positive effect of proton availability on the reaction rate.
In particular, the polarizable acrylic moiety of BP, stabilized by the
dipolar solvent, showed a decrease in addition reactivity. The same sta-
bilizing effect may be responsible for the very low reaction rate
d BP
d
BP MP
⎡⎣ ⎤⎦
= − ⎡⎣ ⎤⎦ ⎡⎣ ⎤⎦t k
2
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Table 2. Kinetic constants for the polyaddition reaction* with DMP.
Solvent k1 (1/min M) k2 (1/min M)
Water 0.804 0.0961
Methanol 0.143 0.0158
Etylene glycol 1.013 0.0946
Formamide 0.042 0.0030
Water – DMP / 0.0972
*In 0.1 M Hydrochloric acid with 0.05% of different organic solvents at 250 nm.
observed in dimethylformamide, a classical aprotic dipolar solvent,
which also had a very low autoprotolysis constant (pKa  30).
CONCLUSIONS
The kinetic constants, hence the polymerization rates for typical
Michael-type stepwise polyadditions leading to PAA have been studied
in different solvents. It was found that the solvent’s nature is the key
factor governing the reactivity of the system, and general correlations
were established. In particular, the reaction is of second order in 
solvents carrying mobile hydrogens and, in solvents of comparable 
polarity, the kinetic constants are roughly proportional to the autopro-
tolysis constants. Solvent polarity has a negative effect on the reaction
rate, as demonstrated by the remarkable sluggishness of the reaction
in formamide, a solvent with high polarity and high autoprotolysis
constant. In polar solvents with low autoprotolysis constant, the reac-
tion constant is extremely low.
Until now, the preferred reaction solvent for PAA preparation was
water. It would appear that lower alcohols and glycols may be suitable
alternatives as reaction media. From a practical standpoint, this may
extend the scope of PAA synthesis to water-insoluble amines and 
bis-acrylamides.
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CommunicationPoly(amidoamine)s with 2-Dithiopyridine
Side Substituents as Intermediates to
Peptide–Polymer ConjugatesElisabetta Ranucci,* Paolo Ferruti, Marco Alessandro Suardi,
Amedea ManfrediCystamine, when employed as a cross-linking agent, leads to poly(amidoamine) networks,
which on reaction with 2,20-dithiodipyridine turn into linear poly(amidoamine)s with side
dithiopyridyl groups that easily undergo exchange reactions with reduced L-glutathione, a
model thiol-containing biologically active peptide. The resultant products represent the
first examples of soluble poly-
(amidoamine)–peptide conju-
gates in which the peptide
moieties are linked to the poly-
mer chain by S–S bonds stable
in blood, but cleavable inside
cells.Introduction
Biocompatible polymers that bear disulfide linkages
in their structure can be regarded as stimuli-sensitive
systems stable in the blood but apt to intracellular release
of active substances triggered by disulfide reduction.[1,2]
In particular, significant interest has been focused on
disulfide cross-linked non-viral gene delivery systems
designed to mediate the intracellular release of DNA.[3–8]
Poly(amidoamine)s (PAAs) are a family of synthetic
functional polymers developed for use as polymer
therapeutics.[9] Linear PAAs are commonly prepared by
the polyaddition of primary mono-amines or bis-
sec-amines to bis-acrylamides. Primary bis-amines usually
lead to cross-linked PAAs.[9–12] PAAs are normally degrad-E. Ranucci, P. Ferruti, M. A. Suardi, A. Manfredi
Dipartimento di Chimica Organica e Industriale and Centro
Interdipartimentale Materiali ed Interfacce Nanostrutturati
(CIMAINA), Universita` degli Studi di Milano, via Venezian 21, 20133
Milano, Italy
Fax: þ39-02-50314129; E-mail: elisabetta.ranucci@unimi.it
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 2007 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheimable in aqueous media[13] and many of them are only
moderately toxic in spite of their polycationic nature.[12,14]
Amphoteric PAAs that carry pendant carboxy groups are
approximately as biocompatible as dextran, and when
injected in animals they are endowed with ‘stealth-like’
properties and passively concentrate in solid tumors by
the EPR (enhanced permeation and retention) effect.[14]
These PAAs are pH-dependent membrane responsive and
have been examined as anticancer drug carriers and
endosomolytic vectors for gene and toxin delivery.[12–16]
Recently, ‘smart’ PAAs that bear disulfide linkages
regularly arranged along the backbone, and are therefore
amenable to both hydrolytic and reductive degradation,
have been reported.[17–19]
Based on this premise, we describe here a synthetic
route to novel linear PAAs that bear pendant 2-ethenyl-
dithiopyridine moieties (PAA-SSPy), which involves the
disulfide–disulfide exchange reaction of cystamine cross-
linked PAAswith 2,20-dithiodipyridine. These polymers are
intermediates for the synthesis of new bioactive macro-
molecular conjugates amenable to exchange reaction with
thiol-containing active molecules. 2-Ethenyldithiopyridine-DOI: 10.1002/marc.200700139 1243
E. Ranucci, P. Ferruti, M. A. Suardi, A. Manfredi
1244derived disulfides are, in fact, extremely active towards
these reactions, the driving force of which is the produc-
tion of 2-mercaptopyridine which, upon predominantly
forming the tautomeric 2-thiopyridone, is an excellent
leaving group.[20]Experimental Part
Instruments and Methods
1H and 13C NMR spectra were run on a Bruker Advance 400
spectrometer operating at 400.132 (1H) and 100.623 (13C) MHz.
Size exclusion chromatography (SEC) traces of water-soluble
polymers (pullulan standards) were obtained with Toso-Haas
486 columns using 0.1 M Tris buffer pH 8.000.05 as a mobile
phase, with a UV detector operating at 230 nm. SEC traces of
polymers insoluble in the above buffer (polystyrene standards)
were obtained with Phenomenex Phenogel 500, 103, and 104 A
columns, with a UV detector operating at 254 nm, and a 9/1 (v/v)
dichloromethane/methanol mobile phase.Swelling Tests
The tests were carried out on sheets with dimensions 10 20
1 mm3. The average weight, in the dry state, was 21.2 0.6 mg.
Each specimen of initial mass M0 was placed inside a 10 mL
test-tube that contained 5 mL of solvent at 37 8C. After 12 h the
specimenwas taken out of the test-tube andweighed afterwiping
off any visible surface moisture. The percentage water absorbed
was calculated using Equation (1):Macrom
 2007abs% ¼ Mt
M0
 100 (1)whereMt is the water mass absorbed at time t andM0 is the mass
of the sample at time zero.
UV spectra were run on a Perkin–Elmer Lambda EZ210 spectro-
meter. 2-Mercaptopyridine was determined at 343 nm in 0.1 M
TRIS buffer pH 8.5 (e¼8 070 mol1  cm1). Specific optical rota-
tions were measured with a Jasco P-1030 polarimeter.Materials
Where not otherwise specified all materials and analytical grade
HPLC solvents were purchased from Fluka and used as received,
apart from 2-methylpiperazine (MeP), which was re-crystallized
from heptane. D2O (99.9%), CD3OD (99.8%), and 2,2
0-dithiodipyridine
were purchased from Aldrich. 2,2-Bis(acrylamido)acetic acid
(BAC)[21] and bis(acryloyl)piperazine (BP)[22] were synthesized as
previously described.Synthesis
HG-BP30: BP (1.960 g, 10.0 mmol), cystamine di-hydrochloride
(0.338 g, 1.5 mmol), and lithium hydroxide monohydrate (0.126 g,
3.0 mmol) were dissolved in water (3.5 mL) under nitrogen andol. Rapid Commun. 2007, 28, 1243–1250
WILEY-VCH Verlag GmbH & Co. KGaA, WeinheimMeP (0.701 g, 7.0 mmol) was added under stirring. The homo-
geneous solution settled into a hydrogel. After 120 h the hydrogel
was finely ground, extensively extracted with water and acetone,
and dried at 37 8C and 0.1 Torr. Yield¼2.46 g (84%.)
HG-BP20, HG-BP10, HG-BAC30, HG-BAC20 and HG-BAC10 were
prepared following the same procedure as described for HG-BP30
(see Table 1 for the kind and the amount of reagents). The HG-BAC
series was treated with ethanol in place of acetone before drying.
BP30-SSPy: HG-BP30 (5.00 g, 1.13mmol disulfide) was soaked in
ethanol (30mL) and 2,20-dipyridyldisulfide (0.750 g, 3.4 mmol) and
a catalytic amount of 2-mercaptopyridine were added. The gel
dissolved in a few hours. The resultant solution was stirred for a
further 24 h at room temperature, and then diluted to 100mLwith
water. Excess 2,20-dipyridyldisulfide precipitated out. The mixture
was then filtered through a HPLC filter (0.45 mm), and then
ultrafiltered through a membrane with a nominal molecular
weight cut-off of 3 000 after adjusting the pH to 2.5 (HCl). The
product was recovered by freeze drying. Yield¼4.28 g (81%).
BP20-SSPy and BP10-SSPy were prepared as for BP30-SSPy,
using a three-fold molar excess of 2,20-dipyridyldisulfide over
disulfide units.
BAC10-SSPy, BAC20-SSPy and BAC30-SSPy were prepared by
following the same procedure, using a 2 : 1 (v/v) water/ethanol
mixture as reaction medium.
NMR of BP–SSPy series (as hydrochlorides): 1H NMR (CD3OD):
d¼ 1.38 (d, CH3), 2.88–3.65 (m, br, CO–CH2, N–CH, N–CH2, S–CH2),
7.35 (m, pyridine, N–C–CH), 7.84–7.87 (m, pyridine, N–C–CH–CH),
8.43 (m, pyridine, N–CH–C). 13C NMR (CD3OD): d¼ 14.18 (CH3),
26.94–28.34 (C–CO), 41.46–56.48 (C–N, C–S), 122.14 (pyridine, N–
C–CH), 122.82 (m, pyridine, N–CH–C), 139.24 (pyridine, N–C–C–C),
149.76 (pyridine, N–C), 156.86 (pyridine, N–C), 170.59–171.11
(C––O).
NMR of BAC-SSPy series (as hydrochlorides): 1H NMR (CD3OD):
d¼ 1.38 (CH3), 2.70–2.74 (m, br, CO–CH2), 2.85–3.62 (m, br, N–CH,
N–CH2, S–CH2), 5.56 (m, br, CH–COO), 7.35 (m, pyridine, N–C–CH),
7.79–7.87 (m, pyridine, N–C–CH–CH), 8.44 (m, pyridine, N–CH–C).
13C NMR (CD3OD): d¼ 13.93 (CH3), 28.74–31.60 (C–CO), 48.37–
58.21 (C–N, C–S), 122.14 (pyridine, N–C–CH), 122.78 (m, pyridine,
N–C–CH), 139.27 (pyridine, N–C–C–CH), 149.62 (pyridine, N–CH),
156.86 (pyridine, N–C), 171.36–172.91 (C––O).
BP30-SSG: BP30-SSPy hydrochloride (0.3 g, 0.149 mmol SSPy
units)was dissolved under nitrogen in 20mL of 0.1mol TRIS buffer
pH 8.50 (20 mL) and reduced L-glutathione (0.0458 g, 0.149 mmol)
was added. The solution immediately turned intensely yellow.
The reaction went to completion in a matter of minutes, as
ascertained by UV determination of the amount of 2-mercapto-
pyridine evolved. The solution was then diluted with water
(300 mL), ultrafiltered through a membrane with a nominal
molecular weight cut-off of 3 000, and freeze-dried. Yield¼0.266 g
(82.8%.)
a½ 25D ¼7.4 deg dm1  g1  cm3 (c¼1 in H2O). For comparison
purposes, reduced L-glutathione had a½ 25D ¼17.2 deg dm1 
g  1  cm3 (c¼2 in H2O).
1H NMR (D2O): d¼1.29 (d, CH3), 2.15 (glutamic acid residue, H2N–
C–CH2), 2.51 (glutamic acid residue, H2N–C–C–CH2), 2.55–2.70 (m,
br, CO–CH2), 2.70–3.65 (m, br, N–CH, N–CH2, S–CH2), 3.77 (glycine
residue, HO–CO–CH2–NH), 5.50 (m, br, CHCOO).
13C NMR (D2O):
d¼ 14.18 (CH3), 26.28 (glutamic acid residue, H2N–CH–CH2),DOI: 10.1002/marc.200700139
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Scheme 1. Polyaddition reaction leading to cystamine-cross-linked PAAs and subsequent disulfide–disulfide exchange reaction. In the BP
series: R¼CH2–CH2 and R0 ¼CH2. In the BAC series: R¼CH–COOH and R0 ¼H.
124626.94–28.34 (C–CO), 31.59 (glutamic acid residues, H2N–C–C–CH2),
43.33 (glycine residue, HO–CO–C–NH), 41.46–56.48 (C–N, C–S),
170.59–171.11 (C––O).
BAC30-SSG was prepared by a similar procedure. Yield¼78.2%.
a½ 25D ¼5.4 deg dm1  g1  cm3  (c¼1 in H2O).
1H NMR (D2O): d¼ 1.38 (d, CHCH3), 2.09 (glutamic acid
residue, H2N–C–CH2), 2.51 (glutamic acid residue, H2N–C–C–
CH2), 2.88–3.65 (m, br, CO–CH2, N–CH, N–CH2, S–CH2), 3.77
(glycine residue, HO–CO–CH2–NH).
13C NMR (D2O): d¼ 14.18
(CH3), 26.28 (glutamic acid residue, H2N–C–CH2), 28.30–28.93, 30.8
(C–CO), 31.59 (glutamic acid residues, H2N–C–C–CH2), 43.33
(glycine residue, HO–CO–CH2–NH), 48.1–55.9 (C–N, C–S), 58.25
(CCOO), 170.93–173.02 (C––O).Results and Discussion
The aim of this work was to obtain a new family of PAAs
with pendant 2-ethenyldithiopyridine moieties, to be used
for the preparation of smart soluble polymer conjugates
sensitive to reductive cleavage. The synthetic approach
involved two steps: the preparation of cross-linked PAA
networks using cystamine as a tetrafunctional cross-
linking agent, and their conversion into linear soluble
PAAs that bear activated disulfide pendants by disulfide–
disulfide exchange reaction with 2,20-dithiodipyridineMacromol. Rapid Commun. 2007, 28, 1243–1250
 2007 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim(Scheme 1). Disulfide–disulfide exchange reactions have
been previously reported and their mechanism described.[23]
Six different cross-linked PAA samples were obtained by
reacting BP (HG-BP10, HG-BP20, and HG-BP30) or BAC
(HG-BAC10, HG-BAC20, and HG-BAC30) with MeP as co-
monomer and three different amounts of cystamine as
cross-linker (Table 1). More precisely, in HG-BP10 and
HG-BAC10 the amount of the amine hydrogens of
cystamine over the total number of amine hydrogens
was 10%, whereas in HG-BP20 and HG-BAC20 this amount
was 20%, and in HG-BP30 and HG-BAC30 30%. The molar
ratios of the reagents used in each preparation are reported
in Table 1. It may be observed that the composition of the
cystamine cross-linked PAA networks are in good agree-
ment with the feed ratios.
The exchange reactions were performed on finely
ground PAA gels swollen in ethanol (HG-BP series) or in
a 2:1 (v/v) water/ethanol mixture (HG-BAC series) under
slightly alkaline conditions (pH of the swelling liquors
after dilution with water 8.5). The exchange reaction is
triggered by catalytic amounts of 2-mercaptopyridine (see
Scheme 2). A 3:1 excess of 2,20-dipirydyldisulfide with
respect to cystamine moieties was employed to force the
reaction to completion. The reaction mixture turned into a
clear homogeneous solution in a few hours, the dissolutionDOI: 10.1002/marc.200700139
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Scheme 2. Mechanism of the thiol-disulfide exchange reaction between PAA hydrogels and 2,20-dithiodipyridine.
1248time largely dependant on the particle size of the gels. The
mixtures were then allowed to react for a further 24 h,
filtered through an HPLC filter, and ultrafiltered. The
resultant products (Table 2) were finally recovered by
freeze drying the retained portion. The elemental analyses
of the products reported in the same table are in good
agreement with the expected composition fromNMR data.Scheme 3. Exchange reaction of reduced L-glutathione with BP-SSPy (a) and BAC-SSPy (b).Similar results were ob-
tained by substituting 5,50-
dithiobis(2-nitrobenzoic acid)
(Ellman’s reagent) for 2,20-
dipyridyldisulfide (data not
reported). The chemical reac-
tivity of the resultant products
was approximately the same.
An alternative synthetic
route was also tried based on
the polyaddition of commercial
2-(2-pyridyl)dithioethylamine,
by its primary amine group,
to bis-acrylamides. However,
most of the pendant disulfide
groups decomposed under the
conditions of PAA synthesis.
The molecular weights of
the linear PAAs obtained,
BP10-SSPy, BP20-SSPy, BP30-
SSPy BAC10-SSPy BAC20-SSPy
and BAC30-SSPy, were of the
same order as those of most
PAAs described so far.[10–12]
Moreover, their NMR spectra
revealed that no terminal
double bonds were present.
These results prove that all the
four amine hydrogens of
cystamine participate in the
polyaddition reaction not-
withstanding the chemicalMacromol. Rapid Commun. 2007, 28, 1243–1250
 2007 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheimconstrains of a cross-linked network, in agreement with
a previous HR-MAS NMR study on ethylenediamine-
crosslinked PAA networks.[24]
Polymers of the BP series, as hydrochlorides, were
soluble in water, methanol, dimethyl sulfoxide (DMSO),
and N,N-dimethylformamide (DMF), but insoluble in
chloroform, acetone, toluene, ether and ethyl acetate. AsDOI: 10.1002/marc.200700139
Poly(amidoamine)s with 2-Dithiopyridine Side Substituents . . .free bases they were soluble in DMSO, DMF, chloroform,
and methanol, but insoluble in water, acetone, toluene,
ether, and ethyl acetate. Polymers of the BAC series, both
as hydrochlorides and free bases, were soluble in water
and methanol, but insoluble in DMSO, DMF, chloroform,
acetone, toluene, ether, and ethyl acetate. Moreover, the
solubility properties of both BP-SSPy and BAC-SSPy
polymer series were somewhat different from those of
the corresponding PAAs derived from 2-methylpiperazine
and BP (MeP-BP) or BAC (ISA23), which have similar main
backbones, but are devoid of dithiopyridine side substi-
tuents. In particular, the PAAs of the BP-SSPy series, as free
bases, were insoluble in water, whereas MeP-BP was,[9,10]
and those of the BAC-SSPy series, both as hydrochlorides and
free bases, were soluble in methanol, whereas ISA 23 was
not.[9,25]
All dithiopyridyl-containing linear PAAs were fully
characterized by 1H and 13C NMR spectroscopy. The n/m
ratio between the MeP units and the 2-(2-aminoethyl)-
dithiopyridyl units was calculated from the integral ratio
of the signals at 1.38 and 7.35, assigned to the methyl
group of MeP and to the H-5 of the pyridyl residue,
respectively (Table 2).
The ability of PAA-SSPy of both series to undergo fast
exchange reactions with thiols, according to a general and
well-established mechanism,[26] was ascertained for
BP30-SSPy and BAC30-SSPy with reduced L-glutathione
as a model thiol-containing peptide (Scheme 3). After
purification, the NMR spectra of the resultant products
(BP30-SSG and BAC30-SSG) showed L-glutathione diagnos-
tic peaks at 2.09, 2.51, and 3.77, whereas the diagnostic
peaks of pyridine at 7.35, 7.85, and 8.43 ppm were absent.
As expected, both BP30-SSG and its BAC-deriving counter-
part BAC30-SSG showed optical rotation power. The
measured a½ 25D values (c¼ 1 in H2O) were 7.4
(deg  dm1  g1  cm3) and 5.4 (deg dm1  g1  cm3),
respectively, to be compared with the a½ 25D of reduced
glutathione (17.2 deg  dm1  g1  cm3, c¼ 2 in H2O).Conclusion
Cystaminewas used as a cross-linking agent to obtain PAA
networkswith various amounts of S–S interchain linkages.
These networks reacted with 2,20-dipyridyl disulfide to
yield linear PAAs that carry activated disulfide moieties as
side substituents, which under remarkablymild conditions
underwent exchange reactions with reduced L-glutathione,
chosen here as a model thiol-containing peptide. There-
fore, it may be reasonably concluded that the results
reported in this preliminary Communication open a general
and facile synthetic route to PAA conjugates of biologically
active peptides and proteins that contain SH groups.Macromol. Rapid Commun. 2007, 28, 1243–1250
 2007 WILEY-VCH Verlag GmbH & Co. KGaA, WeinheimThe bond between the two components of these hybrid
materials is expected to be stable in the bloodstream, but
amenable to reductive cleavage inside cells.
As a minor remark, the molecular weights of the linear
PAAs obtained in this work were in the range of those of
most PAAs obtained by direct polyaddition of bis-amines
to bis-acrylamides,[9–12] and no evidence of terminal
double bonds is present in their NMR spectra. Therefore,
all the amine hydrogens of cystamine participated in the
polyaddition reaction.
Received: February 23, 2007; Revised: March 28, 2007; Accepted:
April 4, 2007; DOI: 10.1002/marc.200700139
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Novel Poly(amidoamine)-based Hydrogels as Scaffolds 
for Tissue Engineering 
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Summary:  Poly(amidoamine)s are biocompatible biodegradable polymers, 
which can be easily functionalized with a number of bioactive and biomimetic 
compounds. Co-polymerization of these polymers with 4-aminobutyl 
guanidine (agmatine) leads to an RGD mimicking structure. Hydrogels based 
on this structure showed an enhanced cell adhesion and could be chemically 
linked to a glass substrate to create a bioadhesive support for cell growth. 
Preliminary optimization and cell adhesion tests on Madin-Darby Canine 
Kidney cells were performed, both on functionalized and non-functionalized 
structures, with promising results. 
 
Keywords: Hydrogels, Poly(amidoamine), biocompatible surfaces, agmatine, 
RGD mimic. 
 
Introduction 
The advancement of biological sciences and biomaterials has given a fundamental 
contribution to the development of techniques for dealing with proteins, cells and tissues 
both in vitro and in vivo. These technologies require reliable support materials with good 
biocompatibility and cell adhesion, and would greatly profit from new materials that are 
reliable, disposable and simple to use.[1, 2] Among synthetic materials, hydrogels present 
unrivalled tissue-like properties for interactions with living cells,[3] such as similar water 
content and permeability to oxygen and metabolites. In principle, synthetic hydrogels, as 
opposed to naturally derived materials (e.g. gelatin, chitosan etc.) should be most 
advantageous, giving the possibility of a complete control over hydrogel composition, 
surface properties and other key parameters such as water absorption and (bio)degradation 
time. Moreover, hydrogel structures could be used to encapsulate cells, proteins and 
signaling factors, as well as bioactive moieties to be slowly released during cell growth. 
Provided cell adhesion is effective, supported or free standing micro-and nano-structured 
hydrogels could be advantageously exploited for tissue engineering, as matrixes for in 
vitro cell screening, and for microarray technology.[4]  
Cell adhesion on synthetic hydrogels, however, is still an issue for many of these 
materials, such as poly(hydroxyethyl)metacrylate (PHEMA) or crosslinked 
poly(ethyleneoxide) (PEG) derivatives.[5,6] A number of chemical and physical 
modifications have been proposed to overcome this problem, often relying on modification 
of the synthetic surface with biological or biomimetic moieties, peptides or proteins.[7,8] 
Cell adhesion is a complex process, mediated by specific interactions between surface 
ligands and cell receptors;[9] several studies have shown that the arginin-glycin-aspartic 
acid (RGD) tripeptide and some of its analogues can interact with adhesion regulating 
proteins of the integrin family, and promote cell adhesion and spreading.[10-12] 
Modifications of chemical structures in order to include an RGD or RGD-like groups have 
been proposed for a number of applications where interaction with cells was desired, to 
enhance adhesion or recognition by cellular receptors.[13-14] 
Research in our group has been for several years focused on biomaterials based on 
poly(amidoamine)s (PAAs). PAAs are synthetic polymers endowed with many 
biologically interesting properties, being highly biocompatible, non toxic and 
biodegradable.[15,16] They are obtained by Michael-type addition of bis-acrylamides to 
primary amines and/or secondary diamines, under mild conditions. Several structures 
including biologic, biomimetic and bioactive compounds, can be incorporated in the PAA 
backbone by covalent attachment during the synthetic process.[17-19] Hydrogels based on 
PAAs besides having both the properties of hydrogels and PAAs, can be easily modified 
by the introduction of functional co-monomers.[20,21] These extremely versatile materials 
are especially interesting when carrying carboxylic groups as well as amino groups, since 
amphoteric PAAs have been demonstrated to have very low toxicity and “stealth” 
properties in vivo.[22] 
In the last years, PAA polymers containing RGD mimic units have been prepared. They 
are obtained by the introduction of 4-aminobutylguanidine (agmatine), used as co-
monomer, to build a functional amphoteric repeating unit that is structurally similar to 
RGD. The soluble polymers carrying these functionalities have extremely low toxicity 
even if they are polycationic at physiologic pH[23] and have shown potential as transfection 
agents.[24] Introducing this structure in a crosslinked amphoteric PAA hydrogel resulted in 
an enhancement of adhesion for fibroblasts.[25] In this work, a similar adhesion promoting 
material was used to prepare a thin film supported on glass, as a model device for cell 
screening. Comparative tests of cell adhesion and growth of RGD-binding αVβ3 integrin 
expressing epithelial Madin-Darby canine kidney (MDCK) cells were performed to assess 
its efficiency, with promising results.[26] 
 
Materials and Methods 
Ethanol, hydrochloric acid (37%), nitric acid (65%), 3-aminopropyltrimethoxy silane, 1,2-
diaminoethane (EDA), 4-aminobutylguanidine sulfate (agmatine sulfate), purity 97%, 
cystamine di-hidrochloride (Fluka, > 98%,), and GRGD peptide were purchased from 
Sigma-Aldrich and used as received. 2-Methylpiperazine was purchased from Fluka and 
used after sublimation. Its final purity (96,8 %) was determined with acidimetric titration. 
N,N’-Bis (acrylamido)acetic acid (BAC) was prepared as reported in the literature[27] and 
purity (97,5%) determined by NMR and titration. Phosphate buffer solution (PBS) 10 mM 
was prepared using Sigma Aldrich tablets according to manufacturer’s instructions. All 
chemicals used in the biological tests were purchased from Sigma-Aldrich. TCPS (tissue 
culture plate surfaces), multiwells, and tissue culture flasks were purchased from 
Zellkultur und Labortechnologie, Switzerland; round glass coverslips as support for 
hydrogels (13 mm in diameter, 0.7 mm thickness) from Zeus super.  
Spin coating was performed using a Laurell WS-400B-6NPP –Lite spin coater. 
1H and 13CNMRspectra were obtained using a Brüker Avance400 spectrometer operating 
at 400.132 MHz (1H) and 100.623(13C), and using Brüker software.   
 
Preparation procedure for AGMA1-75 hydrogel: in a 10 ml round bottomed flask BAC 
(1099 mg, 5.4 mmol) was added under nitrogen atmosphere and stirring to an aqueous 
lithium hydroxide solution (LiOH*H2O, 226.26 mg 5.4 mmol in 1.8 ml). After complete 
dissolution, agmatine sulfate (308.17 mg, 1.35 mmol) and more lithium hydroxide 
monohydrate (81.9 mg, 2.7 mmol) were added and dissolved. This mixture was allowed to 
react for 24 hr at room temperature (20 ± 5°C) in the dark, and then EDA (121.7 mg, 2.05 
mmol) was added. The solution was stirred for 2 minutes, retrieved with a syringe and 
injected in a square mould made of two silanized 10x10 cm glass plates separated by a 0.3 
mm silicone spacer. The hydrogel was allowed to crosslink at room temperature for 72 hr, 
and retrieved as a pliant solid film. The sample was purified by extracting with excess 
ethanol and then with doubly distilled water. To avoid ruptures caused by osmotic shock, 
water was not added at once to the ethanol-swollen hydrogel; instead, the sample was 
exposed to water/ethanol mixtures with increasing water concentrations, until pure water 
was used. The extraction time was at least 30 min for each step.  
ISA23-75 was prepared and purified using the same procedure, and the following reagents: 
BAC (1099 mg, 5.4 mmol), lithium hydroxide monohydrate (226.26 mg 5.4 mmol), 2-
methylpiperazine (135.3 mg, 1.35 mmol), doubly distilled water (1.8 ml), and EDA (121.7 
mg, 2.05 mmol). Structure was confirmed by IR spectroscopy in KBr. 
Soluble AGMA1 was prepared as reported in literature,[23] its structure confirmed by NMR 
and GPC. Molecular weight of the sample used: nM = 5500 and wM = 6500, polydispersity 
=1.25; its NMR was consistent with those reported in the literature. 
Glass amino silane functionalization: Round glass coverslips, 13 mm in diameter, were 
treated as previously reported.[28] They were soaked in aqua regia at room temperature for 
5 hr (20 coverslips were laid out in a glass dish 100 mm in diameter and covered with 12 
ml of the acid mixture), washed several times in doubly distilled water and then in ethanol 
before being soaked in a 10% v/v ethanol solution of 3-aminopropyltrimethoxy silane (15 
ml) overnight. The samples were recovered and washed in ethanol (2 x 20 ml), doubly 
distilled water (3 x 20 ml), and then sonicated in doubly distilled water. They were finally 
dried with soft paper and used within 24 hr. 
Supported hydrogel layer preparation: AGMA1-75: BAC (39 mg 0.197 mmol) was 
dissolved in doubly distilled water (66 µl) together with lithium hydroxide monohydrate 
(14.5 mg, 0.30 mmol). After the solution cleared, agmatine sulfate (11.20 mg 0.05 mmol) 
was added and dissolved. The mixture was allowed to react, in the dark and under 
nitrogen, for 24 hr at room temperature (20±5°C), then EDA (6.4 mg 0.09 mmol) was 
added just before casting. About 20 µl of the solution were cast on each pre-treated glass 
coverslip, using a Pasteur pipette, before spin coating them.  
After deposition, samples were kept in a closed sterile container for 3 days at room 
temperature, to allow the cross linking reaction to proceed. Then they were retrieved, put 
each in a well of a multiwell plate and washed as described for the free hydrogels, each 
sample being soaked in 1 ml solution. 30 min after the last addition of water/ethanol 
mixture, the solution was removed, and replaced with 1 ml of doubly distilled sterile 
water. Samples were kept in water at 37°C overnight, rinsed in doubly distilled water and 
sterilized with UV-rays for ten minutes before use.  
ISA23-75: The procedure was the same as reported above for AGMA1-75, using the 
following quantities: BAC (39 mg, 0.197 mmol) doubly distilled water (66 µl), lithium 
hydroxide monohydrate (8.25mg, 0.197 mmol), 2-methylpiperazine (5.0 mg 0.05, mmol), 
EDA (4.2 mg, 0.68 mmol). 
Cell culture condition: Immortalized MDCK cells were cultured in Dulbecco's Modified 
Eagle's Medium, supplemented with 10% Fetal Bovine Serum, 2 mM L-Glutamine, 0.1 
mM non essential amino acids, 1.5 g/l sodium bicarbonate, 1 mM sodium pyruvate, 100 
units/ml penicillin and 100 µg/ml streptomycin. Cells were grown in tissue culture flasks 
at 37°C in controlled atmosphere (5% CO2). After achieving 70% of confluence into the 
flask, the cells were passed using Trypsin-EDTA solution and seeded at a concentration of 
104 cells/well to 13 mm diameter round glass coverslips coated with AGMA1-75, ISA23-
75 and to TCPS.  
Cell adhesion, proliferation and morphology: We measured MDCK adhesion on 
AGMA1-75, ISA23-75 and TCPS and compared the results. The seeded cells were stored 
into a humidified incubator at 37°C. They were monitored every 30 min during the first 
four hours after cell plating, then every hour for the next 2 or 3 hr. Afterwards they were 
observed once a day until cells achieved confluence. Images from each sample were 
collected with a Power Shot G6 Canon digital camera mounted on a Zeiss Axiovert 40CFL 
inverted optical microscope using 10X objective lens. Four random fields from each 
sample were photographed and the number of cells both adhered and not adhered was 
counted to determine the percentage of adhesion, defined as: 
Adhesion (%) = (number of adhered cells / total number of cells) x 100. 
For the cell adhesion experiments in the presence of soluble AGMA1 or GRGD peptide, 
cells were seeded in culture medium supplemented with 1 mM AGMA1 (calculated on the 
repeating unit concentration), 10 mM AGMA1 or 1 mM GRGD. After 4 hr we calculated 
the inhibition of adhesion defined as: 
Inhibition (%) = [1-(Adhesion (%)/Adhesion (%) in control condition)] x 100,  
where Adhesion (%) in control condition is the result of cell adhesion on each substrate 
(TCPS, AGMA1-75 and ISA23-75) in medium without soluble AGMA1 or GRGD. 
 
Results and Discussion 
Previous papers had reported on the effect of agmatine-functionalized hydrogels on the 
adhesion of fibroblasts (Figure 1).  
 Figure 1. Effect of Agmatine functionalization on cell adhesion and proliferation for 
fibroblasts. 
 
In our case, we decided to exploit the same functionalization to enhance the hydrogel 
adhesion of MDCK epithelial cells, in order to prepare a prototype supported device. The 
presence of a glass support would greatly enhance the hydrogel usefulness in the field of 
cell screening and molecular diagnostics. 
For this reason we have designed, prepared and tested a new bi-layered system. This new 
system is composed by a glass support covered with a functional hydrogel layer. The glass 
substrate provides mechanically robust support and easier handling while the 
functionalized hydrogel layer interacts with the cells. Both glass support and hydrogel are 
optically transparent, as required for several cell characterization techniques, including 
optical microscopy.  
 
 
 
 
 
 
 
 
Figure 2. Structure of AGMA1 (A) and ISA23 (C) and the RGD peptide (B) 
 
As pointed out in the introduction, in this study we chose to compare hydrogels based on 
two amphoteric PAA structures, AGMA1 and ISA23, both known in the literature as 
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highly biocompatible structures. The AGMA1 repeating units are very similar to the well 
known adhesion-modulating RGD peptide sequence. Figure 2 shows the repeating unit of 
AGMA1 polymers (A) and the structure of the RGD peptide (B). ISA23, not carrying any 
guanidine pendant group (structure reported in Figure 2C), can be used as a non-functional 
model, to rule out the effect of mechanical properties and overall surface morphology. 
Linear ISA23 polymers are known to be biocompatible[21,22] and their hydrogels show no 
significant cell adhesion properties.[29]  
A semi-quantitative evaluation of the cell adhesion properties of these systems, in order to 
evaluate the best composition for cell adhesion was performed with different 
compositions. Results are reported in Figure 3. 
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Figure 3. Cell adhesion behavior (normalized against TCPS) versus crosslinker content, 
given as moles ratio, that is (moles of EDA aminic hydrogens /moles of overall aminic 
hydrogens) x 100. 
 
Interestingly, the best composition, which had 19% mol/mol crosslinker, and 12,5% 
mol/mol agmatine content has a composition similar to that of the samples found to be 
effective in the fibroblast tests (16,5 % mol/mol crosslinker content, 8,3 % agmatine). 
 
Cell adhesion: After seeding 10000 cells in each well,  the optical microscope showed 
round and pearly cells until they began to attach to the substrates. Up to 2 hr, cell adhesion 
on AGMA1-75 and ISA23-75 was not markedly different and adherent cells on both 
substrates are much less than on TCPS. At 4 hr cells on ISA23-75 were still few and 
showed the same morphology, whereas on AGMA1-75 the number of cells adhered to the 
substrate was similar to that on TCPS. At longer times, cells on TCPS start to proliferate 
and form clusters. On AGMA1-75, instead, cells proliferated slowly. This behavior 
becomes even more evident at 72 hr when cells seeded on TCPS have achieved confluence 
and begin to die. On AGMA1-75, instead, we still observe cell clusters without 
confluence. This effect may be explained considering that despite the fact that PAA 
hydrogel layer were supported by a rigid material, cells probably experienced a more 
compliant substrate than TCPS. It generally recognized that focal contact formation and 
cytoskeletal assembly may be relatively more difficult on hydrogel surface, retarding cell 
growth.[30] 
MDCK cells grown on ISA23-75 exhibited lower adhesion and slower proliferation than 
the AGMA1-75 and TCPS grown cells. However, after 48 hr, cells attached to some extent 
also on this substrate. This effect might be explained by the partial absorption of adhesive 
proteins from serum on to the hydrogel.  
A quantitative evaluation of MDCK adhesion on substrates as a function of time showed 
that the adhesion had a quadratic trend on TCPS and AGMA1-75 whereas a linear trend 
on ISA23-75, as reported in Figure 4. The histogram shows that, up to 2 hr after seeding, 
cell adhesion on TCPS is higher than on hydrogels, while between 2 and 4 hr MDCK 
adhesion on AGMA1-75 increases remarkably compared to ISA23-75 until reaching an 
adhesion percentage similar to that on TCPS. 
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Figure 4. Cell adhesion vs time on the substrates examined: ISA23-75, AGMA1-75 and 
TCPS. The percentage of cell adhesion on ISA23-75 and AGMA1-75, is comparable in the 
first hour, and much lower than the adhesion on TCPS. After two hrs cell adhesion 
percentage on AGMA1-75 is higher than on ISA23-75 and  similar to the value on TCPS.  
 
Soluble AGMA-1 and GRGD similarly prevent cell-substrate  adhesion: In order to 
confirm that the difference in cell adhesion on the Agmatine-functionalized hydrogels is 
due to its composition and not to other factors, such as non-specific serum protein 
adsorption, we tested the adhesion-inhibiting effect of soluble AGMA1 polymers and 
GRGD peptides. 
The presence in the medium of a soluble polymer obtained by copolymerization of BAC 
and agmatine[23] up to a concentration of 1 mM in repeating units, proved to prevent cell 
adhesion on all the substrates (Figure 5).  
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Figure 5. The presence of a soluble polymer bearing the agmatine-BAC sequence is able to 
prevent cell adhesion on all the substrates. 1 mM GRGD peptide and 1 mM AGMA1 
(calculated on repeating unit concentration) have the same effect on cell adhesion 
inhibition; increasing the soluble polymer concentration to 10 mM does not increase 
significantly the inhibition of cell adhesion. 
 
Increasing the AGMA1 concentration up to 10 mM did not significantly increase the 
inhibition of cell adhesion, suggesting that the interested receptors are already almost 
completely saturated at 1 mM AGMA1. Since 1 mM GRGD peptide and 1 mM AGMA1 
(calculated on repeating unit concentration) have the same effect on cell adhesion 
inhibition, it can be reasonably concluded that both compounds bind the same integrin 
receptors. 
 
Conclusions 
Several possible applications can be envisioned for agmatine-functionalized PAA 
hydrogels. These results are a further step in this direction, showing how the cell-polymer 
interaction can be controlled by a simple chemical modification. Interaction with the cell 
receptors was confirmed, as well as biocompatibility, and a cell adhesion as good as that 
on TCPS for the epithelial MDCK cells. 
Extending of these results on to other cell lines as well as further studies in the mechanics 
of the cell-AGMA1 interactions are ongoing. The growth retarding effect of the hydrogel 
surface can also be interesting in order to apply these substrates to conservation and 
proliferation of stem cells. 
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Understanding the interaction mechanisms of phospholipids with surfaces is crucial for the 
exploitation of lipid bilayers as models of the cell membrane, as well as templates for biosensors. 
Moreover, controlling and manipulating single lipid nanoparticles for the investigation of their 
properties by means of single-particle sensitive surface techniques require the ability to tailor the 
chemical properties of surfaces in order to achieve stable and sparse binding of lipid particles, while 
keeping them from aggregating, or denaturing. Here we present a quantitative morphological and 
structural investigation by Atomic Force Microscopy of supported phospholipid layers and 
nanostructures on cholesterol-functionalized glass surfaces, in comparison with other surfaces with 
different interfacial properties. We show that functionalization of glass coverslips with cholesterol 
groups is a viable route for the production of optically transparent, scanning probe microscopy -
compatible clean substrates, for the effective immobilization of both extended single lipid bilayers, 
and lipid nanoparticles.  
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ABSTRACT 
Poly(amidoamine) (PAA) networks obtained using cystamine as cross-linking agent on reaction with 2,2’-
dithiodipyridine turn into linear PAAs with side dithiopyridyl groups that easily undergo exchange reaction 
with thiocholesterol. The resultant products represent the first examples of amphiphilic PAA–cholesterol 
conjugates in which lipophilic cholesterol moieties are linked to the hydrophilic PAA chain by S–S bonds 
stable in blood, but cleavable inside cells. These conjugates self-assemble in aqueous media into 
nanoaggregates whose inner core consists of lipophilic cholesterol domains. A series of PAA-cholesterol 
conjugates deriving from two different bis-acrylamides, namely 2,2-bis(acrylamido)acetic acid and 1,4-
bis(acryloyl)piperazine, and with different cholesterol content were obtained. All products were 
characterized by 1H and 13C NMR spectroscopy and the average molecular weights of the soluble 
polymers determined by size exclusion chromatography. In all instances, the segregation of cholesterol 
residues from the aqueous medium was revealed by the comparison of their NMR spectra in CDCl3 and 
D2O, respectively. The TEM analysis of the PAA-cholesterol aggregates in aqueous buffers revealed 
homogeneous round-shaped nanospheres, whose average dimensions and dimensions distribution were 
determined by DLS. Preliminary cytocompatibility tests demonstrated that all prepared PAA–cholesterol 
samples are cytobiocompatible, thus showing potential for biotechnological applications.
Keywords: poly(amidoamine)s, cholesterol, bioactive and biocompatible polymers, disulfides, 
nanostructured polymers, amphiphilic polymers 
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